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Multi-responsive, anionic poly(methacrylic acid-co-N-vinyl-2-pyrrolidone) 
microscale hydrogels (microgels) encapsulating polycationic nanoscale hydrogels 
(nanogels) were synthesized with either degradable or nondegradable crosslinks. The pH-
responsive volume phase transition of these formulations was consistent with the pH 
transition experienced during intestinal delivery, as the hydrogels swelled at pH values 
greater than pH 5.  
The physicochemical characteristics of the nondegradable formulations were 
evaluated by microscopy, potentiometric titration, Fourier transform infrared 
spectroscopy, and thermal gravimetric analysis. The nondegradable formulations 
successfully loaded and released a model protein in physiological buffers, but the ability 
of the microgels to release the nanogels upon exposure to intestinal conditions was 
inadequate. 
Therefore, microgels containing enzyme-degradable oligopeptide crosslinks were 
synthesized then characterized using Fourier transform infrared spectroscopy, electron 
microscopy, confocal microscopy, and ImageStream flow cytometry. Degradation of the 
microgels upon incubation in trypsin solutions, simulated gastric fluid, or simulated 
intestinal fluid was evaluated by measuring the change in relative turbidity over time. 
 viii 
Microgels were degraded specifically by the enzyme trypsin, and the rate of degradation 
was dependent upon the microgel to trypsin concentration ratio; for all ratios tested, 
degradation was complete within 4 hours. 
The cytocompatibility of the enzyme-degraded microgels encapsulating nanogels 
was evaluated in both a human and a murine cell line; at microgel concentrations less 
than 0.4 mg/ml the cell viability was greater than 90%. Confocal microscopy was used to 
obtain Z-stack images of the cells following incubation with the microgels, confirming 
that nanogels were released from the degraded microgels and subsequently inteRNAlized 
by RAW 264.7 murine macrophage cells.  
The microencapsulated nanogels were able to load siRNA via electrostatic 
complexation with loading efficiencies ranging from 60-80%. Incubation of loaded 
microgels in simulated intestinal fluid with reduced trypsin concentrations or in rat 
intestinal fluid resulted in successful degradation of the microgel matrix and release of a 
detectable amount of viable siRNA. The degraded microgels with nanogels transfected 
the two different cell lines with up to 20% silencing efficiency. Though the knockdown 
efficiency is not as high as that of nanogels alone, the microgel results are consistent and 
reproducible across two cell lines. 
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Chapter 1: Introduction 
Gene therapy or the modification of gene expression to treat acquired or inherited 
disease, has potential to treat or cure a diverse array of chronic illnesses such as age-
related macular degeneration, cardiovascular disease, and various cancers [1-3]. Since the 
seminal publication identifying gene silencing via RNA interference by Fire and Mello in 
1998 [4], the ability of synthetic, small interfering RNAs (siRNA) to induce gene 
silencing in a therapeutic capacity has been well-documented. However, a marketable 
siRNA-based therapeutic has yet to be fully realized due to the challenges associated with 
delivery of this delicate molecule, including susceptibility to degradation and the 
necessity of cellular uptake for therapeutic efficacy.  
Oral administration of such a therapeutic could overcome certain delivery 
challenges while being conducive to treating diseases of the gastrointestinal (GI) tract. 
Among the GI diseases that stand to benefit from an oral delivery formulation of siRNA 
for gene knockdown are inflammatory bowel disease (IBD) and celiac disease (CD). 
Both IBD [5] and CD [6, 7] are thought to stem from aberrant gene expression ultimately 
resulting in high levels of inflammatory cytokines and destruction of the intestinal 
epithelium.  
One of the current IBD treatments on the market is an antibody that targets the 
inflammatory cytokine tumor necrosis factor-α (TNF-α), which is secreted in high levels 
by macrophage and dendritic cells in patients with IBD [5]. In a similar strategy, anti-
TNF-α siRNA may be used to silence production of TNF-α and treat patients suffering 
from IBD [8-12] or CD. In this application, oral administration of the siRNA therapy 
would not only offer convenient administration for the patient, but local delivery to the 
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intestine may result higher efficacy compared to a systemic delivery route and also limit 
off-target effects. 
The challenges associated with oral delivery of siRNA are not to be taken lightly. 
They include maintaining the stability of siRNA throughout the harsh pH and proteolytic 
environments in the GI tract [13], achieving intracellular delivery [14], and avoiding 
lysosomal degradation within the cell  [15].  
Many pH-responsive hydrogel nanoparticles have been thoughtfully designed as 
siRNA delivery vehicles to overcome some or all of these challenges. For example, the 
composition and architecture of poly[2-(diethylamino) ethyl methacrylate] (PDEAEMA) 
nanogels has been tuned to arrive at a formulation with desired pH response, excellent 
siRNA binding, acceptable cell uptake, and measurable gene silencing effect [16-20]. 
However, polycationic polymers such as these are charged and unstable in the low pH of 
the stomach, rendering them unsuitable for oral delivery applications. 
Thus, researchers have turned toward two-component systems consisting of 
microparticles encapsulating nanoparticles to achieve oral delivery of siRNA [9, 10, 12, 
21, 22]. Typically, the encapsulating material is designed to withstand the harsh 
environment of the upper GI tract while retaining the ability to release the nanoparticles 
for cellular uptake upon entry into the small intestine. The nanoparticles, in turn, are 
usually designed to facilitate complexation with siRNA, cellular uptake, and endosomal 
escape. In this manner it may be possible to develop a siRNA therapeutic delivery system 
that can overcome the oral delivery barriers and benefit patients suffering from incurable 
diseases of the GI tract.  
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Chapter 2: Oral Delivery of Protein and Gene Therapeutics 
2. 1 PHYSIOLOGICAL CONSIDERATIONS 
Delicate therapeutics such as proteins, antibodies, and RNAs administered orally 
encounter harsh environments and delivery challenges along the oral delivery pathway 
[1], shown in Figure 2.1. When a therapeutic in an oral dosage form is ingested it first 
encounters the saliva within the mouth, which contains some enzymes but does not play a 
major role in digestion. Similarly, the primary function of the esophagus is transport from 
the mouth and buccal regions to the stomach rather than digestion [2]. 
Next, the therapeutic enters the gastrointestinal tract, which is comprised of the 
stomach, small intestine, and large intestine. Main functions of the stomach include 
storage and grinding of food into small particulates for release into the small intestine. 
The stomach is coated with a viscous layer of mucus to prevent harm from the variety of 
digestive enzymes, including pepsin and gastrin, and very low pH of the gastric fluid. 
The pH of the stomach has been measured between 1.4-2.1, and is generally accepted as 
2.0 in a state of fasting [3]. The pH is largely dependent upon food consumption; it is 
quite low when the stomach is empty (pH 1-2) but can rise as high as 4-6 following a 
meal [4, 5]. The length of time spent in the stomach varies depending on type of food 
consumed, size of the food particles, and various other physiological conditions, but it 
can ranged from a few minutes to a couple hours [5]. In the fasting state, however, the 
entire emptying pattern, or migrating myoelectric complex (MMC), of the stomach into 
the small intestine is completed in about 2 hours [6]. 
From the stomach, the therapeutic enters the small intestine, which is divided into 
the duodenum, jejunum, and ileum. The small intestine is lined with villi that provide 
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access to blood and lymphatic vessels as well as increase surface area for absorption [7]. 
The epithelium of the small intestine is lined with four main cell types, including goblet 
cells that secrete mucus and enterocytes that are responsible for absorption [7, 8]. The 
mucus layer serves to trap and remove pathogens while lubricating the epithelium [9], 
and can be a significant barrier to penetration by therapeutics as the rate of turnover is 
constant [10], with shedding and clearance on the order of a few hours in rats [11]. 
Enterocytes are covered with a barrier of microvilli and negatively charged glycoprotein, 
known as the brush border, which is home to many digestive enzymes that can impede 
the delivery of delicate therapeutics [12, 13]. Additionally, the concentration of 
microflora increases from the proximal to distal intestine, as the pH increases from acidic 
to more neutral [14, 15]. These microflora produce a number of enzymes that pose a 
threat to delicate therapeutics such as proteins or RNAs. Transit time within the small 
intestine is approximately 3-4 hours, and is not greatly affected by variables such as 
particle size, density, or type of food consumed [16]. Supposing the therapeutic can 
withstand enzymatic degradation, delivery to the small intestine is convenient for 
adsorption and systemic delivery via the bloodstream. 
Within the small intestine, the bacterial concentration increases sharply and 
remains high throughout the colon [14]. The pH throughout the colon ranges from 6-7.5, 
increasing from proximal to distal colon [15]. The ascending colon is characterized by 
antiperistalsis, which serves to retain and mix contents for 10-12 hours [17, 18]. Thus, the 
proximal colon provides a large window for therapeutic delivery making it a potential 
target site, though it is not as well-suited to absorption as the small intestine. The second 
portion is the transverse colon, where the content is divided by annular contractions and 
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moves slowly as water is reabsorbed, potentially trapping the therapeutic within viscous 
fecal content, making this region unsuitable for drug delivery [17]. Finally, the 
therapeutic enters the descending colon, which controls excretion of feces. The total 
retention time in the colon can be anywhere from 24-60 hours [17, 18]. Like the small 
intestine, epithelial cells of the large intestine produce a mucin layer that has a turnover 
rate of 16-24 hours to facilitate clearance of feces, but this also presents an additional 
delivery barrier [19].  
2.2 HYDROGELS FOR ORAL DRUG DELIVERY 
Hydrogels are three-dimensional, hydrophilic polymer networks with the ability 
to absorb large amounts of water or biological fluid. Hydrogels may be further stabilized 
by chemical or physical crosslinks, which render them insoluble and “permanent” [20, 
21]. These crosslinked hydrogels are still able to swell with adsorption of water, which 
contributes to their high biocompatibility [20]. Thus, hydrogels have been used in 
biological applications such as tissue engineering, drug delivery, and diagnostic devices, 
among others [22]. 
In recent years, we have seen steady expansion of research utilizing “intelligent” 
or stimuli-responsive hydrogels, particularly in the fields of drug delivery and tissue 
engineering [23-27]. Stimuli-responsive hydrogels are crosslinked, hydrophilic polymer 
networks that undergo a physicochemical transition in response to a change in exteRNAl 
stimuli such as pH, temperature, light, and analyte concentration, to name a few [27-29]. 
The response to stimuli may be a change in surface charge or hydrophobicity, change in 
phase volume of the gel, breaking of bonds resulting in degradation or gel-sol transition, 
or a combination of these [28, 30]. Gil and Hudson [31] reviewed an extensive list of 
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stimuli-responsive polymers, as well as bioconjugates made with the polymers, including 
the design criteria taken into consideration to achieve desired responses useful for 
biomedical applications.  
For the purposes of oral drug delivery applications, pH responsive hydrogels such 
as acrylic acids have been of particular interest due to their ionization across a pH regime 
corresponding to that of the gastrointestinal tract. Also gaining momentum in the field is 
the use of multi-responsive hydrogels that respond to two or more environmental stimuli 
for increased specificity and control of drug release.  
2.2.1 pH-Responsive Hydrogels 
Stimuli-responsive hydrogels undergo physical or chemical changes in response 
to environmental triggers, such as variation in temperature or pH [32]. Hydrogels that 
contain acidic or basic pendant groups which can be ionized depending on the pH of 
surrounding solution are known as ionic hydrogels [33]. Poly(methacrylic acid) (PMAA), 
an anionic polymer, and poly(diethylaminoethyl methacrylate) (PDEAEMA), a cationic 
polymer, are among the most commonly studied ionic polymers [22]. Additionally, if the 
network contains two polymers that can form hydrogen bonds, such as carboxylic acid 
groups of MAA and ether groups of poly(ethylene glycol) (PEG), the hydrogel is known 
as a complexation hydrogel [34].  
These stimuli-responsive hydrogels can be used as coatings or carriers. Enteric 
coatings can be made of pH-responsive hydrogels, usually acrylic- or cellulose-based, 
and are applied to prevent dissolution of the tablet, capsule, or particle until it reaches the 
small intestine [33]. The coating is typically applied by depositing a layer of linear 
polymer in aqueous solution then allowing the deposited layer to dry, forming a water-
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soluble film coating [35, 36]. Dissolution of the coating is a function of pH; the polymers 
begin to swell and dissolve following gastric emptying into the upper small intestine, 
where the pH rises above 5 [37]. Eudragit® is one of the most common enteric coatings. 
The different formulations of Eudragit® are comprised of varying combinations 
methacrylic acid copolymers, resulting in formulation-dependent pH response ranging 
from 5.5-7.0 [38].  
However, the pH range of the small intestine is similar to that of the colon, 
approximately 6-7.5 [15, 39], and varies among patients as well as between disease 
states, making delivery based on pH-specific dissolution within a narrow range difficult 
to achieve with consistency [33, 38]. Imperfect deposition, adhesion of coating layers, 
and instability over time can present problems with consistent dissolution and release 
from enteric coatings [40]. Additionally, the dissolution of enteric coatings is generally 
only modulated by polymer composition, addition of fillers, and/or deposition of multiple 
coating layers, resulting in several processing steps [41]. Hydrogels offer the ability to 
control diffusion throughout the material, vary crosslinking density and corresponding 
mesh size, or incorporate additional responsive moieties within a single synthesis step to 
better tune the release profile of the therapeutic.  
Acrylic acids, including methacrylic acid, are especially well-suited to oral drug 
delivery applications as the pKa of these monomers falls within the pH gradient of the 
intestinal tract. With a pKa of 4.8-4.9 [42], methacrylic acid chains are protonated at low 
pH such as that of the stomach and hydrogen bonding takes place, maintaining the 
collapsed state of the gel and protecting any payload within. At pH values above the pKa, 
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MAA chains are ionized and ionic repulsion occurs, enhancing the imbibition of 
surrounding fluid by the hydrogel and facilitating release of the payload. 
pH-Responsive hydrogel carriers can be loaded post-synthesis with a therapeutic 
such as a protein or drug by inducing swelling of the gel and allowing sufficient time for 
diffusion of the therapeutic into the gel, followed by subsequent collapse of the gel. Once 
administered, these loaded hydrogels swell as the pH of the physiological fluid changes, 
thereby allowing the therapeutic within to diffuse out through the increased mesh size of 
the network at the desired biological site [20].  
Hydrogel carriers with a MAA backbone and grafted PEG chains were developed 
by Peppas and Klier in the late 1980s [43]. These P(MAA-g-EG) hydrogels were able to 
swell and absorb or release solute as a function of increased pH. Additionally, the 
equilibrium swelling and solute release characteristics of the hydrogel were shown to be 
dependent upon the complexation between MAA and PEG.  
Later, Lowman and Peppas [44] published their studies on the effect of 
complexation on structure and physical properties of hydrogels. Dynamic and 
equilibrium swelling, molecular weight between crosslinks, and tensile strength were all 
found to be a function of solution pH, which in turn affected the complexation state of the 
hydrogel.  
Consequently, sufficient evidence indicates that P(MAA-g-EG) would perform 
well as an oral delivery device for protein therapeutics. Indeed, P(MAA-g-EG) has been 
used as an oral delivery carrier with salmon calcitonin [45, 46]  and insulin [34, 47-49]. 
The results were quite promising, and in vivo studies using P(MAA-g-EG) hydrogel 
particles to deliver insulin via an oral route were completed in rats [47, 50-53]. 
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This complexation hydrogel was a springboard for other anionic hydrogel 
materials designed to facilitate oral delivery of therapeutics. In an effort to reduce 
premature swelling while enhancing release of proteins at high pH, hydrogel 
microparticles comprised of MAA copolymerized with N-vinyl-2-pyrrolidone (NVP) 
were developed [54]. These hydrogel particles were effective at loading insulin, 
protecting the therapeutic in gastric conditions, and releasing on a time scale relevant to 
that needed for delivery to the upper small intestine [55]. Additionally, the material was 
well-tolerated by cells, causing minimal toxicity at all concentrations tested [56].   
Anionic hydrogels continue to be widely investigated as oral drug delivery 
carriers, and much of the research is devoted to overcoming limitations such insufficient 
loading and release of large, oppositely charged, or hydrophobic molecules and 
increasing mucoadhesive properties [26, 57-61]. As an alteRNAtive to anionic hydrogels 
and their inherent shortcomings, biodegradable and multi-responsive hydrogel 
formulations are of great importance to the development of the field of hydrogel-based 
drug delivery.  
2.2.2 Biodegradable Hydrogels 
A chief limitation of pH responsive hydrogels used in drug delivery is their 
inability to be degraded biologically [29]. Biodegradable synthetic polymers for drug 
delivery applications include polyglycolides, polylactides, poly(ε-caprolactone), and 
polyanhydrides [62]. However, natural polymers such as polysaccharides are also 
frequently used due to their wide availability, biocompatibility, chemically reactive 
functional groups and facile modification [63]. Polysaccharides commonly used in 
hydrogel synthesis include alginate, collagen, chitosan, and dextran [64, 65].  
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The polysaccharide dextran is instrumental in colon-targeted drug delivery as it is 
degraded by enzymes produced by bacteria belonging to the Bacteroides genus [66], 
which are significantly more abundant within the colon than other portions of the GI 
tract. In fact, bacterial concentration in the colon is ~10
11 
cfu/ml, with Bacteroides 
bacteria making up a large portion [14]. Dextranases produced by these bacteria 
hydrolyze the glucosidic linkages in dextran chains [67], pictured in Figure 2.2. 
Dextran has been used as a prodrug for colonic delivery of therapeutics for 
decades, and incorporation into hydrogel networks followed suit. In 1995, Hennink et al. 
[68] published a new procedure for methacrylation of dextran which allowed greater 
control over the degree of substitution as well as resulted in yields of 70-90%. The 
methacrylated dextran was then polymerized to form dextran hydrogels, which were 
loaded with Immunoglobin G to evaluate degradation of the gel and release of the protein 
over time [69]. It was found that incorporation of spacers containing hydroxyethyl groups 
could be used to tailor the degradation time of the hydrogel in physiological conditions, 
which was on the order of 1-2 months. Release of the protein was strongly dependent on 
the composition of the hydrogel, and took over a month to reach 100% release, if at all.  
Hovgaard and Brøndsted [70] studied the degradation of dextran hydrogels of 
different molecular weights in vitro in a dextranase solution, as well as in in vivo in rats. 
Increasing the molecular weight of the dextran resulted in hydrogels with a lower degree 
of equilibrium swelling and higher mechanical strength. Release of hydrocortisone was 
greatly improved in the presence of dextranase; 100% release was achieved in 
approximately 2 hours.  
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Proteolytic degradation of hydrogels comprised of polypeptides is also a popular 
targeted degradation mechanism. Enzymatic degradation of peptides and proteins is 
highly selective and biocompatible, making it an attractive mechanism to tailor hydrogels 
for targeted delivery to sites of specific enzymatic activity or overexpression, such as the 
small intestine, mucosa, or even regions of diseased tissue [71, 72]. The lumen of the 
small intestine, for example, contains gram quantities of pancreatic peptidases, which 
consist of the serine proteases α-chymotrypsin, trypsin, elastase, and carboxypeptidases 
[73]. Additionally, there is evidence indicating high levels of serine protease activity in 
the intestine and fecal content of patients suffering with certain types of inflammatory 
bowel disease or irritable bowel syndrome [74, 75].  
Enzyme-degradable oligopeptide crosslinkers are quite prevalent in tissue 
engineering applications [76-78]. Though their use in drug delivery devices has also been 
reported, instances are far fewer. Kopeček et al. [79] published a number of studies 
during the 1980s-1990s describing the synthesis, characterization, and degradation of 
hydrogels degradable by various enzymes, including chymotrypsin. The hydrogel was 
composed of N-(2-hydroxypropyl) methacrylamide crosslinked with oligopeptide 
sequences of varying length and composition. Results showed that the rate of enzymatic 
degradation was dependent upon the structure and length of the peptide sequence, as well 
as degree of swelling of the gels. The study was expanded upon by investigation of the 
release of macromolecules and drugs from the degradable hydrogels [80]. Though 
complete degradation took hundreds of hours, 100% release of the molecules was 
achieved in less than 24 hours. 
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A separate study described controlled release of a therapeutic by enzyme-
responsive swelling of a hydrogel [81]. The PEG-acrylamide hydrogel contained an 
enzyme cleavable linker that leaves the gel with a cationic charge following enzyme 
hydrolysis, causing the gel to swell and release dextran molecules. The hydrogel particles 
were most responsive to the enzymes elastase and thermolysin, and degradation and 
release were evaluated over the course of an hour.   
Nanoparticles incorporating a peptide crosslinker degradable by the enzyme 
cathepsin B have also been synthesized as an intravenously injectable delivery system 
[71]. The particles were loaded with DNA or antibody prior to incubation in a solution of 
cathepsin B to measure the release of each therapeutic. The nanoparticles showed signs of 
degradation in as little as 30 minutes after addition of the enzyme, and were fully 
degraded within 24-48 hours. Though a small amount of the DNA or antibody was 
released prior to exposure to the enzyme, most of the therapeutic was released upon 
degradation.  
Polysacccharide- and oligopeptide-based crosslinking agents have many 
appealing attributes for drug delivery, such as release of payloads on a relevant time 
scale, complete degradation allowing release of large molecules, and site-specific 
enzymatic degradation. 
2.2.3 Multi-responsive Hydrogels 
Hydrogels with specific, tunable, and even reversible responses to environmental 
stimuli have been known for decades as excellent candidates for drug delivery [29, 82] 
and regenerative medicine [24, 25] applications. The Peppas lab and many others have 
dedicated careers to developing complexation and responsive hydrogels suitable for 
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delivery of delicate therapeutics [26, 54, 83-85]. Likewise, innumerable researchers have 
used chitosan [86, 87], poly(N-isopropyl acrylamide) [88] and various other natural and 
synthetic responsive polymers [89] in the areas of tissue engineering and regenerative 
medicine for many years. 
However, the need for a material with both broad utility and increased specificity 
to the application is ever-present. The fourth generation of biomaterials, known as ‘smart’ 
or biomimetic materials that respond to the host environment, is evolving into 
sophisticated materials that respond to multiple stimuli in order to better mimic biological 
processes [90]. Multi-responsive hydrogels are a prime example of these advanced 
systems. These composite, interpenetrating polymer network (IPN) or supramolecular 
hydrogels respond to two or more environmental stimuli, including pH, temperature, 
photons, enzymatic, redox potential, electric or magnetic field, or analyte concentration. 
The output of these functional materials is contraction, swelling, degradation, color 
change, etc., and the exact response may be manipulated by tuning the polymer chemistry 
[28, 30]. This has tremendous advantages in terms of physiological compatibility and 
biomimetic properties [91-93], targeted drug delivery [94], controlled release [95], and 
directed cell growth [96, 97]. 
A multi-responsive hydrogel system can be designed to deliver a therapeutic in 
response to specific analyte presence. As shown by Gu et al. [95], such a system can have 
important implications as a closed-loop treatment for diabetes. Uniform chitosan 
microgels containing insulin and glucose oxidase and catalase nanocapsules were formed 
by a facile electrospray procedure. In the presence of hyperglycemic glucose 
concentrations, the microgels swelled significantly as the enzymatic nanocapsules 
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converted glucose to gluconic acid, enabling the protonation and swelling of chitosan 
chains in the increasingly acidic solution. In these conditions, insulin was released 
steadily over about three hours and was even shown to decrease blood glucose level in 
diabetic mice. The built-in delivery trigger via enzymatic nanocapsules certainly 
enhances the specificity of the response and has great potential for closed-loop delivery, 
but likely would not prevent the microgels from swelling in acidic conditions without the 
presence of glucose. 
Other researchers have developed multi-responsive hydrogel systems that require 
the presence of both stimuli to elicit a response in the material. For example, to achieve 
release of lipid microspheres from an IPN of gelatin and dextran, the presence of both 
dextranase and α-chymotrypsin was required [98]. Upon exposure to just one of the 
enzymes, released of the microspheres was negligible. The requirement of both enzymes 
for release imparts the system with a very high level of delivery specificity, which could 
potentially be tuned to target diseased regions that express a particular combination of 
enzymes.  
Hydrogels incorporating multiple responses can also be useful in encapsulating 
and delivering multiple drugs with different properties. Lv et al. [99] proposed selective 
release of one of multiple encapsulated molecules in response to a specific stimulus, i.e. 
releasing one payload in response to pH and one in response to chemical reduction. This 
was achieved by using a redox and pH sensitive polymer, polyaniline, to create 
nanocontainers that encapsulated the first molecule of interest. The nanocontainers were 
then decorated with gold nanoparticles that could be loaded with a second molecule. The 
molecule contained in the polymer shell was shown to be released only as a function of 
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increasing pH, while the second molecule loaded onto the gold nanoparticles was 
released only as a function of concentration of reducing agent. Though the authors 
proposed this selective release system for anti-corrosion applications, it could easily be 
translated to biomedical applications such as drug delivery given the dynamic 
physiological pH environments and reductive intracellular environments.   
With respect to oral drug delivery, multi-responsive hydrogels that are both pH-
responsive and enzymatically biodegradable are of abundant utility as they can capitalize 
on both the drastic change in pH in transition from the stomach to the intestine as well as 
the local concentration of enzymes in specific regions of the intestine. Biodegradable 
amino acids with free carboxylic acid groups such as poly(aspartic acid) (PASP) and 
poly(glutamic acid) (PGA) have been used by many researchers to develop smart 
hydrogels, since they have both a pH and biodegradable response [100]. Interestingly, 
Jiang et al. [101] found that the acid groups of PASP can be used to complex with gelatin 
to tune the response to stimuli as well as interactions with therapeutics. In the case of 
PASP prepared alone, loading and release of a model drug was highly dependent on pH 
and ionic strength of the environment whereas is it was faster, more predictable, and 
more consistent across pH and ionic strengths when PASP was complexed with gelatin.   
Gao et al. [102] developed copolymer hydrogels containing pH-sensitive 
poly(acrylic acid) derivatives (PAAD) of varying hydrophobicity and biodegradable PGA 
for the oral delivery of insulin. PGA is a polypeptide with a molecule weight that is easily 
controlled, and it is known to be biocompatible and biodegradable. The copolymer 
hydrogels were found to have a swelling response at pH 4-5 regardless of PAAD 
hydrophobicity, which is desirable for oral delivery applications, while the extent of 
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swelling was reduced with the incorporation of more hydrophobic PAAD. The hydrogels 
exhibited some degradation upon exposure to simulated gastric fluid (SGF) containing 
pepsin, but the weight degradation was significantly more rapid upon exposure to 
simulated intestinal fluid (SIF) containing pancreatin enzymes. Additionally, release of 
insulin was significantly greater in SIF than SGF.  
Casadei et al. [103] developed a pH- and enzymatically-responsive hydrogel 
using biodegradable methacrylated dextran crosslinks and the pH-responsive succinic 
acid derivative of the polyaminoacid known as methacrylated α,β-poly(N-2-
hydroxyethyl)-DL-aspartamide. This hydrogel was designed for colonic delivery of an 
antiangiogenic drug for the treatment of colon-rectal cancer. Upon exposure to simulated 
gastrointestinal fluids, the hydrogel swelled minimally in simulated SGF but swelled 
dramatically in SIF. Following 24 hours of incubation with enzymes dextranase or 
esterase, however, the hydrogels showed loss of mass in conjunction with increased 
weight swelling, indicating partial degradation. This system also demonstrated increased 
drug release in the presence of SIF containing enzymes compared to SIF without 
enzymes.   
Another study utilized a different polysaccharide, konjac glucomannan (KGM), 
with methacrylic acid to synthesize an IPN hydrogel that was both pH responsive and 
degradable [104]. The IPNs underwent a phase transition beginning at pH 5 regardless of 
MAA mass ratio, but the degree of swelling was generally increased with higher 
incorporation of MAA at pH 7.4. Inversely, IPNs with greater mass ratio of KGM 
generally experienced greater mass loss over time upon exposure to the enzyme 
mannanase. Interestingly, IPNs incubated with just pH 7.4 buffer or buffer with 
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pancreatin experienced little to no mass loss over time, indicating that the KGM was 
degraded solely by mannanase. Drug release was controlled by both pH and enzyme 
exposure, with greatest release measured in pH 7.4 buffer containing enzymes. This can 
likely be attributed to the effect of pH of enzyme activity.  
Similarly, Yang et al. [105] developed IPN hydrogels using pH-responsive 
chitosan derivatives and biodegradable alginate to achieve comparable pH-responsive 
drug release behavior. However, this system experienced an undesirable “burst” release 
of drug at low pH and the biodegradation of the material was not specifically studied, 
though it was hypothesized to contribute to the increased drug release at high pH.  
These are only a few of the many strategies employed to achieve oral delivery of 
delicate therapeutics to the intestine via hydrogels. As there are advantages to each 
approach, a delivery vehicle which incorporates elements of each strategy might be able 
to consistently deliver a therapeutic to a specific portion of the intestine while 
maintaining its bioactivity.  
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Figure 2.1: Anatomy of the gastrointestinal tract. 
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Figure 2.2: The chemical structure of dextran, showing glucose subunits linked by α-1,6 
glucosidic linkages. 
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Chapter 3: RNA Background1 
In 1998, Fire and Mello published a seminal paper [1] describing the potent, 
specific, and heritable gene silencing effect of double-stranded RNAs. Their discovery of 
this endogenous gene silencing pathway, termed RNA interference (RNAi), earned them 
the Nobel Prize of Medicine in 2006. Shortly following the initial discovery, it was found 
that RNAi could be initiated by synthetic small interfering RNA (siRNA) in mammalian 
cells [2]. Together, these discoveries were heralded as a major development in medicine 
with great potential for clinical applications.  
3. 1 RNA INTERFERENCE 
3.1.1 Mechanism 
The molecules known as small interfering RNAs (siRNAs) are fragmented pieces 
of double-stranded RNA about 21-23 nucleotides in length that induce RNAi by 
facilitating the selective cleavage of perfectly complementary messenger RNA (mRNA) 
strands, depicted in Figure 3.1 [3]. Following introduction in the cell cytosol, siRNA is 
loaded with protein Argonaute-2 (AGO-2) into the RNA-induced silencing complex 
(RISC) [4]. There, AGO-2 cleaves the sense-strand of the siRNA, activating the RISC 
[5]. The anti-sense strand serves to guide the activated RISC to seek out and pair with 
complementary mRNA [6, 7]. Finally, AGO-2 is responsible for the cleaving of the 
mRNA strand, inhibiting translation of mRNA into protein and thereby silencing that 
specific gene [8]. The activated RISC then continues to cleave many other strands of 
                                                 
1 Portions adapted from Knipe, J.M., Peters, J.T., and Peppas, N.A., Theranostic agents for intracellular 
gene delivery with spatiotemporal imaging. Nano Today, 2013. 8(1): p. 21-38. Knipe specifically 
contributed the gold nanoparticle and quantum dot sections, Peters specifically contributed the magnetic 
nanoparticle section, and Peppas oversaw the project.  
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complementary mRNA, exemplifying the potency of RNAi [9]. In fact, the therapeutic 
effect of siRNA has been observed for up to a week in rapidly dividing cells, and on the 
order of weeks in non-dividing cells [10]. 
3.1.2 Therapeutic Potential 
The therapeutic potential of RNAi was immediately identified and articles 
suggesting the possible impact of RNAi as a treatment for various disease targets began 
appearing in rapid succession [11-13]. Novina et al. [14] demonstrated in 2002 the ability 
of siRNA to silence a principle receptor for HIV-1 on HeLa-derived cells, thereby 
inhibiting cellular entry of the virus. While siRNA targeted to a gene within the virus was 
also shown to inhibit virus replication in HeLa-derived cells, the researchers found that 
transfection efficiency and expression reduction was much lower in primary cell lines 
such as a more therapeutically relevant T-cell line. In a similar approach, Gitlin et al. [15] 
showed the ability of two virus-specific siRNAs to suppress replication and provide 
immunity from a different RNA virus, poliovirus, in HeLa cells. Both of these studies 
provided proof-of-concept of siRNA as a treatment for a viral disease, but also identified 
the need for an improved transfection mechanism for primary cell targets. 
One of the first reports of RNAi in vivo also appeared in 2002, when McCaffrey 
et al. [16] delivered naked firefly luciferase siRNA or unrelated siRNA using a 
luciferase-expression plasmid to the liver of mice. By monitoring luciferase expression 
via whole-body imaging, the researchers showed that the inhibition of luciferase 
expression was specifically achieved only by the luciferase-specific siRNA, reducing 
expression by an average of 81%. Additionally, the researchers demonstrated therapeutic 
potential by targeting human hepatitis C virus expressed within mice. In this case, the 
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siRNA was successful in reducing virus expression by 75%, suggesting feasibility as a 
therapeutic. However, the authors acknowledged that delivery of siRNA was a “major 
obstacle” and could perhaps take advantage of viral and non-viral gene vectors for 
improved therapeutic effect.  
Less than a year later, Sørensen et al. [17] published their results on the ability of 
synthetic siRNAs to knockdown tumor necrosis factor-α (TNF-α) expression in adult 
mice. Not only was anti-TNF-α siRNA capable of reducing target protein expression in 
murine macrophage cells, but it also reduced expression in mice and protected them from 
lipopolysaccharide-induced sepsis as indicated by a higher survival rate compared to 
mice treated with inactive siRNA. This was a key advancement, demonstrating that 
siRNAs have the ability to reduce expression of pathogenic proteins in vitro and in vivo, 
opening the door for numerous protein expression targets. However, the authors noted 
that the therapeutic effect of a single dose of siRNA was only about 4-6 days.  
In the decade or so since, the volume of siRNA research has grown tremendously, 
therapeutic targets for treatment of diseases including cancer, neurological diseases, and 
infectious diseases, continue to be identified [18-20], and companies are racing to 
develop siRNA products and bring them to market [21, 22]. It is noteworthy that thus far 
the primary modes of administration of siRNA therapies are topical, local injection, and 
systemic administration to the eye, skin, kidneys, liver, spleen, or tumors [23]. A 
successful mechanism for oral delivery of siRNA has yet to be developed, though such a 
formulation would be especially conducive to treating diseases of the gastrointestinal 
(GI) tract like inflammatory bowel disease (IBD) or celiac disease.  
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Inflammatory bowel disease (IBD) can be classified into two routes of 
pathogenesis known as ulcerative colitis and Crohn’s disease, which collectively affect 
1.5 million people and cost more than $6.3 billion annually in the United States [24]. 
Though the exact cause of IBD is unknown, it is thought to be an aberrant immune 
response to microflora in the gut within a genetically susceptible host [25]. The resultant 
inflammation affects the colon and rectum in patients with ulcerative colitis, but can be 
present anywhere along the GI tract in patients with Crohn’s disease [26]. Symptoms of 
IBD can include diarrhea, abdominal pain, rectal bleeding, weight loss, malnutrition, and 
fatigue, and usually manifest in early adulthood or between the ages of 50-70 [27]. 
There is no cure for IBD, but treatment options do exist and are dependent upon 
the severity and location of the inflammation. Adjunctive agents, diet, and surgery can be 
used to manage symptoms and combat complications such as osteoporosis and cancer, 
but these do not treat the underlying inflammation [26]. 5-Aminosalicylate–based 
compounds and corticosteroids have been used to treat mild to severe IBD, but come with 
a range of uncomfortable to serious side effects such as headache, nausea, diarrhea, 
osteoporosis, hypertension, and diabetes due to their lack of specificity to the 
inflammation site [24, 26, 28]. When these treatments are no longer effective, the patient 
may resort to weekly injections of an immunomodulatory drug, but several weeks of 
treatment are needed before results are observed and the patient is prone to serious 
infection [26]. 
AlteRNAtively, IBD can be treated by targeting the cytokines which signal the 
inflammatory response. In particular, tumor necrosis factor-α (TNF-α) is secreted in high 
levels by macrophage and dendritic cells in patients with IBD [25]. The anti-TNF-α 
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monoclonal antibody treatment infliximab has been demonstrated as an effective 
treatment in studies where the therapeutic was administered by infusion three times over 
a six week period [26, 27]. However, the mechanism and long-term efficacy of this drug 
is unknown, and it is quite expensive [26]. In a similar strategy, anti-TNF-α siRNA may 
be used to silence production of TNF-α and treat patients suffering from IBD [29-33]. 
Celiac disease is a second condition of the GI tract that may benefit from oral 
delivery of siRNAs. Celiac disease is an autoimmune disease of the small intestine, in 
which T-cells initiate an inappropriate immune response to ingested gluten protein in 
genetically susceptible people, destroying the villi and crypts of the small intestine [34]. 
The disease is associated with human leukocyte antigen (HLA) DQ2 and DQ8, which are 
expressed on macrophages and dendritic cells and serve to bind and present the gluten 
peptides to T cells which initiate a Th-2 (autoimmune) or Th-1 (inflammation) response 
[35, 36]. 
Celiac patients suffer from symptoms such as abdominal pain, diarrhea, and 
weight loss, and if untreated the condition can lead to other diseases like diabetes, iron 
deficiency anemia, or autoimmune disorders [36, 37]. In most cases, a gluten-free diet 
(GFD) is sufficient to reduce or eliminate symptoms and reverse damage [34]. However, 
inadvertent exposure to gluten occurs in up to 30% of patients, resulting in nonresponsive 
celiac disease [37]. Additionally, patients on a GFD may still present symptoms as a 
result of associated or secondary conditions [37]. 
Like IBD, celiac disease is associated with high expression of cytokines such as 
TNF-α [36] and interferon-ϒ [35]. Orally delivered siRNA could be used to silence 
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expression of these cytokines, providing an alteRNAtive treatment to patients who are 
nonresponsive or unable to achieve a sufficient GFD. 
Thus, the therapeutic potential of siRNA has been well established and various 
worthwhile oral delivery targets do exist. As many researchers have noted since the 
identification of RNAi as a therapeutic mechanism, the principal challenge lies in 
delivering genetic material within a cell to initiate the gene silencing machinery.  
3.2 DELIVERY OF SIRNA 
As applications for siRNA-mediated gene silencing are ever-growing, there is a 
need to develop effective carriers that can withstand various administration methods and 
overcome physiological barriers to deliver siRNA within cells. It is generally accepted 
that the single biggest obstacle to effective and marketable siRNA therapies is delivery 
[19, 20], and consequently any success with in vivo trials has been limited. 
3.2.1 Challenges to Delivery of siRNA 
The many barriers to effective delivery of siRNA are shown schematically in 
Figure 3.2. The first challenge in delivery of siRNAs is their lack of stability; unmodified 
siRNA are highly susceptible to degradation by endogenous enzymes along the GI tract 
as well as renal clearance, resulting in a half-life on the order of minutes in serum [38]. 
Additionally, unmodified siRNA duplexes are especially labile in acidic conditions such 
as gastric conditions or the environment within lysosomes and endosomes [21].  
After reaching the site of delivery whether by direct, systemic, or oral 
administration, biologically active siRNA must cross the cell membrane into the cell 
cytoplasm for RNAi to transpire, depicted schematically in Figure 3.3. Besides low 
bioavailability due to degradation, siRNA are large molecules (~13 kDa) with a net 
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negative charge, making transport into the cell cytoplasm a formidable prospect [23]. The 
negatively charged mucus lining the GI tract, shown in Figure 3.2, is particularly 
challenging to cellular uptake. The siRNA typically enter the cell by an active transport 
mechanism such as endocytosis. Even after cellular uptake, though, delivery challenges 
exist. The therapeutic must escape the endosome to the cytoplasm, where it can avoid 
lysosomal degradation and proceed with RNAi [39].  
Chemical modifications to siRNA such as phosphorothioate modifications or 
replacement of sugars have been shown to increase serum stability, cellular uptake, and 
cytosolic release of siRNA [21, 40, 41]. For example, Soutscheck et al. [40] delivered 
modified siRNA that was conjugated with cholesterol via tail-vein injection in mice to 
achieve knockdown of the apolipoprotein B mRNA. Results indicated that cholesterol 
conjugation was necessary to achieve delivery of active siRNA and consequent 
knockdown of mRNA expression via the systemic administration route, likely because 
the conjugated cholesterol mediated cell uptake. This study was promising in that 
modified siRNAs could achieve silencing of an endogenous gene by systemic 
administration, but it left room for further modifications and improvements to increase 
efficacy, as high dosages were required. It is possible that once the siRNA was taken up 
into the cell it became trapped and degraded in an endosomal compartment. 
Therefore, transfection vectors, either viral or nonviral, have become widely used 
in conjunction with chemical modifications to improve siRNA stability and delivery into 
the cell cytosol. Viral vectors, though extremely effective with long-lasting effect, can 
present deleterious or even fatal side effects such as endogenous virus recombination, 
oncogenic effects, and unanticipated immune response [42]. In addition to those risks, a 
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stoichiometric excess of siRNA within the cell could saturate the RNAi mechanism and 
interrupt normal cell function and processes, leading to unexpected side effects [20]. 
Nonviral vectors such as nanometer-scale liposomes and polymeric hydrogels avoid these 
undesirable effects while enhancing intracellular delivery of siRNA by increasing half-
life circulation, facilitating cellular uptake and endosomal escape, and employing 
functionalization and targeting schemes [3, 43]. Polymer nanoparticles are particularly 
advantageous because they offer increased protection of the therapeutic, greater control 
over size, structure, and surface charge, they can be functionalized with poly(ethylene 
glycol) (PEG) or targeting ligands to increase bioavailability and cellular uptake, and 
synthesis is scalable [23, 38].  
3.2.2 Cationic Polymer Systems 
The surface charge of a synthetic vector greatly affects its interaction with both 
therapeutic molecules and surrounding cells [23]. The primary advantage of cationic 
surfaces is their ability to form condensed complexes with siRNA due to electrostatic 
interactions [44]. Cationic surfaces are also known to induce increased cellular uptake 
due to ionic interaction with the negatively charged cell surface [45]. Hence, most 
synthetic vectors are comprised of cationic lipids or polymers to capitalize on these 
surface properties with the goal of enhancing cellular uptake of siRNA. 
Polycationic nanoparticles provide one additional advantage- due to the high 
charge density on the repeat units of the polymer, they can induce what is known as the 
“proton sponge effect” [46]. It is generally accepted that polycationic nanoparticles are 
taken up into endosomal compartments that are gradually acidified; as the pH lowers, the 
cationic repeat units become protonated, inducing a flux of ions into the compartment, 
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which is known as the “proton sponge effect”. Eventually, the difference in osmotic 
pressure results in endosomal rupture, releasing the siRNA payload into the cell cytosol.  
Various cationic polymers have been used to design nanoparticles for gene 
delivery, some of the most common being polyethyleneimine (PEI), poly(L-lysine) 
(PLL), chitosan, and poly[2-(diethyleamino)ethyl methacrylate] (PDEAEMA) [47-51]. 
Recently, a novel UV-initiated emulsion synthesis of polycationic 2-(diethylamino)ethyl 
methacrylate nanoparticles crosslinked with tetra(ethylene glycol) dimethacrylate 
(TEGDMA) and grafted with PEG was developed by Fisher and Peppas [52]. 
PDEAEMA undergoes a phase transition near the physiologically relevant pH of 7.4, 
making it of great utility for drug delivery applications. It was determined that 
crosslinking density could be utilized to control the network mesh size and affect the 
loading of insulin and gold colloids. Consequently, higher crosslinking density also 
improved biocompatibility.  
Fisher et al. [53] improved upon the original PDEAEMA nanogel formulation by 
incorporating hydrophobic comonomers into the synthesis. They demonstrated the ability 
to tune the loading of protein with the hydrophobic comonomer, as well as functionalize 
primary amines with a targeting moiety via a zero-length linkage. Polycationic 
nanoparticles loaded with fluorescently-labeled albumin were shown to be taken up by 
two different cell lines. Considering the pH responsive behavior, size, and ability of these 
particles to be uptaken by cells, they had excellent potential as intracellular delivery 
vehicles. 
Liechty et al. [54] continued to develop and tune the pH-responsive properties of 
the PDEAEMA copolymer nanogels by comparing the effects of tert-butyl methacrylate 
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(TBMA) versus 2-(tert-butylamino)ethyl methacrylate (TBAEMA) as comonomers. The 
nanoparticles had a mean calculated dry diameter of approximately 50-65 nm and a 
hydrated diameter of approximately 90 nm regardless of copolymer composition. 
Interestingly, though, the copolymer composition could be used to tune the relative 
swelling volume as a function of pH, with the more hydrophobic TBMA formulations 
having a depressed pH phase transition point as a function of TBMA content.  
Expanding on the effect of polymer composition on physicochemical properties, 
Forbes and Peppas [55] investigated the effect of polymerization method on molecular 
structure. As components of the molecular structure such as hydrophobic clustering and 
cross-linking density can affect drug delivery performance, the authors compared the 
composition and structure of PDEAEMA nanogels prepared by UV-initiated 
polymerization versus activator regenerated by electron transfer (ARGET) atom transfer 
radical polymerization (ATRP). They found that the heterogeneity of nanoparticles was 
decreased by the ARGET-ATRP method, as evidenced by narrower molecular weight 
distribution and sharper temperature transitions.  
Forbes et al. [56] also compared the drug delivery properties of the polycationic 
nanogels prepared by the two synthesis methods. The ability to load a hydrophobic drug 
was comparable, but the biocompatibility and drug release was increased in the UV-
initiated formulations. However, the differing structural properties of the UV-initiated 
and ARGET-ATRP nanogels made little impact when evaluated as carriers for siRNA 
delivery [57]. The siRNA binding, biocompatibility, and cellular uptake were not 
significantly different between nanogels synthesized by the two methods. As the 
ARGET-ATRP nanogels presented promising gene knockdown results, further 
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investigation was conducted using the ARGET-ATRP formulation with the greatest 
TBMA content to evaluate various transfection conditions to optimize cellular uptake of 
the particles and gene silencing effect in murine macrophage cells [58]. Cellular uptake 
of the nanogels was confirmed by confocal microscopy and was determined to be a 
function of both nanogel concentration and incubation time. Knockdown experiments 
using AllStars death siRNA also showed the dependence of gene silencing on both 
nanogel and siRNA concentration. 
Over the past 6 years, the composition and architecture of the PDEAEMA 
nanogels has been tuned to arrive at a formulation with desired pH response, excellent 
siRNA binding, acceptable cell uptake, and measurable gene silencing effect. However, 
drawbacks to cationic polymer nanoparticle delivery vehicles include their inherent 
toxicity and unspecific reactions with proteins and molecules systemically [50, 59]. 
Additionally, polycationic polymers are charged and unstable in the low pH regime, such 
as that in the stomach, making them unsuitable for oral delivery applications. There is a 
need to further modify this delivery system to make it suitable for oral delivery 
application without appreciable toxic effect. Also of interest is incorporation of a tracking 
modality to better monitor and study systemic distribution, cellular uptake, and clearance 
from the body.  
3.2.3 Theranostic Systems 
A biomaterial or device that not only delivers a therapeutic but also possesses a 
targeting or imaging modality is known as a “theranostic” agent and could have 
monumental utility in siRNA delivery. Such theranostic agents enable improved disease 
treatment due to targeted delivery and the ability monitor particle localization in a 
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noninvasive manner [60]. Theranostic agents are typically comprised of nanoscale 
inorganic particles, such as gold or iron oxide, modified with a lipid or polymeric coating 
and targeting moiety, and finally loaded with a therapeutic agent. Many theranostic, 
inorganic-based particles for the delivery and spatiotemporal tracking of oligonucleotide 
transfection and gene therapy are summarized in Table 3.1.  
Gold nanoparticles have been used to study aspects of gene delivery such as 
serum stability and Dicer recognition, essential components of RNAi [61]. Mirkin et al. 
developed gold nanoparticles functionalized with fluorescein-labeled siRNAs. Since the 
gold quenches the fluorescent signal from the fluorescein, the fluorescence intensity will 
increase upon degradation and cleavage of the siRNA from the gold nanoparticle. The 
siRNA-Au-NP, with various commonly used types of siRNA, were incubated with either 
Dicer to test specific cleavage or FBS to test nonspecific degradation. A greater increase 
in fluorescence intensity demonstrated that Dicer has a preference for siRNA with a 3’ 
overhang, though these siRNA were also more 10-15-fold more susceptible to 
nonspecific degradation. The serum stability of chemically modified siRNAs was then 
tested, and the results showed that these modifications can decrease nonspecific 
degradation by ~40%, but Dicer recognition was decreased by ~60%. Finally, the 
researchers found that serum stability depended upon the orientation of the siRNA on the 
nanoparticle; siRNA with the more thermally stable base pair distal to the nanoparticle 
experienced greatly reduced nonspecific degradation while maintaining comparable Dicer 
recognition. As might be expected, increased serum stability enhanced cellular uptake by 
300% and resulted in ~85% GFP knockdown. 
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Research has been done in the area of targeted intracellular delivery of siRNA 
using hyaluronic acid (HA) to induce HA-mediated endocytosis [62]. Cysteamine-
modified gold nanoparticles (AuCM) were coated with siRNA, PEI, and HA by layer-by-
layer assembly. Addition of each layer was confirmed by TEM, atomic force microscopy, 
UV-Vis, and zeta-potential measurements. The AuCM/siRNA/PEI/HA complexes were 
stable in serum-containing media up to 24 hours, presenting no aggregation or 
precipitation. Cellular uptake of the complexes was visualized by TEM after 24 hours of 
incubation with B16F1 cells; the complexes were distributed throughout the cytoplasm 
with no large aggregates present. An MTS cell viability assay showed cell viability of at 
least 90% for the AuCM/siRNA/PEI/HA complexes as well as the various controls. Anti-
luciferase siRNA was used to determine a gene silencing efficiency of ~50% for 
AuCM/siRNA/PEI/HA complexes in 10 vol% serum. In 50 vol% serum, silencing 
efficiency of the AuCM/siRNA/PEI/HA complexes improved to 70-80%, which may be 
attributed to the stability of this formulation in serum. This highlights the large effect 
protein adsorption and serum stability may have on intracellular uptake. Anti-VEGF 
siRNA was also tested, and RT-PCR showed ~70% reduction in gene expression, which 
outperformed the 20% reduction by siVEGF/Lipofectamine 2000. Dark field microscopy 
confirmed that cells with HA receptors did uptake AuCM/siRNA/PEI/HA complexes, but 
the same cells pretreated with HA did not, demonstrating effective targeting of the HA 
receptors by the complexes. Gene knockdown results corresponded with cellular uptake; 
gene silencing in the presence of free HA was significantly lower than that without free 
HA. Finally, the target-specific systemic delivery of the AuCM/siRNA/PEI/HA complex 
with anti-ApoB siRNA to the liver was tested. Following injection into the tail-vein of 
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Balb/c mice, most of the complexes accumulated in the liver and spleen, as determined 
by inductively coupled plasma-atomic emission spectroscopy. The ApoB mRNA in the 
liver was reduced to ~20%, demonstrating effective target-delivery and gene down 
regulation. 
Quantum dots (QDs) have been considered as potential gene delivery devices due 
to their convenient size and inherent stability against photobleaching while imaging, 
making them an effective theranostic agent. QDs have also enabled imaging of individual 
molecules within the cell environment, which can be particularly useful in gene silencing 
therapies.One of the earliest reports appeared in 2005, in which QDs were used to 
monitor siRNA transfection [63]. A conventional transfection agent, Lipofectamine 2000 
(Invitrogen), was loaded with both CdSe-core ZnS-shell QDs and siRNA targeting the 
Lamin A/C gene. Fibroblast cells were then transfected with the loaded liposomes for 5 
hours. Following transfection, siRNA uptake and silencing efficacy was measured by 
flow cytometry, western blotting, and immunofluorescence staining. Cells transfected 
with QDs and siRNA showed a strong correlation between gene silencing and 
fluorescence.  Additionally, cells transfected with QDs and siRNA underwent ~90% gene 
knockdown, while cells transfected with siRNA alone experienced only ~20-30% gene 
knockdown [63]. This paper demonstrated that not only are QDs a suitable probe to track 
siRNA delivery, but that they may also increase gene silencing efficiency. This study 
became a springboard for further investigation of QD-mediated siRNA delivery. 
Other research groups have terminated QDs with a positively charged molecule or 
coating such as chitosan [64] or other cationic polymers [65, 66] in an effort to achieve 
effective cellular transfection and gene knockdown with low cytotoxic effect from the 
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particles. One of the first reports utilized the endosome-disrupting polymer PEI, grafted 
with PEG to mitigate the cytotoxic effects associated with PEI [65].  (PEI-g-PEG) was 
attached to CdSe/CdS/ZnS QDs by a ligand exchange reaction, resulting in a 
hydrodynamic size of 21-22 nm. It was noted that the PEG grafted nanoparticles were 
quite stable in acidic conditions as well as biological media. Confocal microscopy was 
used to image the modified QDs, and it was observed that cellular uptake via endocytosis 
or macropinocytosis began as early as 1-2 hours into incubation. It was also noted that the 
amount of grafted PEG greatly influenced cellular uptake and intracellular distribution. 
QDs with four grafted PEG chains were apparently trapped in organelles, while QDs with 
only two grafted PEG chains had apparently escaped endosomal compartments and were 
released into the cytoplasm, as is necessary for effective siRNA delivery. However, QDs 
with four PEG chains displayed less cytotoxicity, as determined by a standard MTT 
assay. The ability to tune endosomal escape and cytotoxicity by grafted PEG chains gives 
a greater degree of control over the properties of the QD nanoparticle, though an optimal 
formulation was not reported.  
In a more recent report, L -arginine (L-Arg)-modified CdSe/ZnSe quantum dots, 
with or without β-cyclodextrin (β-CD), were used as siRNA delivery devices to silence 
the gene HPV18 E6 [67]. L-Arg provided a positive surface charge onto which negatively 
charged siRNA could be electrostatically bound, and β-CD had been shown to induce 
greater biocompatibility and lower cytotoxicity. HeLa cells were transfected with the 
QD/siRNA complexes for 24 hours, and cell viability remained >70% for QD 
concentrations less than 70 μg/mL over this period of time. Confocal microscopy was 
used to track the QD/siRNA location in real time. Fluorescence intensity measured by 
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flow cytometry was used to quantify cellular uptake. A gene silencing efficiency of 
nearly 80%, as well as 80% protein suppression was achieved using the QD/siRNA 
complexes, as determined by reverse transcription- polymerase chain reaction (RT-PCR) 
and western blotting, respectively. These values were greater than that of commercial 
transfection agents also tested [67]. 
Further expanding the dexterity of quantum dots, fluorescent resonance energy 
transfer (FRET) may be utilized to gather information regarding spatial conformation of 
QDs and siRNA within the cell. FRET is the transfer of energy from a donor fluorophore 
to an acceptor fluorophore across nanometer-scale distances, resulting in a lower 
fluorescence intensity for the donor and a higher fluorescence intensity for the acceptor 
[68]. FRET has been employed with QDs to observe the intracellular delivery of siRNA 
[69, 70] and DNA [71-73], though most studies utilize QDs as an imaging modality in 
addition to a polymeric or lipid-based transfection agent [74, 75]. 
In one study, electrostatic binding of FITC-labeled siRNA to amphiphilic 
polymer-encapsulated QDs was perceived by the quenching of the FITC signal via FRET 
induced by the excited QDs [70]. Time-lapse confocal microscopy was used to monitor 
the QD-siRNA intracellular interaction; at approximately 1.5 hours after transfection, the 
particles were present inside the cell and decomplexation between the QD and siRNA 
was indicated by the appearance of a signal in the FITC channel. At 5 hours post-
transfection, siRNA was dispersed throughout the cell. Increased death in cells 
transfected with HER2 siRNA compared to those transfected with random or no siRNA 
was indicative of endosomal escape and gene knockdown by RNAi, but was not 
conclusive. The amphiphilic polymer coating outperformed a conventional polymer, PEI, 
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and was comparable to the commercial transfection agent Lipofectamine in terms of gene 
silencing efficiency. The nanocomplex carrier has the added benefit of less cytotoxic 
effect than these other carriers [70]. Similarly, Lee et al. employed FRET to track the 
delivery of cyanine-labeled siRNAs electrostatically bound to the QD-PEI complexes 
[69]. The QD-PEI complexes displayed knockdown of the VEGF gene comparable to 
that of commercially available Lipofactamine.  
Theranostic inorganic nanoparticles are effective vectors for gene delivery, even 
outperforming standard transfection vectors in some instances, while providing 
mechanisms for targeting, imaging and tracking of gene delivery.  In recent years, gold, 
magnetic, and quantum dot nanoparticles have proven themselves superior in their ability 
to execute controlled and targeted delivery.  Advances in imaging technology have 
established the capability to image spatiotemporal gene transfection at the single-
molecule level with the aid of these theranostic particles.  These small successes have 
opened up new doors for the development of gene therapy options, yet the goal for highly 
efficient, specific in vivo delivery and tracking of oligonucleotides has still not been fully 
recognized.   
Recent research has focused on increasing transfection efficiency in vitro while 
minimizing cytotoxicity.  In order to successfully administer genetic therapies, the 
coatings that were successful in vitro need to be combined with common in vivo targeting 
mechanisms.  Some work has looked to combining these areas of research; however, the 
success has been limited to unique disease models, such as cancer.  Disease models 
without unique anatomies need to be pursed in order to test the limits of nanoparticle-
mediated gene delivery.   
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The success of nanoparticle theranostics will depend on the target diseases and the 
genes used to treat them.  The correct combination of nanoparticle, coating, and targeting 
mechanism will need to be tailored to each disease/gene combination.  Substantial 
progress has been made toward improving cytotoxicity and transfection efficiency, and 
future work needs to focus on treatment of specific disease models in vivo, as well as the 
development of real-time in vivo imaging capability.  Further, specific targeting 
mechanisms and minimum dosage levels must be determined in order for theranostic 
gene delivery to become a treatment standard.    
3.2.4 Oral Delivery Systems  
siRNA as a therapeutic has been a major area of research for well over a decade 
now, but the prevalent method of delivery is still by local injection or intravenous 
administration. In fact, of the thirty recent or active clinical trials involving siRNA 
therapy, at least twenty of the studies utilized these methods of administration and none 
administered the treatment orally [76]. The advantages of oral delivery, especially for the 
treatment of diseases of the GI tract, include elimination of systemic effects, increased 
patient compliance and comfort, and reduction of associated costs [77]. Though there 
have been only small number of groups investigating oral delivery of siRNA, several 
reviews highlighting the great potential as well as challenges of oral siRNA delivery have 
been published in recent years [78-80]. 
It is important to note that nearly all siRNA oral delivery strategies target TNF-α, 
a cytokine that signals the inflammatory response. High levels of TNF-α are associated 
with diseases of the GI tract such as Crohn’s disease, ulcerative colitis, and celiac 
disease, making it a logical target for gene knockdown by orally delivered siRNA [81]. 
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The first study aimed at developing an orally administered carrier for siRNA 
delivery was published in 2009, in which β1,3-ᴅ-glucan microshells were incubated with 
RNA-PEI complexes to form a cationic core, which was then loaded with Endo-Porter, a 
peptide to facilitate intracellular delivery, followed by fluorescently-labeled siRNAs 
targeting TNF-α, and finally an additional incubation period with PEI to trap the cargo 
[29]. Uptake of the β-1,3-ᴅ-glucan-encapsulated siRNA particles (GeRPs) by 
macrophages was observed in vitro using confocal microscopy, and 70-80% knockdown 
of target mRNA was measured after transfection. GeRPs with specific and scrambled 
siRNA sequences were then administered orally to mice; target mRNA expression was 
reduced by 70% and TNF-α expression was reduced by 80% compared to the scrambled 
sequence of RNA. At the dosage administered, this oral delivery formulation was up to 
250 times more potent in vivo than systemic delivery formulations that had been reported. 
However, the GeRPs were also found in other tissues throughout the body, indicating 
migration of macrophages containing the siRNA therapy and lack of tissue-specific 
targeting, which is not desirable. 
Amiji et al.[82, 83] developed a hybrid nanoparticle-in-microsphere (NiMOS) 
oral delivery system to the intestinal mucosa in which FITC-gelatin nanoparticles were 
embedded in a poly(ε-caprolactone) (PCL) matrix of less than 2-5 μm in diameter. This 
system has been used to encapsulate reporter plasmid DNA [82] and TNF-α specific as 
well as scrambled siRNA [30, 31] and has been administered orally to rats or Balb/c 
mice, respectively. In the case of the NiMOS containing TNF-α siRNA given to mice 
with induced colitis symptoms, the group receiving the formulation had the lowest TNF-α 
mRNA and protein expression compared to the controls at both 10 and 14 days after 
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administration. Though the NiMOS particles performed well in vivo, in vitro studies 
showed that some therapeutic was released prematurely (~20%) and performance of 
NiMOS through pH variation is unknown. 
In 2010, results were published describing thioketal nanoparticles (TKNs) loaded 
with siRNA against TNF-α for oral delivery to the intestines [32]. These particles were 
designed to be degraded by reactive oxygen species produced by phagocytes at the site of 
inflammation. It was shown that the TKNs localized delivery of siRNA to the colon of 
mice with induced colitis symptoms, and that TNF-α mRNA was reduced 10-fold by 
TNF-α-TKNs compared to the controls. The therapeutic effect of this siRNA carrier, 
however, is limited to diseases where intestinal inflammation is present.  
In 2011, Laroui et al. [33] published a report on branched PEI that was complexed 
with TNF-α siRNA, loaded into polylactide, and covered with polyvinyl alcohol in a 
multi-step synthesis process. The particles were then encapsulated in alginate or chitosan 
and administered orally to C57BL/6 mice. After four days of administration inflammation 
was induced in the mice by injection of lipopolysaccharide (LPS). Results indicated that 
the siRNA-loaded particles outperformed Lipofectamine in vitro, and in vivo the particles 
were targeted to the colon and effectively reduced LPS-induced TNF-α production. 
Though the efficacy of this system is promising, the synthesis of these multi-layered 
particles is laborious.  
In the past couple years, a number of papers describing the development of an 
oral delivery system for siRNA have come out of the Yin laboratory. Trimethyl chitosan-
cysteine conjugates (TMC-Cys) were initially synthesized using 10, 100, or 200 kDa 
chitosan to evaluate performance as a drug carrier with plasmids encoding enhanced 
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green fluorescent protein (pEGFP) [84]. It was thought that the tryimethyl and cysteine 
groups would improve interactions between chitosan and the epithelial mucosa during 
oral delivery to facilitate cellular uptake. Following formation of nanocomplexes via 
electrostatic interaction between the plasmid and TMC-Cys, the nanocomplexes were 
incubated with HEK293 cells. It was observed that release of the plasmid was increased 
in the presence of glutathione as it is capable of reducing disulfide bonds between the 
thiolated chitosan chains, a positive result as glutathione is present within cellular 
endosomes. Cell uptake and transfection by the plasmid were confirmed by increased 
GFP expression of the cells and were dependent upon the molecular weight of the TMC 
conjugates, with higher molecular weight chitosan performing better.  
As this system was promising with plasmid DNA, the researchers explored its 
capability to deliver siRNA, a much smaller molecule [85].  It was determined that TMC-
Cys conjugates electrostatically complexed with siRNA targeting interleukin 6 (IL-6) had 
increased stability and intestinal permeation when physically crosslinked via ionic 
gelation with sodium tripolyphosphate. Intestinal permeation is critical for a system 
administered orally to have systemic effect. This formulation was also shown to 
significantly reduce expression of IL-6 in RAW 264.7 murine macrophage cells 
compared to other TMC nanocomplex formulations.  
Next, the molecular weight of the TMC-Cys conjugates was further increased to 
100, 200, or 500 kDa chitosan, and nanoparticles were prepared complexation with 
siRNA targeting TNF-α followed by ionic gelation with sodium tripolyphosphate [86]. 
Nanoparticles were administered to mice via a single oral gavage or an intraperitoneal 
injection, and interestingly the expression of TNF-α was significantly reduced using the 
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200 kDa molecular weight formulation administered orally as compared to intraperitoneal 
administration.  
Finally, 200 kDa TMC-Cys conjugate nanoparticles were modified with mannose 
in an effort to improve intracellular uptake via interaction with mannose receptors on M 
cell surfaces [87]. These mannose-modified nanoparticles complexed with siRNA 
targeting TNF-α were effective in reducing serum levels of TNF-α over 4 hours 
compared to a scrambled siRNA sequence, and the effect was potent at various 
nanoparticle dosages. However, there was no comparison between mannose-modified 
and unmodified TMC-Cys nanocomplexes to confirm increased cellular uptake by virtue 
of the mannose molecule. Studies using uptake pathway inhibitors suggested that the 
mannose receptors mediated endocytosis of the nanoparticles, but were inconclusive. 
Nonetheless, the researchers have made great strides in developing a nanoparticle siRNA 
carrier that can overcome some of the challenges of oral delivery.  
Chitosan/siRNA nanoparticles were employed by a separate group of researchers 
for oral delivery to the gastrointestinal tract. Ballarín-González et al. [88] prepared 
nanoparticles by complexation between chitosan and fluorescently labeled anti-TNF-α 
siRNA, then administered them to mice by oral gavage. Though the design of the two-
component carrier is quite simplistic, the authors report siRNA stability at the higher 
chitosan to siRNA ratios in simulated gastric and intestinal fluids as evaluated by native 
polyacrylamide gel electrophoresis. Northern blot analysis from various gastrointestinal 
and other tissues indicated systemic distribution of siRNA following oral administration, 
as stable siRNA was accumulating in the liver, spleen, and kidney just 1 hour after 
gavage. However, the extent of accumulation in each location was a function of the 
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chitosan to siRNA ratio, most likely due to the influence of the chitosan on stability and 
cellular interactions. This study is remarkable for a couple reasons, first that oral delivery 
of intact siRNA was achieved with simple siRNA-chitosan complexes, and second that 
systemic distribution of siRNA is possible via oral administration.  
3.3 CONCLUSIONS 
RNAi has exciting potential as a gene therapy for many diseases, particularly 
diseases of the GI tract, but there are many extracellular and intracellular barriers to oral 
siRNA delivery. Additionally, oral delivery is advantageous in terms of cost and patient 
compliance. The current strategies for oral delivery of siRNA to the intestine are 
relatively few in number, but are effective in some capacity though they leave much 
room for improvement, particularly in terms of increasing cellular uptake, maintaining 
siRNA integrity, and increasing dosage efficacy. Consequently, there is great need to 
design an improved polymer carrier which can not only protect siRNA from harsh gastric 
conditions and target delivery specifically to the intestine, but can also facilitate cell-
specific uptake and endosomal escape into the cytoplasm where RNAi occurs. 
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Figure 3.1: Mechanism of RNAi with siRNA. Adapted from [3]. 
  
 
RNA-induced 
silencing complex 
(RISC) loading of 
siRNA 
Sense-strand 
cleavage 
Activated RISC 
Specific gene 
silencing 
  
 
57 
 
Figure 3.2: Barriers and challenges to the oral delivery of siRNA. Adapted from [81]. 
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Figure 3.3: Schematic of cellular uptake of siRNA delivery carrier, followed by 
endosomal escape and RNAi. 
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Table 3.1: Summary of inorganic theranostic particles used in gene therapy [121]. 
Particle  
Type 
Imaging Delivery/ 
release method 
Coating In vitro or  
in vivo 
Gene  
Therapy 
Ref. 
MNP Fluoresence Magnetofection Acidic/Neutral PEI In vitro DNA [89] 
MNP Fluoresence Magnetofection Chitosan In vitro DNA [90] 
MNP Fluoresence Magnetofection PEI In vitro DNA/siRNA [91] 
MNP Fluoresence Magnetofection PPI dendrimer In vitro/In 
vivo 
siRNA [92] 
MNP Fluoresence Magnetofection PAMAM 
dendrimer 
In vitro asODN [93] 
MNP Fluoresence Magnetofection Chitosan/PEI/PEG In vitro DNA [94] 
MNP Fluoresence Magnetofection ODN In vitro DNA [95] 
MNP Fluoresence Magnetofection PEI/DNA In vitro DNA [96] 
MNP MRI/ 
Fluoresence 
Magnetofection Dextran In vitro shRNA [97] 
MNP Fluoresence Magnetofection Cationic Lipid In vivo siRNA/DNA [98] 
MNP Fluoresence Magnetofection Cationic Lipid/PEI In vitro pDNA [99] 
MNP Fluoresence Magnetofection Cationic Lipid In vitro DNA [100] 
MNP Fluoresence Magnetofection Clustered PEI 
MNPs 
In vitro siRNA [101] 
MNP Fluoresence Magnetofection deacylated PEI In vitro pDNA [102] 
MNP Fluoresence Magnetofection DNA In vitro  DNA [103] 
MNP Fluoresence Magnetofection DNA In vitro DNA [104] 
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Table 3.1: Summary of inorganic theranostic particles used in gene therapy [121] 
(cont.). 
Particle  
Type 
Imaging Delivery/ 
release method 
Coating In vitro or  
in vivo 
Gene  
Therapy 
Ref. 
MNP Fluoresence Magnetofection Cationic 
Lipospheres 
In vitro siRNA [105] 
AuNR SERS, 
Fluorescence 
microscopy, 
Maestro 
N/A PEG In vivo 
(mouse) 
N/A [106] 
AuNP SERS, Dark-
field 
microscopy, 
TEM 
Electrostatic PEI/chitosan In vitro  shRNA [107] 
AuNS Fluorescence 
microscopy, 
Flow 
cytometry 
Laser-induced   In vitro ssDNA [108] 
AuNS Fluorescence 
microscopy, 
Dark-field 
microscopy 
Laser-induced  L-lysine  In vitro siRNA, 
ssDNA 
[109] 
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Table 3.1: Summary of inorganic theranostic particles used in gene therapy [121] 
(cont.). 
Particle  
Type 
Imaging Delivery/ 
release method 
Coating In vitro or  
in vivo 
Gene  
Therapy 
Ref. 
AuNS Fluorescence 
microscopy, 
TEM 
Laser-induced  PEG, lipid bilayer, 
Tat peptide 
In vitro siRNA [110] 
AuNP Fluorescence 
microscopy 
Dicer cleavage  In vitro siRNA [61] 
AuNP Light 
microscopy 
Dicer cleavage  In vitro miRNA [111] 
AuNP TEM, Dark-
field 
microscopy 
Electrostatic PEI, Hyaluronic 
acid 
In vitro siRNA [62] 
AuNR Dark-field 
microscopy 
Electrostatic Polyelectrolytes In vitro siRNA [112] 
AuNP TEM, 
Fluorescent 
microscopy 
N/A N/A In vitro N/A [113] 
AuNP TEM, 
Fluorescent 
microscopy 
N/A N/A In vitro N/A [114] 
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Table 3.1: Summary of inorganic theranostic particles used in gene therapy [121] 
(cont.). 
Particle  
Type 
Imaging Delivery/ 
release method 
Coating In vitro or  
in vivo 
Gene  
Therapy 
Ref. 
AuNS TEM, 
Contrast 
microscopy 
N/A DMSA In vitro N/A [115] 
QD Flow 
cytometry 
 Lipofectamine 
2000 
In vitro siRNA [63] 
QD Flow 
cytometry 
Disulfide 
reduction 
F3 peptide In vitro siRNA [116] 
QD Fluorescent 
imaging, 
TEM 
Disulfide 
reduction 
Lipofectamine, 
RGD and Tat 
peptides 
In vitro siRNA [117] 
QD Time-lapse 
fluorescent 
imaging 
  In vitro ASON [118] 
QD Confocal 
microscopy 
Electrostatic PEI-g-PEG In vitro  [65] 
QD Flow 
cytometry, 
Fluorescent 
imaging 
Electrostatic PEG-amine In vitro siRNA [119] 
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Table 3.1: Summary of inorganic theranostic particles used in gene therapy [121] 
(cont.). 
Particle  
Type 
Imaging Delivery/ 
release 
method 
Coating In vitro or  
in vivo 
Gene  
Therapy 
Ref. 
QD Confocal laser 
scanning 
microscopy, 
TEM 
Electrostatic 2-vinylpyridine In vitro siRNA [120] 
QD Confocal 
microscopy, 
Flow 
cytometry 
Electrostatic L-arginine, β-
cyclodextrin 
In vitro siRNA [67] 
QD FRET, Time-
lapse confocal 
microscopy 
Electrostatic Amphiphilic 
polymer 
In vitro siRNA [70] 
QD FRET, Time-
lapse confocal 
microscopy 
Electrostatic PEI In vitro siRNA [69] 
QD FRET, Time-
lapse confocal 
microscopy 
Electrostatic Polycation In vitro pDNA [71] 
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Chapter 4: Research Objectives 
A multi-component hydrogel system is needed to harness the potential of siRNA 
as a gene silencing therapeutic while overcoming the challenges of oral delivery of 
siRNA. A combination of “intelligent” pH-responsive behavior of ionic polymers, 
mechanical integrity and hydrophilicity of hydrogel networks, and targeted oral delivery 
strategies was employed to create a novel, two-component oral delivery strategy for 
siRNA. The objectives of this research were to: 
1. Design, synthesize, and characterize microgel matrices that are capable of 
encapsulating and protecting polycationic nanogels upon exposure to gastric 
conditions; 
2. Impart multi-responsive behavior in the microencapsulation system in the form of 
swelling and/or degradation in response to pH and/or enzyme concentration, 
which is capable of triggering release of polycationic nanogels in intestinal 
conditions; and 
3. Achieve loading and intracellular delivery of stable siRNA that is capable of 
inducing gene knockdown in an in vitro cell model. 
The multi-component system was a collaborative effort comprised of a 
polyanionic microgel matrix encapsulating polycationic nanogels. The synthesis and 
characterization of the encapsulated polycationic nanoparticles prepared by 
copolymerization of 2-(diethylamino)ethyl methacrylate with tert-butyl methacrylate and 
grafted with poly(ethylene glycol) were investigated in great detail by Drs. William B. 
Liechty and Diane C. Forbes within the Peppas laboratory. These researchers 
demonstrated the effect of molecular structure and physicochemical properties on the 
 78 
ability of the nanogels to complex with siRNA, cross the cell membrane, promote 
endosomal escape, and induce gene silencing [1-5]. 
The focus of the body of work herein is the development of a microgel matrix 
designed to protect polycationic nanogels and siRNA through gastric conditions and 
release the nanogels upon exposure to intestinal conditions for cellular inteRNAlization 
and siRNA delivery, depicted schematically in Figure 4.1. The polyanionic microgels 
were synthesized using methacrylic acid (MAA) copolymerized with N-vinylpyrrolidone 
(NVP) and covalently crosslinked with poly(ethylene glycol) dimethacrylate 
(PEGDMA), tetra(ethylene glycol) dimethacrylate (TEGDMA), or a biodegradable 
crosslinking agent. Structures of the monomers are shown in Figure 4.2. Synthesis and 
characterization of the microgel systems were completed for formulations with varying 
amounts of incorporated polycationic nanoparticles and different crosslinking agents. 
Formulations capable of releasing nanogels were evaluated in vitro to evaluate simulated 
oral delivery performance, cytocompatibility, and cell uptake and gene silencing ability.  
The following specific aims were addressed within this research: 
Specific Aim 1: Develop, characterize, and compare varying formulations of 
microencapsulation systems; 
Specific Aim 2: Incorporate a biodegradable crosslinking agent into the matrix network; 
Specific Aim 3: Evaluate and optimize release of polycationic nanoparticles from the 
system in response to pH and/or simulated gastrointestinal conditions; and 
Specific Aim 4: Investigate siRNA gene silencing efficiency of the best performing 
microencapsulation system using cell models. 
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Figure 4.1: Schematic of the two-part microencapsulated-nanogel system for the oral 
delivery of siRNA I) to the intestine and II) to the cell cytosol. 
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Figure 4.2: Structures of monomers used in the anionic hydrogel synthesis.  
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Chapter 5: Non-degradable Crosslinked Microgels Encapsulating 
Polycationic Nanogels2 
5.1 INTRODUCTION 
Stimuli responsive hydrogels are three-dimensional, crosslinked polymer 
networks that respond in an intelligent manner to environmental changes such as pH, 
temperature, or analyte concentration while maintaining structural integrity [1, 2]. Stimuli 
responsive hydrogels may exhibit change in shape, surface characteristics, solubility, 
permeability, mechanical strength, or molecular self-assembly [2, 3]. The specific 
response of the polymer network may be controlled by incorporation of functionalities 
such as chain side groups, branches, and crosslinks [1].  
In the case of pH responsive hydrogels, the polymer network contains weak acid 
or base pendant groups that become ionized as a function of pH, ionic strength, and ionic 
composition, among other factors [4]. Additionally, changes in the pH of the environment 
will affect the porosity of the hydrogel; polyanionic hydrogels will be deswollen at low 
pH and swollen at high pH while the opposite is true for polycationic hydrogels [5]. 
These polymers are categorized as polyelectrolytes when they contain many ionizable 
pendant groups [6].  
These hydrogels have been studied for a number of applications, including 
controlled drug delivery [5-10], biosensors [11-13], tissue engineering [14, 15], catalysis 
[16, 17], and separations [18, 19].  Such polyelectrolytes may be used within separation 
processes [10] as semipermeable membranes for counter-ions [1] or to separate and 
                                                 
2 Knipe, J., Chen, F. and Peppas, N. Multiresponsive polyanionic microgels with inverse pH responsive 
behavior by encapsulation of polycationic nanogels. J. Appl. Polym. Sci., 2014. 131: p. 40098. Knipe was 
the primary contributor, while Chen contributed to certain experiments and Peppas oversaw the project. 
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recover target proteins by phase separation or sorption by electrostatic or hydrophilic 
interactions [20-22].  
Recent developments with “intelligent” hydrogels have focused on the 
combination of multiple responsive properties to achieve a unique physiochemical 
response for specific applications [23-26]. In many instances, this hybrid is achieved by 
incorporating nanoparticles within polyelectrolytes [17, 27]. These hybrid morphologies, 
such as multilayer and core-shell particles, are promising tools for drug delivery, 
theranostics, and binding and immobilization of proteins [28-32].   
In this study, we show the facile synthesis and characterization of polycationic 
nanogels encapsulated within polyanionic microgels. Previously within our lab, 
hydrophilic microgels with domains of hydrophobic nanogels were developed for the 
delivery of hydrophobic chemotherapeutics [27]. Building upon this idea, polycationic 
nanogels were incorporated into the polymerization of polyanionic microgels to achieve a 
system encompassing inverse pH responsive behavior. Basic polymer characterization, 
including scanning electron microscopy (SEM), Fourier transform infrared spectroscopy 
(FTIR), and thermal gravimetric analysis (TGA) was completed. Additionally, the pH 
response was evaluated by dynamic and equilibrium swelling experiments as a function 
of pH as well as potentiometric titration. A cell proliferation assay and protein/small 
molecule loading and release were determined for drug delivery or protein separation 
applications. 
5.2 EXPERIMENTAL METHODS 
5.2.1 Chemicals 
Methacrylic acid (MAA), N-vinyl-2-pyrrolidone (NVP), and tetra(ethylene 
glycol) dimethacrylate (TEGDMA) were obtained from Sigma-Aldrich (St. Louis, MO). 
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Poly(ethylene glycol) (400) dimethacrylate (PEGDMA) was purchased from 
Polysciences, Inc. (Warrington, PA).  Irgacure 184
®
 (1-hydroxy-cyclohexyl-
phenylketone) was purchased from Sigma-Aldrich. All reagents were used as received. 
Polycationic nanogels were synthesized as described previously [8, 33].  
5.2.2 Synthesis of P(MAA-co-NVP) Hydrogels 
P(MAA-co-NVP) hydrogels were synthesized by photoinitiated, free-radical 
polymerization. MAA and NVP were added at a 1:1 molar ratio to a 1:1 (w/w) deionized 
water and ethanol solution to yield a 1:1 (w/w) total monomer to solvent ratio. 
Polycationic nanogels were added to the solution at 0, 1, 2, or 5 wt% with respect to total 
monomer weight. One of two crosslinking agents, TEGDMA or PEGDMA, was added at 
1 mol% of the total monomer molar content. Photoinitiator Irgacure 184
®
 was added at 1 
wt% with respect to total monomer weight.  
The mixture was homogenized by sonication, then loaded into a sealed glove box 
(MBraun, Garching, Germany). The solution was purged with nitrogen for 10 minutes, 
then pipetted between glass slides (150 x 150 x 3 mm
3
) separated by a Teflon spacer (0.7 
mm). The plates were exposed to UV light (Dymax 2000-EC Light Curing System, 
Torrington, CT) at 70% intensity and allowed to polymerize for 30 minutes. Following 
polymerization, the film was removed from the slides and purified from unreacted 
reagents in deionized water for 7 days with daily water changes. The purified film was 
dried under vacuum at 30°C for two days. The dried film was crushed into particles less 
than 75 μm in size using a mortar and pestle and stored in a dessicator at room 
temperature. 
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5.2.3 Characterization 
5.2.3.1 Scanning Electron Microscopy 
SEM samples were prepared by dusting carbon tape-covered aluminum stubs with 
vacuum-dried, crushed microgels. The samples were coated with 12-15 nm of Pt/Pd 
coating using a Cressington 208 Benchtop sputter coater (Watford, England). Scanning 
electron microscopy images were obtained using an FEI Quanta 650 FEG scanning 
electron microscope (Hillsboro, OR).  
5.2.3.2 Fluorescent Microscopy 
Polycationic nanogels were reacted with 4-chloro-7-nitrobenzofurazan (NBD-Cl, 
98%) (Sigma-Aldrich), which generates a fluorescent product upon reaction with amines 
present on the surface of the nanogels. Nanogel presence within the microgels was then 
confirmed using a Zeiss Axiovert 200 M fluorescence microscope (Thornwood, NY). 
5.2.3.3 Fourier Transform Infrared Spectroscopy 
Fourier transform infrared spectroscopy (FTIR) spectra for each sample were 
obtained using a Thermo Mattson Infinity Gold spectrometer (Thermo Fisher Scientific 
Inc., Waltham, MA). Samples were pressed in KBr (Sigma-Aldrich) disks. For all 
formulations background spectra was subtracted from the sample spectra. Copolymer 
compositions were calculated using a standard band of 650 cm
-1 
according to the 
calculation procedure reported previously [34]. Characteristic absorption bands of 1290 
cm
-1
 and 2983 cm
-1 
were used as analytical bands for NVP and MAA, respectively.  
5.2.3.4 Thermogravimetric Analysis 
Thermogravimetric analysis (TGA) was performed using a Mettler-Toledo 
TGA/DSC 1 (Columbus, OH). Samples were loaded in aluminum oxide crucibles. 
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Temperature increased from 40-600°C at a rate of 10°C/minute under nitrogen flowing at 
50 ml/min.  
5.2.3.5 Swelling Studies 
Dynamic swelling studies were carried out in 0.1 M 3,3-dimethylglutaric 
acid/NaOH buffers ranging in pH from 3.2-7.6; pH 1.2 and 2.2 buffers were achieved 
using 3,3-dimethylglutaric acid/HCl and were stable during the relevant timescale. All 
buffers had an ionic strength of 0.1 M by addition of NaCl and were heated to 37°C. 
Hydrogel disks of 10 mm in diameter were stepped through each buffer from lowest to 
highest pH, spending 10 minutes in each buffer. The weights of the disks were measured 
between each buffer. 
Equilibrium swelling studies were completed using a 0.1 N HCl solution and pH 
7.4 phosphate buffered saline (PBS) solution. Hydrogel disks of 10 mm in diameter were 
placed in 37°C low pH solution for 24 hours, weighed in air and a nonsolvent, heptane, 
then placed in 37°C high pH buffer for 24 hours. At the conclusion of the study, the disks 
were again weighed in air and heptane. 
5.2.3.6 Potentiometric Titration 
To determine the MAA content of the hydrogels, a 3.5 mg/ml solution of 
microgels in deionized water was titrated to pH 11.5 using 0.2 N NaOH (standardized 
with potassium hydrogen phthalate) at 25°C with constant stirring. pH was measured 
with a Mettler-Toledo SevenEasy™ (Columbus, OH) pH probe and was recorded when 
the pH reached a steady value (±0.01 pH units in three consecutive measurements over 5 
minutes). The equivalence point was used in conjunction with a charge balance to 
determine the amount of MAA present in each formulation.  
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5.2.3.7 Cytotoxicity Study 
The cytotoxic effect of the microgels was evaluated using a CellTiter 96® 
Aqueous One Solution Cell Proliferation Assay (Promega, Madison, WI). Microgel 
concentrations ranged from 1.25-10 mg/ml in DMEM without phenol red; studies were 
completed with human colon adenocarcinoma Caco-2, mucus-secreting HT29-MTX, and 
murine fibroblast L929 cells. Cells were incubated with microgels for two hours at 37°C 
and 5% CO2, and then the microgel solution was removed. MTS assay was added to the 
wells and incubated for 90 minutes at the same conditions before absorbance 
measurements were made at 490 nm using a Bio-Tek Synergy™ HT multi-mode plate 
reader (Winooski, VT). 
Caco-2 and L929 cells were obtained from American Type Culture Collection 
(ATCC, Rockwell, MD) and HT29-MTX cells, a sub-population of HT29 cells that were 
adapted to 10
-6
 M methotrexate (MTX) [35], were a gift from Dr. Thecla Lesuffleur, 
INSERM, Paris, France.  All cell lines were cultured in Dulbecco’s modified Eagle 
medium (DMEM) (Mediatech, Herndon, VA) supplemented with 10% heat-inactivated 
fetal bovine serum (Cambrex, East Rutherford, NJ), 1% non-essential amino acids 
(Mediatech), 100 U/ml penicillin, and 100 μg/ml streptomycin (Mediatech).   
5.2.3.8 Loading and Release Studies 
Microgels were loaded by equilibrium partitioning post-synthesis with two 
models, bovine serum albumin (BSA) (Sigma-Aldrich) and FITC-dextran (MW 3,000-
5,000, Sigma-Aldrich). Microgels were incubated at 37°C overnight in a 0.5 mg/mL BSA 
or FITC-dextran solution of pH ~5.5 at a ratio of 7:1 microgel:therapeutic by weight. The 
microgels were then collapsed by addition of 1 N HCl, followed by a wash with 0.2 N 
HCl and recovery by vacuum filtration. The microgels were lyophilized and stored in a 
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dessicator. Protein loading was evaluated with a MicroBCA assay (Pierce-Thermo, 
Rockford, IL)) and FITC-dextran loading by fluorescence. 
Release studies were completed in pH 7.4 PBS buffer at 37°C at a microgel 
concentration of 0.6 mg/mL buffer. Samples were taken at 0, 5, 10, 15, 30, 60, and 120 
minutes. Protein or FITC-dextran concentration was evaluated in the same manner as the 
loading study.  
5.3 RESULTS AND DISCUSSION 
Eight different formulations were synthesized, as listed in Table 5.1. Nanogel 
weight percent is the feed percentage. The formulations will be referred to henceforth by 
their descriptive name in Table 5.1. All films had an opaque appearance and were glassy 
and brittle when dry at room temperature. 
5.3.1 Microgel Morphology 
Hydrogel fims were dried and crushed into microgels resembling a fine, white 
powder. SEM images of dried microgels, as seen in Figure 5.1, showed the wide 
polydispersity of size and morphology attributed to the crushing of the hydrogel film. At 
least two dimensions of the microgels are less than 75 μm as ensured by the sieving 
process, but other dimension of the microgel may vary due to the inability to control 
particle size and shape during the crushing of the film. In comparing Figure 5.1A and 
5.1D, there is no observable distinction of the nanogels within the microgel. There is also 
no noticeable difference in morphology between the TEGDMA and PEGDMA 
crosslinking agents, shown in Figure 5.1A and 5.1C, respectively. 
To confirm the nanogels remain within the microgels throughout synthesis and 
purification, the nanogels were labeled with NBD-Cl, which binds to primary amines 
present on the surface of the nanogels. Upon reaction with the amine the NBD-Cl 
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becomes a fluorescent compound (γex=464 nm, γem=512 nm), effectively labeling the 
nanogels [36]. Fluorescent microscopy was used to evaluate the fluorescence of 
microgels containing 0 and 5 wt% nanogels before and after reaction with NBD-Cl. As 
shown in Figure 5.2, microgels containing no particles exhibited only a background level 
of fluorescence, while there was a definite increase in the fluorescence intensity of 
microgels containing 5 wt% nanogels after reacting with NBD-Cl. 
5.3.2 FT-IR Spectroscopic Analysis  
The FTIR spectra for all formulations are shown in Figure 5.3. The characteristic 
IR band of the nanogels was indistinguishable as it was masked by the wide band in the 
2800-3100 cm
-1
 range attributed to the stretching mode of hydrogen-bonded carboxylic 
acid dimers [37]. However, several important bands appear in the 1200-2000 cm
-1
 range, 
shown in Figure 5.3. In the carbonyl stretching region, the band at 1700 cm
-1
 is attributed 
to the carbonyl of the carboxylic acid, and the band at 1725 cm
-1
 is indicative of 
complexation between the hydroxyl group of the acid and carbonyl of the PNVP [37]. 
Similarly, the stretching band at 1680 cm
-1
 is attributed to the carbonyl of PNVP and is 
shifted to 1640 cm 
-1 
when hydrogen bonding is present [38]. The band at 1290 cm
-1 
is 
ring C-N stretching coupled with ring CH2 wagging in PNVP [38].  
Using the reported reactivity ratios of r1=0.56 and r2=0.04 for MAA and NVP 
respectively [39], an equimolar feed ratio of MAA:NVP should result in an 
approximately alteRNAting structure of 60:40 MAA:NVP as calculated by the copolymer 
equation. Copolymer molar compositions were calculated based on peak absorbance 
relative to a standard band absorbance [34]. Using this method, the calculated molar 
ratios were comparable to the theoretical compositions, as shown in Table 5.2. As the 
copolymer equation does not take into account the effect of the crosslinking agent, the 
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calculated values are reasonable. The incorporation of nanogels into the feed appears to 
have little to no effect on reactivity. 
5.3.3 TGA Analysis 
The TGA results from the TEGDMA microgels are shown in Figure 5.4A and the 
PEGDMA microgels in Figure 5.4B. TGA indicated that all formulations have a similar 
degradation profile, suggesting the same degradation mechanism. The first stage of 
degradation, beginning at about 60°C and accounting for approximately 6% weight loss, 
may be attributed to the loss of water and smaller molecules or oligomers [40]. The 
second stage of degradation begins at about 160-175°C and accounts for up to 5% weight 
loss. This loss is likely anhydride formation and some decarboxylation within the MAA, 
resulting in release of water and carbon dioxide [41]. It is interesting to note that this loss 
occurs at higher temperatures relative to that of pure PMAA, as has been observed by 
Polacco et al. with PMAA/PVP complexes [42].  The nanogels undergo significant 
degradation in this region, which may also contribute to the weight loss. The transition 
occurred approximately 10°C earlier in gels with PEGDMA crosslinker than in gels with 
TEGDMA crosslinker.  The crosslinker likely affects intramolecular bonding within the 
gel, causing variances in stability as a function of temperature. All formulations showed 
massive degradation from 300-500°C, with a maximum at about 430°C. This is a result 
of the decomposition of the polymer backbone primarily into monomer units, but also 
some oligomers [40, 42].  
5.3.4 Swelling Studies 
Dynamic swelling studies were conducted to evaluate the hydrogels’ response to 
pH variation on a short time scale (10 min/buffer). Weight swelling ratios were calculated 
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using Equation 1, where WD is the dry weight of the hydrogel disk and WS is the swollen 
weight.  
𝑞 =
𝑊𝑆
𝑊𝐷
 (5.1) 
As shown in Figures 5.5A and 5.5B, all formulations exhibit an increase in weight 
swelling ratio at pH values greater than ~5, which is expected as the pKa of methacrylic 
acid is approximately 4.8 [43]. Beyond the pKa of MAA, the carboxylic acid groups are 
ionized, and ionic repulsion drives the swelling of the hydrogel to weight swelling ratios 
ranging from 1.3-1.6. It was especially important to confirm that the hydrogels do not 
swell prematurely at low pH, which is a concern as the nanogels are ionized at low pH.  
The pH response of formulations with TEGDMA crosslinker, shown in Figure 
5.5A, is affected by the incorporation of nanogels as demonstrated by greater swelling 
ratios at low pH in formulations with higher nanogel content. This is because the 
nanogels are ionized at low pH and swelling facilitated by ionic repulsion allows 
increased imbibition of solution, resulting in increased weight swelling ratios. Around pH 
5, however, the 2 wt% TEGDMA gels reach greater swelling ratios than the 5 wt% 
TEGDMA gels as the cationic nanogels collapse upon exposure to high pH solution, 
resulting in a decrease in weight swelling ratio that is more apparent with greater nanogel 
content. 
On the other hand, formulations with PEGDMA crosslinker are not as sensitive to 
the nanogel incorporation and the weight swelling ratios are similar regardless of nanogel 
content, shown in Figure 5.5B. In the case of the PEDGMA gels, the longer crosslinker 
allows the network to be swollen to the point where any weight loss resulting from the 
collapse of nanogels is negligible. This characteristic may have unique applications in 
oral drug delivery as it allows nanogel incorporation while minimizing pH-dependent 
swelling variations. 
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Equilibrium swelling studies were conducted to obtain the maximum weight 
swelling ratio of the gels and calculate the swollen mesh size. All formulations had a 
weight swelling ratio of ~1.3 in the 0.1 N HCl buffer (data not shown). For many 
formulations, including all of the TEGDMA gels, swollen weights at pH 7.4 could not be 
measured due to the fragility and destruction of the gels prior to reaching equilibrium. 
For those that reached equilibrium swelling, the mesh size was calculated using the 
Peppas-Merrill equation. Weight swelling ratios at pH 7.4 for the PEGDMA gels, as well 
as the calculated swollen mesh size, are reported in Table 5.3. The swollen mesh sizes 
ranged from ~21-35 nm for the PEGDMA gels. The equilibrium weight swelling ratios of 
the PEGDMA gels are much greater than the dynamic swelling weight ratios at pH 7.4, 
indicating some tortuosity present in the hydrogel that retards swelling on a short time 
scale. This may be due to regions of crystallinity or the glassiness of the hydrogel in a 
dried state.  
5.3.5 Potentiometric Titration 
Potentiometric titration studies were completed with crushed microgels to 
determine the actual MAA incorporation in each formulation and whether the 
crosslinking agent or addition of nanogels had any effect. As shown in Table 5.2, 
formulations with the TEGDMA crosslinker had 46-50 mol% MAA which was the 
inverse of what was calculated from the FTIR spectra. However, the lower relative 
content of MAA explains why these formulations exhibit some swelling at a low pH as 
observed in the dynamic swelling studies, since the hydrophilicity of the NVP dominates. 
On the other hand, formulations with the PEGDMA crosslinker had 53-66 mol% MAA, 
which was in close agreement with what was calculated from the FTIR spectra though a 
bit higher for formulations that contained nanogels. The higher relative amount of MAA 
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in the PEGDMA gels explains the dynamic swelling profile of these gels; the swelling 
response is controlled by the ionization of MAA rather than the hydrophilicity of NVP. 
As in the case of the FTIR analysis, the amount of crosslinker and nanogels incorporated 
was not taken into account so some error is expected. Additionally, the polycationic 
nanogels are ionized at pH values less than ~6, but the charge of this species was ignored 
due to the low relative content.  
5.3.6 Cytotoxicity  
Cytotoxicity studies were performed with various microgel concentrations to find 
the maximum concentration that Caco-2 and murine fibroblast L929 cells (data not 
shown) could withstand without disruption to metabolic activity. Figures 5.6A and 5.6B 
shows Caco-2 cell viability relative to a positive control without microgels. Viability 
greater than 80% (black line) is considered acceptable in our evaulation. For all 
formulations, concentrations greater than 1.25 mg/ml caused significant disruption to cell 
metabolic activity. This may reflect a chemical impediment of cellular activity due to a 
reduction in pH resulting from higher concentrations of charged functional groups, or a 
physical impediment of cellular activity due to the density of the sedimenting particles 
covering the cell monolayer. The trend suggests that higher incorporation of nanogels 
may cause loss of cell viabilty; this is in agreement with reports of tocixity associated 
with cationic polymers [44]. This leads us to believe that the charged funcational groups 
within the polymer play a role in the cytotoxicty results, but at low concentrations this 
effect is not very pronounced. Additionally, for drug delivery applications it is not likely 
that local concentrations higher than 1.25 mg/ml would exist.  
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5.3.7 Loading and Release of Model Therapeutic 
Two formulations were chosen to proceed with loading and release studies based 
on results from the aforementioned characterization studies. The PEGDMA hydrogels 
with 0 wt% and 5 wt% nanogels were used to evaluate potential influence of nanogel 
presence on ability to load and release model therapeutics. It was hypothesized that in a 
loading buffer of pH ~5.5, the P(MAA-co-NVP) matrix and nanogels should both 
undergo swelling due to partial ionization. In that case, there is a possibility that the 
therapeutic could partition into the nanogels, which would remain collapsed at a high pH 
~7.4 and fail to release the therapeutic. This could have applications in both drug delivery 
and protein separations. 
The first therapeutic tested was BSA, a large (66.5 kDa) model protein. Loading 
efficiency was calculated by Equation 2 and weight efficiency was calculated by 
Equation 3, where co is the initial protein concentration,  cf is the final protein 
concentration,  masso is the initial mass of protein in solution, massf is the final mass of 
protein in solution, and massp is the mass of polymer in solution. 
 
𝐿𝑜𝑎𝑑𝑖𝑛𝑔 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 =  
𝑐𝑜−𝑐𝑓
𝑐𝑜
∗ 100    (5.2) 
 
𝑊𝑒𝑖𝑔ℎ𝑡 𝐿𝑜𝑎𝑑𝑖𝑛𝑔 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 =  
𝑚𝑎𝑠𝑠𝑜−𝑚𝑎𝑠𝑠𝑓
𝑚𝑎𝑠𝑠𝑜−𝑚𝑎𝑠𝑠𝑓+𝑚𝑎𝑠𝑠𝑝
∗ 100  (5.3) 
As shown in Figure 5.7, the weight loading efficiencies were very similar 
regardless of nanogel content. Though the loading and weight efficiencies of BSA were 
lower than desired at ~40-45% and ~5.5-5.6% respectively, they were comparable to 
those reported for similar hydrogel systems with large proteins [45].  
The release of BSA from microgels was calculated relative to the total weight of 
therapeutic based on the weight loading efficiency for each formulation. For both 
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formulations, a burst release was observed in pH 7.4 buffer, reaching a maximum of ~50-
60% in approximately 20 minutes as shown in Figure 5.8A. We can infer that the 
therapeutic was not loaded into the nanogels in the 5 wt% formulation, since we would 
expect to see lower release relative to that of the 0 wt% formulation as the nanogels 
would remain collapsed at pH 7.4. This disproves the hypothesis that the nanogels could 
be loaded simultaneously at pH 5.5, but there is a possibility that the loading procedure 
could be modified to achieve simultaneous loading of nanogels and microgels in the 5 
wt% formulation. 
With respect to the 0 wt% formulation, the percent release of BSA was low 
compared to reported release of other proteins from comparable systems [45]. This is 
likely due to a combination of the large size of BSA restricting diffusion along with some 
surface loading rather than partitioning within the hydrogel. A small amount of the 
protein is likely removed from the particle surface during the wash steps following the 
loading procedure, which would result in artificially high loading efficiencies and 
seemingly low percent release. Charge repulsion between the protein and microgel may 
also factor into the low release percentages; at pH 7.4 both the BSA and microgels carry 
a negative charge, which may impede diffusion of BSA from the microgel. 
To determine if the size of the therapeutic was affecting partition loading and 
release, a smaller model therapeutic, FITC-dextran (3-5 kDa) was also evaluated. The 
loading efficiencies were higher for this model, at around ~65-67% loading efficiency as 
shown in Figure 5.7, while the weight loading efficiencies were nearly the same as BSA 
at ~5.3-5.6%. Again there was little difference between the 0 wt% and 5 wt% 
formulations. These efficiencies were comparable to a similar system loaded with a 
smaller protein [46].  
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As in the case of BSA, both the 0wt% and 5 wt% formulations showed similar 
release profiles and percentages, disproving the hypothesis that the nanogels would be 
loaded with model therapeutic. The release of FITC-dextran in pH 7.4 buffer, shown in 
Figure 5.8B, was unexpectedly low at 20-25% release for the 0 wt% formulation. It was 
anticipated that the 0 wt% nanogel formulation would exhibit a much higher percent 
release than the 5 wt% nanogel formulation, since the therapeutic could have been 
contained within the nanogels in the 5 wt% formulation, but the data did not support this. 
This suggests that the model therapeutic is not partitioning into the nanogels, or that the 
therapeutic diffused from the nanogels as the microgels collapsed in the acidified 
environment. Since accurate fluorescence measurements could not be obtained after 
collapsing the particles by acidification of the solution, it is possible that some of the 
loaded FITC-dextran was forced out of the microgels as the structure collapsed and the 
actual loading efficiencies were lower, causing depressed release efficiencies. It is also 
possible that hydrogen bonding between the microgel and polysaccharide chains inhibited 
adequate loading and release. 
5.4 CONCLUSIONS 
Formulations with two different crosslinking agents and varying cationic nanogel 
content were synthesized by UV-initiated bulk free radical polymerization. The microgels 
have similar morphology across formulations and retain the nanogels through synthesis 
and purification, as shown by fluorescent microscopy. Copolymer composition based 
upon feed ratio and FTIR is in good agreement at approximately 60:40 MAA:NVP and 
does not vary across formulations. However, the swelling behaviors of the gels do 
indicate some differences, with the TEGDMA hydrogels experiencing higher weight 
swelling ratios with increased nanogel content while the swelling of the PEGDMA gels 
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are not dependent upon nanogel content, which is favorable for drug delivery 
applications. Two model therapeutics were loaded into the PEGDMA microgels, but the 
release of the models was lower than expected in both cases and nanogel content did not 
affect loading or release efficiency. It is likely that the release is poor due to surface 
loading rather than equilibrium partitioning with in microgels. 
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5.5 TABLES 
Formulation 
Nanogel %, Crosslinker 
Nanogel 
weight% 
Crosslinker 
0 wt%, TEGDMA 0 TEGDMA 
1 wt%, TEGDMA 1 TEGDMA 
2 wt%, TEGDMA 2 TEGDMA 
5 wt%, TEGDMA 5 TEGDMA 
0 wt%, PEGDMA 0 PEGDMA 
1 wt%, PEGDMA 1 PEGDMA 
2 wt%, PEGDMA 2 PEGDMA 
5 wt%, PEGDMA 5 PEGDMA 
Table 5.1: P(MAA-co-NVP) hydrogel formulations with and without nanogels, with 
TEGDMA or PEGDMA crosslinking agents. 
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 MAA NVP 
 FTIR Titration FTIR Titration 
0%, TEGDMA 53% 47% 47% 53% 
1%, TEGDMA 55% 50% 45% 50% 
2%,  TEGDMA 53% 46% 47% 54% 
5%, TEGDMA 53% 48% 47% 52% 
       
0%, PEGDMA 53% 53% 47% 47% 
1%, PEGDMA 55% 61% 45% 39% 
2%, PEGDMA 58% 66% 42% 34% 
5%, PEGDMA 56% 62% 44% 38% 
Table 5.2: Molar ratios of MAA and NVP in P(MAA-co-NVP) microgels determined 
by FTIR and potentiometric titration. 
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Formulation qpH 7.4 (g/g) Swollen mesh size (nm) 
0 wt% PNP, PEGDMA N/A
a
 N/A
a
 
1 wt% PNP, PEGDMA 14.3 25-35 
2 wt% PNP, PEGDMA 14.7 25-35 
5 wt% PNP, PEGDMA 11.7 21 
Table 5.3: Equilibrium weight swelling ratios and calculated swollen mesh size of 
P(MAA-co-NVP) 10 mm disks. 
a
Could not be determined due to disk 
rupture. 
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5.6 FIGURES 
 
Figure 5.1: Representative SEM micrographs of crushed P(MAA-co-NVP) microgels. 
Gels were crushed and sieved to <75 μm. A) A) 0 wt% nanogels, TEGDMA 
crosslink; B) 5 wt% nanogels, TEGDMA crosslink; C) 0 wt% nanogels, 
PEGDMA crosslink; D) 5 wt% nanogels, PEGDMA crosslink. (Scale bar = 
20 μm) 
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Figure 5.2: Brightfield (left) and fluorescent microscopy (right) images of crushed 
P(MAA-co-NVP) microgels with PEGDMA crosslinks. A) Film with no 
nanogels reacted with NBD-Cl; B) Film with 5 wt% nanogels reacted with 
NBD-Cl. (Scale bars = 50 μm) 
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Figure 5.3: FT-IR spectra of crosslinked P(MAA-co-NVP) copolymers with 
encapsulated nanogels at varying weight percentages (0-5 wt%) pressed in a 
KBr disk . Crosslinking was achieved with either poly(ethylene glycol) 
(400) dimethacrylate or tetra(ethylene glycol) dimethacrylate at 1 mol%.  
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Figure 5.4: TGA curves of P(MAA-co-NVP) copolymers with TEGDMA (A) or 
PEGDMA (B) crosslinks and 0-5 wt% encapsulated nanogels. 15 mg 
samples were run at 10°C/min from 40-600°C under nitrogen gas. 
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Figure 5.5: Weight swelling ratio of crosslinked P(MAA-co-NVP) hydrogel disks in 
response to dynamic change in buffer pH. Hydrogels were crosslinked with 
TEGDMA (left) or PEGDMA (right) and contained 0-5 wt% 
nanogels.Studies were completed in DMGA/NaOH or HCl buffer with 0.1M 
NaCl at 37°C (N=3). 
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Figure 5.6: Evaluation of cell viability after microgel exposure using an MTS cell 
proliferation assay (Promega). Caco-2 human colorectal adenocarcinoma 
cells were incubated with microgel solutions ranging from 1.25-5 mg/mL in 
culture media for 2 hours. Following removal of the microgels, the MTS 
assay was allowed to incubate for 90 minutes. Percent viable cells is relative 
to the positive control (culture media only, gray bar). Microgels were 
crosslinked with TEGDMA (left) or PEGDMA (right) and contained 0-5 
wt% nanogels. (N=3). 
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Figure 5.7: Loading efficiencies of P(MAA-co-NVP) microgels with PEGDMA 
crosslinker and 0 wt% or 5 wt% nanogels. Bovine serum albumin (BSA, 
MW 66.5 kDa) and FITC-dextran (FITC-Dex, MW 3-5 kDa) were loaded 
into the microgles. Loading efficiency was based on amount of protein or 
dextran loaded into microgels relative to initial amount in solution. Weight 
loading efficiency is weight of loaded protein or dextran relative to total 
weight of microgel and protein or dextran. Microgels were loaded over 24 
hours (N=3). 
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Figure 5.8: Release of model therapeutics from P(MAA-co-NVP) microgels with 
PEGDMA crosslinker in pH 7.4 PBS buffer at 37ºC over two hours. 
Microgels encapsulated either 0 wt% (●) or 5 wt% (□) nanogels. A) Release 
of bovine serum albumin (MW 66 kDa) ; B) release of FITC-dextran (MW 
3-5 kDa). 
 
 
  
0
5
10
15
20
25
30
35
0 20 40 60 80 100 120
%
 R
el
e
a
se
 
Time (min) 
    
0
10
20
30
40
50
60
70
0 20 40 60 80 100 120
%
 R
el
ea
se
 
Time (min) 
 109 
REFERENCES 
[1] Peppas, N.A., Hilt, J.Z., Khademhosseini, A., and Langer, R., Hydrogels in biology 
and medicine: From molecular principles to bionanotechnology. Adv Mater, 
2006. 18(11): p. 1345-1360. 
 
[2] Peppas, N.A., Bures, P., Leobandung, W., and Ichikawa, H., Hydrogels in 
pharmaceutical formulations. Eur J Pharm Biopharm, 2000. 50: p. 27-46. 
 
[3] Jeong, B. and Gutowska, A., Lessons from nature: Stimuli-responsive polymers and 
their biomedical applications. Trends Biotechnol, 2002. 20(7): p. 305-311. 
 
[4] Firestone, B.A. and Siegel, R.A., Kinetics and mechanisms of water sorption in 
hydrophobic, ionizable copolymer gels. J Appl Polym Sci, 1991. 43(5): p. 901-
914. 
 
[5] Kost, J. and Langer, R., Responsive polymeric delivery systems. Adv Drug Deliver 
Rev, 2012. 64: p. 327-341. 
 
[6] Qiu, Y. and Park, K., Environment-sensitive hydrogels for drug delivery. Adv Drug 
Deliver Rev, 2012. 64: p. 49-60. 
 
[7] Hoffman, A.S., Stimuli-responsive polymers: Biomedical applications and challenges 
for clinical translation. Adv Drug Deliver Rev, 2013. 65(1): p. 10-16. 
 
[8] Liechty, W.B., Scheuerle, R.L., and Peppas, N.A., Tunable, responsive nanogels 
containing t-butyl methacrylate and 2-(t-butylamino)ethyl methacrylate. Polym, 
2013. 54(15): p. 3784-3795. 
 
[9] Gran, M.L., Metal-polymer nanoparticulate systems for exteRNAlly-controlled 
delivery, in Chemical Engineering. 2010, The University of Texas at Austin: 
Austin. 
 
[10] Bajpai, A.K., Shukla, S.K., Bhanu, S., and Kankane, S., Responsive polymers in 
controlled drug delivery. Prog Polym Sci, 2008. 33(11): p. 1088-1118. 
 
[11] Tokareva, I., Minko, S., Fendler, J.H., and Hutter, E., Nanosensors based on 
responsive polymer brushes and gold nanoparticle enhanced transmission surface 
plasmon resonance spectroscopy. J Am Chem Soc, 2004. 126: p. 15950-15951. 
 110 
 
[12] Stuart, M.A.C., Huck, W.T.S., Genzer, J., Müller, M., Ober, C., Stamm, M., 
Sukhorukov, G.B., Szleifer, I., Tsukruk, V.V., Urban, M., Winnik, F., Zauscher, 
S., Luzinov, I., and Minko, S., Emerging applications of stimuli-responsive 
polymer materials. Nat Mater, 2010. 9: p. 101-113. 
 
[13] Peppas, N.A. and Byrne, M.E., New biomaterials for intelligent biosensing, 
recognitive drug delivery and therapeutics. Bull. Gattefossé, 2003. 96: p. 23-25. 
 
[14] Martins, A.M., Alves, C.M., Kurtis Kasper, F., Mikos, A.G., and Reis, R.L., 
Responsive and in situ-forming chitosan scaffolds for bone tissue engineering 
applications: An overview of the last decade. J Mater Chem, 2010. 20(9): p. 1638. 
 
[15] Han, L.-H., Lai, J.H., Yu, S., and Yang, F., Dynamic tissue engineering scaffolds 
with stimuli-responsive macroporosity formation. Biomaterials, 2013. 34(17): p. 
4251-4258. 
 
[16] Gao, T., Ye, Q., Pei, X., Xia, Y., and Zhou, F., Grafting polymer brushes on 
graphene oxide for controlling surface charge states and templated synthesis of 
metal nanoparticles. J Appl Polym Sci, 2013. 127(4): p. 3074-3083. 
 
[17] Xiao, L., Isner, A.B., Hilt, J.Z., and Bhattacharyya, D., Temperature responsive 
hydrogel with reactive nanoparticles. J Appl Polym Sci, 2013. 128(3): p. 1804-
1814. 
 
[18] Marambio, O.G., Pizarro, G.d.C., Jeria-Orell, M., and Geckeler, K.E., Swelling 
behavior and metal ion retention from aqueous solution of hydrogels based onn-
1-vinyl-2-pyrrolidone andn-hydroxymethylacrylamide. J Appl Polym Sci, 2009. 
113(3): p. 1792-1802. 
 
[19] Tokarev, I. and Minko, S., Stimuli-responsive porous hydrogels at interfaces for 
molecular filtration, separation, controlled release, and gating in capsules and 
membranes. Adv Mater, 2010. 22(31): p. 3446-3462. 
 
[20] Kayitmazer, A.B., Seeman, D., Minsky, B.B., Dubin, P.L., and Xu, Y., Protein–
polyelectrolyte interactions. Soft Matter, 2013. 9(9): p. 2553. 
 
[21] GeRNAndt, J. and Hansson, P., Core–shell separation of a hydrogel in a large 
solution of proteins. Soft Matter, 2012. 8(42): p. 10905. 
 111 
 
[22] Yigit, C., Welsch, N., Ballauff, M., and Dzubiella, J., Protein sorption to charged 
microgels: Characterizing binding isotherms and driving forces. Langmuir, 2012. 
28(40): p. 14373-14385. 
 
[23] Liu, J., Chen, G., Guo, M., and Jiang, M., Dual stimuli-responsive supramolecular 
hydrogel based on hybrid inclusion complex (hic). Macromolecules, 2010. 43(19): 
p. 8086-8093. 
 
[24] Motornov, M., Roiter, Y., Tokarev, I., and Minko, S., Stimuli-responsive 
nanoparticles, nanogels and capsules for integrated multifunctional intelligent 
systems. Prog Polym Sci, 2010. 35(1-2): p. 174-211. 
 
[25] White, E.M., Yatvin, J., Grubbs, J.B., Bilbrey, J.A., and Locklin, J., Advances in 
smart materials: Stimuli-responsive hydrogel thin films. J Polym Sci, Part B: 
Polym Phys, 2013. 51(14): p. 1084-1099. 
 
[26] Fleige, E., Quadir, M.A., and Haag, R., Stimuli-responsive polymeric nanocarriers 
for the controlled transport of active compounds: Concepts and applications. Adv 
Drug Deliver Rev, 2012. 64(9): p. 866-884. 
 
[27] Schoener, C.A., Hutson, H.N., and Peppas, N.A., Ph-responsive hydrogels with 
dispersed hydrophobic nanoparticles for the oral delivery of chemotherapeutics. J 
Biomed Mater Res A, 2013. 101A(8): p. 2229-2236. 
 
[28] Welsch, N., Becker, A.L., Dzubiella, J., and Ballauff, M., Core–shell microgels as 
“smart” carriers for enzymes. Soft Matter, 2012. 8(5): p. 1428. 
 
[29] Chapel, J.P. and Berret, J.F., Versatile electrostatic assembly of nanoparticles and 
polyelectrolytes: Coating, clustering and layer-by-layer processes. Curr Opin 
Colloid Interface Sci, 2012. 17(2): p. 97-105. 
 
[30] Knipe, J.M., Peters, J.T., and Peppas, N.A., Theranostic agents for intracellular 
gene delivery with spatiotemporal imaging. Nano Today, 2013. 8(1): p. 21-38. 
 
[31] Satarkar, N.S., Biswal, D., and Hilt, J.Z., Hydrogel nanocomposites: A review of 
applications as remote controlled biomaterials. Soft Matter, 2010. 6(11): p. 2364. 
 
 112 
[32] Döring, A., Birnbaum, W., and Kuckling, D., Responsive hydrogels – structurally 
and dimensionally optimized smart frameworks for applications in catalysis, 
micro-system technology and material science. Chem Soc Rev, 2013. 42(17): p. 
7391. 
 
[33] Forbes, D.C., Creixell, M., Frizzell, H., and Peppas, N.A., Polycationic 
nanoparticles synthesized using ARGET ATRP for drug delivery. Eur J Pharm 
Biopharm, 2013. 84(3): p. 472-478. 
 
[34] Pekel, N., Sahiner, N., Guven, O., and Rzaev, Z.M.O., Synthesis and 
characterization of n-vinylimidazole-ethyl methacrylate copolymers and 
determination of monomer reactivity ratios. Eur Polym J, 2001. 37: p. 2443-2451. 
 
[35] Lesuffleur, T., Porchet, N., Aubert, J.-P., Swallow, D., Gum, J.R., S.Kim, Y., Real, 
F.X., and Zweibaum, A., Differential expression of the human mucin genes muc1 
to muc5 in relation to growth and differentiation of different mucus-secreting ht-
29 cell populations. J Cell Sci, 1993. 106: p. 771-783. 
 
[36] Ghosh, P.B. and Whitehouse, M.W., 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole: A 
new fluorigenic reagent for amino acids and other amines. Biochem. J. , 1968. 
108: p. 155. 
 
[37] Lee, J.Y., Painter, P.C., and Coleman, M.M., Hydrogen bonding in polymer blends. 
4. Blends involving polymers containing methacrylic acid and vinylpyridine 
groups. Macromolecules, 1988. 21: p. 954-960. 
 
[38] Zhu, X., Lu, P., Chen, W., and Dong, J., Studies of uv crosslinked poly(n-
vinylpyrrolidone) hydrogels by ftir, raman and solid-state nmr spectroscopies. 
Polym, 2010. 51(14): p. 3054-3063. 
 
[39] Bianco, G. and Gehlen, M.H., Synthesis of poly(n-vinyl-2-pyrrolidone) and 
copolymers with methacrylic acid initiated by the photo-fenton reaction. J 
Photochem Photobiol A, 2002. 149: p. 115-119. 
 
[40] Loría-Bastarrachea, M.I., Herrera-Kao, W., Cauich-Rodríguez, J.V., Cervantes-Uc, 
J.M., Vázquez-Torres, H., and Ávila-Ortega, A., A tg/ftir study on the thermal 
degradation of poly(vinyl pyrrolidone). J Therm Anal Calorim, 2010. 104(2): p. 
737-742. 
 
 113 
[41] Ho, B.-C., Lee, Y.-D., and Chin, W.-K., Thermal degradation of polymethacrylic 
acid. J Polym Sci, Part A: Polym. Chem, 1992. 30: p. 2389-2397. 
 
[42] Polacco, G., Cascone, M.G., Petarca, L., and Peretti, A., Thermal behaviour of 
poly(methacrylic acid)/poly(n-vinyl-2-pyrrolidone) complexes. Eur Polym J, 
2000. 36: p. 2541-2544. 
 
[43] Blanchette, J. and Peppas, N.A., Oral chemotherapeutic delivery: Design and 
cellular response. Ann Biomed Eng, 2005. 33(2): p. 142-149. 
 
[44] Fischer, D., Li, Y., Ahlemeyer, B., Krieglstein, J., and Kissel, T., In vitro 
cytotoxicity testing of polycations: Influence of polymer structure on cell viability 
and hemolysis. Biomaterials, 2003. 24: p. 1121-1131. 
 
[45] Carr, D.A., Gomez-Burgaz, M., Boudes, M.C., and Peppas, D.N.A., Complexation 
hydrogels for the oral delivery of growth hormone and salmon calcitonin. Ind Eng 
Chem Res, 2010. 49: p. 11991-11995. 
 
[46] Carr, D.A. and Peppas, N.A., Assessment of poly(methacrylic acid-co-n-vinyl 
pyrrolidone) as a carrier for the oral delivery of therapeutic proteins using caco-
2 and ht29-mtx cell lines. J Biomed Mater Res A, 2009. 92A: p. 504-512. 
 
 
 
  
 114 
Chapter 6: Multi-responsive and biodegradable crosslinked microgels  
6.1 INTRODUCTION 
Multi-responsive hydrogels, or hydrophilic, crosslinked polymer networks that 
undergo physicochemical changes in response to multiple environmental stimuli, offer 
the specificity of highly tunable stimuli-responsive systems combined with excellent 
biocompatibility [1-4]. As the next generation of biomaterials, these “intelligent” systems 
are better able to mimic biological processes [5]. This capability could be instrumental in 
achieving various biomedical advances, including tissue regeneration and oral delivery of 
delicate therapeutics. 
Hydrogels with pH-responsive behavior are among the most widely utilized 
“intelligent” hydrogel systems for oral drug delivery applications. Polyanionic hydrogels 
such as poly(methacrylic acid) (PMAA) exhibit complexation via hydrogen bonding at 
low pH conditions, such as that of gastric fluid, and undergo increased swelling due to 
ionization of the carboxylic groups at neutral pH conditions, such as that of the intestine 
[6]. Thus, many researchers have utilized PMAA copolymers as  oral drug delivery 
carriers for their ability to protect a loaded therapeutic from denaturation and proteolytic 
degradation as it travels through gastric conditions yet swell and release the therapeutic at 
the site of absorption in the small intestine [7-12].  
Though enzymatic attack on a therapeutic as it travels through the gastrointestinal 
tract is undesirable, the power of enzymes may be harnessed to facilitate delivery of a 
therapeutic from its carrier at a specific site [13, 14]. A relatively small number of 
researchers have investigated the use of hydrogels with enzyme-degradable peptide 
components for the purpose of drug delivery to the small intestine [13, 15, 16], where 
enzymes such as trypsin, chymotrypsin, and cathepsin-β are prevalent [17]. In particular, 
 115 
peptide crosslinks are an appealing route to achieve enzyme-specific degradation of the 
network and subsequent drug delivery [13, 15, 16, 18, 19]. 
 Here, a poly(methacrylic acid-co-N-vinylpyrrolidone) (P(MAA-co-NVP)) 
polymer backbone is used to impart hydrophilic and  pH-responsive behavior that may 
inhibit or enhance proteolytic degradation as a function of pH-responsive swelling. The 
polymer backbone is crosslinked by a facile bioconjugation reaction with an oligopeptide 
rich in arginine and lysine groups specifically targeted for degradation by the enzyme 
trypsin. Synthesis, degradation, cytocompatibility, and therapeutic loading and release of 
the pH- and enzyme-responsive, biodegradable P(MAA-co-NVP) with peptide crosslinks 
are detailed herein.   
6.2 EXPERIMENTAL METHODS 
6.2.1 Chemicals 
Methacrylic acid (MAA), N-vinyl-2-pyrrolidone (NVP), and Irgacure 184
®
 (1-
hydroxy-cyclohexyl-phenylketone) were obtained from Sigma-Aldrich (St. Louis, MO). 
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) was obtained 
from Sigma-Aldrich. N-hydroxysuccinimide (NHS) was obtained from Pierce 
Biotechnology, Inc. (Rockford, IL). The custom sequence oligopeptide GRRRGK was 
synthesized by CHI Scientific (Maynard, MA). All reagents were used as received. 
Fluorescamine was purchased from Acros Organics (Geel, Belgium). Purified pepsin 
from porcine gastric mucosa (≥2500 U/mg) and pancreatin from porcine pancreas (4x 
USP specifications) were purchased from Sigma-Aldrich. Trypsin-EDTA solution (1X) 
and Nα-benzoyl-L-arginine ethyl ester hydrochloride (BAEE) trypsin substrate were 
obtained from Sigma-Aldrich. Recombinant human insulin (≥27.5 IU/mg) was obtained 
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from Sigma-Aldrich. All other solvents and buffers were purchased from Fisher 
Scientific (Waltham, MA). 
6.2.2 Synthesis and Purification 
6.2.2.1 Synthesis of Linear Polymer 
P(MAA-co-NVP) linear polymer was synthesized by photoinitiated, free-radical 
polymerization. MAA and NVP were added at a 1:1 molar ratio to a 1:1 (w/w) deionized 
water and ethanol solution to yield a 1:3 (w/w) total monomer to solvent ratio. 
Photoinitiator Irgacure 184
®
 was added at 1 wt% with respect to total monomer weight.  
The mixture was homogenized by sonication then the round bottom flask was 
sealed with a rubber septum. The solution was purged with nitrogen for 20 minutes, then 
the reaction was initiated with a Dymax BlueWave® 200 UV point source (Dymax, 
Torrington, CT) at 100mW/cm
2
 intensity and allowed to polymerize for 30 minutes while 
stirring. 
Following polymerization, the linear polymer was purified from unreacted 
monomer by addition of 1 N hydrochloric acid (HCl) to precipitate polymer, 
centrifugation, and resuspension in deionized water. After 3 wash cycles, the polymer 
solution was frozen in liquid nitrogen (LN2) and lyophilized for at least 24 hours.  
6.2.2.2 Synthesis of Peptide Crosslinked Gels 
Linear P(MAA-co-NVP) was dissolved in a 1:1 (v/v) water:ethanol solution at a 
concentration of 50 mg/ml. EDC was dissolved in ethanol at a concentration of 50 mg/ml 
and NHS was dissolved in ethanol at a concentration of 16 mg/ml. The EDC and NHS 
solutions were added to the polymer solution at a ratio of 6:3:1 polymer:EDC:NHS by 
weight. The mixture was vortexed briefly, then allowed to react for ~3 min with shaking. 
The pH was raised to ~8 by the addition of 1 N sodium hydroxide (NaOH), and then a 
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volume of 100 mg/ml peptide in ethanol solution was added to achieve a 2:1 weight ratio 
of polymer:peptide. The mixture was allowed to react overnight with shaking then 
purified by 3 wash cycles with water and centrifugation at 10,000 x g for 5 minutes. 
Following the washes, the polymer was frozen in LN2 and lyophilized for at least 24 
hours. 
After lyophilization, the polymer was milled into a fine power by crushing with 
mortar and pestle. The powder was sifted to the size ranges of 30-75 μm and less than 30 
μm by ultraprecision ASTM sieves (Precision Eforming, Cortland, NY).  
6.2.3 Characterization 
6.2.3.1 Potentiometric Titration 
To determine the MAA content of the linear polymer, a 3.5 mg/ml solution of 
microgels in deionized water was titrated to pH 11.5 using 0.2 N NaOH (standardized 
with potassium hydrogen phthalate) at 25°C with constant stirring. pH was measured 
with a Mettler-Toledo SevenEasy™ (Columbus, OH) pH probe and was recorded when 
the pH reached a steady value (±0.01 pH units in three consecutive measurements over 5 
minutes). The equivalence point was used in conjunction with a charge balance to 
determine the amount of MAA present in each formulation.  
6.3.2.2 Fluorescamine Assay 
The fluorescamine solution was prepared fresh before each test. 3 mg of 
fluorescamine (Sigma-Aldrich) was dissolved in 10 ml filtered acetone. SupeRNAtant 
from the EDC-NHS reactions were mixed in a range of dilutions with phosphate buffered 
saline (PBS) and the fluorescamine solution with agitation. After reacting at room 
temperature with shaking for 15 min,  200 μl of each sample was transferred in triplicate 
 118 
to a black 96-well plate and the  fluorescence at 360 ex/460 em was measured using a 
Bio-Tek Synergy™ HT multi-mode plate reader(Winooski, VT), sensitivity=85.  
6.2.3.3 Fourier Transform Infrared Spectroscopy 
Fourier transform infrared spectroscopy (FTIR) spectra were obtained using a 
Thermo Mattson Infinity Gold spectrometer (Thermo Fisher Scientific Inc., Waltham, 
MA). The incubation buffer of degraded samples was exchanged with water using 30,000 
MWCO centrifugal filters (Millipore, Billerica, MA) over 5 washes. Samples were 
lyophilized and then pressed in KBr (Sigma-Aldrich) disks. For each sample, 512 scans 
were performed with a resolution of 4 cm
-1
 and gain of 1.0, and background spectra of a 
KBr blank disk was subtracted from the sample spectra.  
6.2.3.4 Scanning Electron Microscopy 
Scanning electron microscopy (SEM) samples were prepared by dusting carbon 
tape-covered aluminum stubs with lyophilized, crushed microgels. The samples were 
coated with 5 or 10 nm of Pt/Pd coating using a Cressington 208 Benchtop sputter coater 
(Watford, England). Scanning electron microscopy images were obtained using an FEI 
Quanta 650 FEG scanning electron microscope (Hillsboro, OR) and a Zeiss Supra 40V 
scanning electron microscope (Jena, Germany).  
6.2.3.5 Degradation Study 
Microgels were degraded at various trypsin concentrations in 1X phosphate 
buffered saline solution (pH 7.4), simulated gastric fluid, simulated intestinal fluid, rat 
gastric fluid or rat intestinal fluid.  
Simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) were prepared 
according to USP 29 [20]. Briefly, the SGF was prepared by dissolving 2 g of sodium 
chloride and 3.2 g of purified pepsin from porcine stomach mucosa was dissolved in 
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~800 ml deionized water. 7 ml of HCl was added, then enough water to make up to 1 L 
and the pH adjusted to 1.2. SIF was prepared by dissolving 6.8 g monobasic potassium 
phosphate in 250 ml deionized water, then 77 ml of 0.2 N NaOH was added while 
stirring. 500 ml additional water was added then 10 g pancreatin was mixed into the 
solution. The pH was adjusted to 6.8 using 0.2 N NaOH or HCl then the solution was 
made up to 1 L with water.   
Gastrointestinal fluids were harvested from Sprague Dawley juvenile male rats 
(250-300 g) according to a protocol published by Yamagata et al. with some 
modifications [21]. Briefly, after sacrificing the rat the stomach was excised and ligated 
at both ends. A needle was inserted to inject 5 ml of pH 1.2 HCl-NaCl buffer (same as 
SGF minus pepsin) and the gastric contents were collected in a 50 ml centrifuge tube. 
Similarly, a ~20 cm section of the upper small intestine was cannulated and flushed twice 
with 10 ml cold PBS (1X, pH 7.4). The fluid was collected as intestinal fluid in a 50 ml 
centrifuge tube. Both the harvested fluids were centrifuged at 3,200 x g, 4°C, for 15 min 
to separate solids from the fluids. The supeRNAtants were retained as rat gastric fluid 
and rat intestinal fluid, respectively. Fluids were stored at -20°C until use. 
 Degradation was evaluated by measuring relative turbidity of the samples over 
time, as reported by Klinger and Landfester [22]. Microgels were suspended in trypsin 
solutions of varying concentration, PBS, SGF, SIF, or rat gastrointestinal fluids at various 
concentrations. 100 μl of each solution was added to a 96-well plate in triplicate, and the 
absorbance was measured at 500 nm in 5 minute intervals over 90 minutes using a Bio-
Tek Synergy™ HT multi-mode plate reader (Winooski, VT). The temperature was 
controlled at 37°C and the plate underwent shaking for 3 seconds before each 
measurement.   
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Activity of the trypsin following incubation with particles and deactivation 
methods including addition of serum-containing cell culture media and5 minutes 
incubation at 60°C, 70°C, or 80°C, was evaluated using a trypsin activity assay adapted 
from the protocol by Yanes et al. [23]. Briefly, degradation supeRNAtant was combined 
with 1 mg/ml BAEE in PBS at a 1:9 sample:BAEE ratio by volume. Immediately after 
addition of the BAEE, absorbance at 253 nm was measured at the minimum interval 
(typically 40-50 seconds) for 5 minutes using a Bio-Tek Synergy™ HT multi-mode plate 
reader (Winooski, VT). 
6.2.3.7 In vitro Cytotoxicity Study 
Lines of L929 and RAW 264.7 cells were obtained from American Type Culture 
Collection (ATCC, Rockwell, MD). All cell lines were cultured in Dulbecco’s modified 
Eagle medium (DMEM) (Mediatech, Herndon, VA) supplemented with 10% heat-
inactivated HyClone™ Fetal Bovine Serum, USDA Tested (Fisher Scientific), 1% 200 
mM L-glutamine solution (Mediatech), 100 U/ml penicillin, and 100 μg/ml streptomycin 
(Mediatech). Cytotoxicity studies were performed using DMEM without phenol red 
supplemented with 2% heat-inactivated HyClone™ Fetal Bovine Serum, USDA Tested 
(Fisher Scientific), 1% non-essential amino acids (Mediatech), 100 U/ml penicillin, and 
100 μg/ml streptomycin (Mediatech). Cells were incubated at 37°C in a 5% CO2 
environment. 
Cells were seeded at a density of 10,000 cells/well in a 96-well plate and allowed 
to incubate for 24 hours prior to the experiment. Microgels were degraded in 1.25 or 
0.625 mg/ml trypsin in PBS at concentrations ranging from 1.3-6 mg/ml. Degradation 
took place at 37°C with shaking for at least 4 hours. Trypsin was deactivated by addition 
of 2X volume DMEM without phenol red containing 2% fetal bovine serum. Cells were 
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incubated with degraded microgels for 8 hours at 37°C and 5% CO2. The cytotoxic effect 
of the microgels was evaluated using a CellTiter 96® Aqueous One Solution Cell 
Proliferation MTS Assay (Promega, Madison, WI). MTS assay was added to the wells 
and incubated for 90 minutes at the same conditions before absorbance measurements 
were made at 490 nm using a Bio-Tek Synergy™ HT multi-mode plate reader 
(Winooski, VT). Cytotoxicity is reported as ‘relative cell proliferation’, or normalization 
of the assay absorbance values to the average assay absorbance for cells incubated in only 
culture media.  
5.2.3.8 Loading and Release Studies 
Microgels were loaded by equilibrium partitioning post-synthesis with 
recombinant human insulin (Sigma). Microgels were incubated at 37°C for 4 hours in a 
0.5 mg/mL insulin solution of pH ~5.5 at a ratio of 7:1 microgel:therapeutic by weight. 
The microgels were collected by centrifugation at 10,000 x g for 5 minutes then collapsed 
by resuspension in 0.5 N HCl. Microgels were separated from supeRNAtant by 
centrifugation at 10,000 xg for 5 minutes. The loaded microgels were lyophilized and 
stored at -20°C for further studies. Protein loading was evaluated with a MicroBCA assay 
protein quantification assay (Pierce-Thermo, Rockford, IL). 
Release studies were completed in SGF or dilute Trypsin-EDTA solution in 1X 
PBS buffer at 37°C at a microgel concentration of 0.6 mg/mL buffer. Samples were taken 
at 0, 5, 10, 15, 30, 60, and 90 minutes. Concentration of released protein was evaluated 
using the MicroBCA assay and a human insulin ELISA kit (Abnova, Taiwan). 
6.3 RESULTS AND DISCUSSION 
Synthesis of the uncrosslinked P(MAA-co-NVP) was optimized to a 1:3 (w/w) 
total monomer to solvent ratio after varying the ratio from 1:5 to 1:1; the optimization 
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was based on the ratio with the highest monomer content that yielded a solution with a 
workable viscosity as opposed to a solid or solution so viscous that it could not be easily 
purified or dissolved. Purification and lyophilization yielded white, fluffy polymer. It was 
noted that the pH of the solution prior to freeze drying and lyophilization affected the 
appearance and solubility; polymer lyophilized at pH ~4 appeared more granular and 
required prolonged mixing to go into aqueous solution, whereas polymer lyophilized at 
pH ~8 looked similar to cotton balls and dissolved easily in aqueous solutions. This is 
likely due to the phase transition of MAA from hydrophobic to hydrophilic due to its 
ionized state above pH 5.    
Linear polymer lyophilized at pH ~8 was predominately used in the peptide 
crosslinking reactions due to its high solubility in aqueous conditions. Potentiometric 
titration was used to determine that the linear polymer was 45 mol% or 39 wt% MAA. 
Scheme 6.1 shows the mechanism of the EDC-NHS crosslinking reaction with the linear 
P(MAA-co-NVP). Upon dissolution of the polymer in the ethanol-water solution, the pH 
was adjusted to ~5 to favor the activation of the carboxylic acid groups by EDC and 
increase the stability of the active ester intermediate [24]. EDC was added at a molar ratio 
of 1:2 to the MAA groups on the linear chains, and NHS was added at a molar ratio of 
1:1.8 to the EDC. Upon addition of the EDC and NHS the solution became turbid but no 
precipitation was evident. Both the EDC and NHS were dissolved in ethanol to limit 
instability due to hydrolysis. 
After activation of the carboxylic acid groups, the pH was raised to ~7-8 to 
facilitate attack on the primary amines of the oligopeptide [24]. It was noted that without 
raising the pH, the crosslinking reaction would not proceed. Various 
polymer:EDC:NHS:peptide weight ratios, some of which are shown in Table 6.1, were 
tested to identify the formulation with the highest peptide incorporation and 
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reproducibility. All formulations with peptide content below a polymer:peptide ratio of 
~3:1 failed to produce hydrogels. After testing at least 25 synthesis recipes, a best 
performing formulation of solvents, polymer, and EDC-NHS was chosen to be an 
ethanol-water mixture with a polymer:EDC:NHS:peptide weight ratio of 20:10:3.3:10.  
Peptide was added at a molar ratio of 1:3.6 relative to the EDC; the free amine 
groups were in 1.4x excess relative to the theoretical maximum of activated carboxyl 
groups. Upon addition of the peptide solution the mixture was immediately turbid and 
precipitation of crosslinked polymer was evident. After reacting for at least 8 hours the 
crosslinked polymer typically resembled a hydrogel with an amorphous shape. The 
hydrogel was not broken vigorous shaking or mixing by vortex, indicating the 
mechanical integrity of the crosslinks.  
During the washes to remove impurities the hydrogel typically swelled at least 
twice in volume, and following lyophilization it appeared as fluffy white chunks, as seen 
in Figure 6.1 (initial). The dried hydrogel was easily crushed into a powder consisting of 
particles <30 μm in size, shown in the SEM micrograph in Figure 6.2.  
6.3.1 Fluorescamine Assay  
The fluorescamine assay was used to quantify the amount peptide remaining in 
solution following the EDC-NHS crosslinking reaction. The fluorescamine reagent is 
commonly used as a fluormetric assay of free amine content, thereby an indirect 
measurement of protein or peptide content [25]. A known concentration of peptide was 
used as the standard to obtain quantitative results. Assay of the reaction conditions minus 
peptide showed no background fluorescence, which is expected as the peptide is the sole 
source of free amines.  
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First, the fluorescamine assay was used to roughly optimize the ratio of linear 
polymer to peptide. The reaction efficiencies of a 1:1 and a 2:1 polymer:peptide weight 
ratio were compared as determined by peptide remaining in solution at the completion of 
the reaction. In the case of the 1:1 ratio, 16.6% of the peptide remained in solution. 
However, at the 2:1 ratio only 1.8% of the peptide remained in solution. As this was very 
satisfactory reaction efficiency, all subsequent reactions were carried out at the 2:1 
polymer:peptide weight ratio.  
The fluorescamine assay was also used to determine the effect of pH on reaction 
efficiency. According to the assay, only ~2-6% of the peptide remained in the 
supeRNAtant following the crosslinking reactions at a polymer:peptide weight ratio of 
2:1. The peptide incorporation was further affected by pH of the EDC-NHS reaction; 
nearly 98% of the peptide reacted when the carboxylic acid groups were activated at pH 
~5, while about 93% of the peptide reacted following activation at a neutral pH. 
Therefore, pH of the reaction conditions was carefully monitored and adjusted to pH ~5 
during the activation, then raised to pH ~7-8 prior to the addition of the primary amine 
groups. 
6.3.2 FTIR Spectroscopy  
FTIR spectroscopy of the linear polymer in high and low pH conditions was 
performed to confirm the presence of hydrogen bonding at low pH. As shown in Figure 
6.3, the shift in the carbonyl stretching bands from 1680 cm
-1 
to 1725 cm
-1
 and 1640 cm
-1 
between the pH 8 and pH 4 conditions confirmed the presence of hydrogen bonding 
between the carboxyl groups of the MAA and the carbonyl of the NVP [9]3.The bands at 
2500 cm-1 and 3000 cm-1 suggest intermolecular hydrogen bonding of the carboxyl 
                                                 
3 See also Section 5.3.2 
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groups on the MAA [26]. Additionally, the appearance of the band at 1560 cm
-1 
at pH 8 is 
characteristic of carboxylic groups in the ionized state [27], causing breaking of hydrogen 
bonds at high pH.  
FTIR spectroscopy was also used to evaluate the composition of the peptide-
crosslinked microgels before and after degradation. As shown in Figure 6.4, the 
characteristic bands of the carboxylic groups of MAA are present at 2900 cm
-1
 and 1560 
cm
-1
 and the bands of carbonyl groups in MAA and NVP are present at 1640 cm
-1
. 
Characteristic bands of the peptide that may be attributed to CN and NH2 stretching 
appear at 1140 cm
-1
 and 800 cm
-1 
[27]. Incorporation of the peptide into the crosslinked 
gel was confirmed by the presence of these bands. Figure 6.5 shows that there was no 
disceRNAble difference between the spectra of intact and degraded microgels. However, 
as demonstrated with the linear polymer, upon exposure to the low pH of the SGF the 
characteristic carbonyl bands were shifted compared to that in SIF, indicating the 
presence of hydrogen bonding within the microgels at low pH conditions. Interestingly, 
though, the characteristic peak of ionized carboxylic groups remained even in the low pH 
conditions of SGF, indicating that the hydrogels was not fully protonated and complexed. 
This could present issues in protected the therapeutic from the harsh gastric environment. 
6.3.3 Degradation 
The peptide crosslink was designed with multiple arginine and lysine residues so 
that it would be targeted specifically by trypsin but would not be susceptible to attack by 
pepsin [17]. Trypsin is known to cleave at the C-terminal of arginine and lysine residues 
[28] and each peptide link has 4 possible cleavage sites as shown in Scheme 6.1.  
First, degradation of the microgels was assessed visually in SGF containing the 
enzyme pepsin, SIF containing the enzyme trypsin, or PBS. As seen in Figure 6.1, the 
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hydrogel in trypsin solution is no longer visible after only 30 minutes. However, the 
hydrogel in the pepsin and PBS solutions are easily visible up to 4 hours of incubation. 
SEM was used to discern the morphology of partially degraded microgels, shown in 
Figure 6.6. The microgels were incubated in buffers for 90 minutes then flash frozen in 
liquid nitrogen and lyophilized to preserve the structure and morphology of the gels 
during swelling and degradation. Due to this process, salts crystals from the buffer 
solutions can be seen on the surface of the microgels. A microgel in SGF is shown in 
Figures 6.6A and 6.6D and a microgel in PBS is shown in Figures 6.6C and 6.6F; in both 
cases, the edges are crisp and a porous structure is easily disceRNAble. A microgel in 
SIF is shown in Figures 6.6B and 6.6E, and in this case the edges are smooth and rounded 
and the structure is more collapsed rather than porous, as if it were melting, confirming 
the loss of structural integrity due to degradation of the crosslinks. 
As the method of synthesis yields amorphous hydrogel pieces on the order of 
millimeters in size, gravimetric analysis of degradation over time is extremely difficult to 
execute. Thus, a different method of assessing degradation was sought. Turbidity is 
commonly used to evaluate the temperature-dependent phase transition and swelling of 
thermoresponsive polymers such as poly(N-isopropyl acrylamide) [29, 30], and Klinger 
and Landfester [31] showed that for photo-degradable poly(methyl methacrylate) 
particles the increase in hydrodynamic radius as a function of swelling and degradation 
correlated well with the decrease in turbidity.  
Per the second report by Klinger and Landfester [22], change in relative turbidity 
could be used to evaluate degradation as a function of time. Klinger and Landfester 
attribute the reduction in turbidity during degradation to a loosening of the network, 
resulting in greater swelling of the gel therefore less contrast between the refractive 
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indices of the solvent and the polymer [31]. Mathematically, it can be explained by the 
following equation for turbidity as described by Lechner [32]: 
𝜏 =
𝜑𝑄𝑒𝑥𝑡3
2𝑑
  (6.1) 
  where φ is the volume fraction of the particles, Qext is the Mie extinction efficiency, and 
d is that particle diameter. In most cases, it is useful to make the substitution  
𝜑 =
𝑐
𝜌
   (6.2) 
where c= mass concentration of the particles and ρ=density of the particles. Qext is a 
function of the ratio of refractive indices of the particles and solvent, np/n0, as well as the 
size of the particles, and decreases as the ratio np/n0 decreases.  
Therefore, it was hypothesized that as the enzymatically-degradable microgels 
swelled then degraded into smaller particles and linear polymer chains with minimal 
contrast between refractive indices of the polymer and solvent, the turbidity should 
decrease over time in correlation with the extent of degradation. Absorbance of the 
degrading microgel solutions was measured at an arbitrary value of 500 nm as the 
absorbance of the solutions plateaued in the 300-800 nm range. Measurements were 
made in 5 minute intervals over a period of at least 90 minutes. The absorbance value 
was first converted to percent transmittance using the following equation  
𝐼 = 10(2−𝐴)  (6.3) 
then to turbidity using the equation 
𝜏(𝑡) = −ln (
𝐼𝑡
𝐼0
) (6.4) 
where It is transmittance of the sample at time t and I0 is transmittance of pure solvent. 
Finally, relative turbidity was calculated as  
𝜏𝑟𝑒𝑙 =
𝜏(𝑡)
𝜏(𝑡=0)
  (6.5) 
and plotted as a function of time.  
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As hypothesized, upon incubation with trypsin solutions of various concentrations 
the turbidity of the microgel solutions decreased over 90 minutes, shown in Figure 6.7. 
Since the mass concentration of particles was held constant, it is logical that trypsin 
concentration was directly related to extent of reduction in relative turbidity; the higher 
the trypsin content, the greater the degradation.    
Interestingly, when microgels were incubated in low trypsin concentrations or in 
PBS there was an initial increase in turbidity followed by decreasing turbidity or a 
plateau in the case of PBS. As the particles are expected to swell in PBS and swell then 
degrade in the trypsin, this behavior is incongruent with the explanation set forth by 
Klinger and Landfester [31], in which turbidity is expected to decrease with swelling of 
the particles. Looking at the relationship for turbidity established by Lechner in Eq. 6.1, 
turbidity is dependent upon particle size and concentration as well as the contrast 
between polymer and solvent refractive indices. This initial increase in turbidity may be 
attributed to the increase in size of the particles, which can increase turbidity due to light 
scattering. The imbibition of solvent by the swollen particles likely reduced the refractive 
index of the particles but was not sufficient to overcome the effect of the particle size 
contribution, particularly at this particle concentration. At approximately 30 minutes the 
particles in PBS reached equilibrium swelling, at which point the relative turbidity 
became constant. The point at which the degradation by trypsin was sufficient enough to 
overcome the effect of particle size and reduce the relative turbidity was dependent upon 
the concentration of trypsin, with the transition to decreasing relative turbidity happening 
sooner at higher trypsin concentrations where degradation is presumably happening on a 
faster timescale.  
The degradation of the microgels during incubation with the rat gastrointestinal 
fluids versus trypsin solutions is shown in Figure 6.8.  As in the previous case, the 
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relative turbidity of the microgels in PBS solution increased for the first ~30 minutes then 
was relatively constant over the remainder of the 4 hour incubation period. Relative 
turbidity of particle solutions at both the 0.3 and 0.6 mg/ml trypsin concentrations 
decreased to well below 10% by the end of the 4 hour incubation, though the solution 
with higher trypsin concentration arrived at a lower value in a shorter period of time. The 
relative turbidity of the particles incubated with gastric fluid was approximately constant 
for nearly 3 hours, at which time the evaporation of the fluid started to have an effect on 
the enzyme concentration, the absorbance path length, or both, and turbidity decreased 
slightly. Most encouraging, though, was the significant degradation of the microgels 
incubated in rat intestinal fluid. The relative turbidity steadily decreased across the 4 hour 
incubation period, arriving at a final reduction in relative turbidity of 85%. Though the 
degradation was not as rapid as the trypsin solutions, the intestinal fluid was significantly 
diluted during harvest so it is quite possible that the physiological trypsin concentration is 
higher, resulting in more rapid degradation in vivo. These results are extremely promising 
for oral drug delivery applications, as the degradation is specific to intestinal fluid and 
occurs on a timescale relevant to small intestinal residence time [33]. 
The activity of trypsin can be evaluated by spectrophotometric measurement 
using BAEE, an arginine-based trypsin substrate that absorbs at 253 nm upon cleavage by 
trypsin. Trypsin activity is correlated to rate of absorbance increase over the initial 5 
minutes of the reaction, which reaches a plateau when the reaction is complete [34]. Due 
to the scale of the degradation reactions, the assay was adapted and optimized for a 96-
well assay format on the microliter-scale as opposed to the previously reported milliliter-
scale protocols.  
Using the optimized reaction conditions for the 96-well assay, various 
degradation and trypsin deactivation conditions were evaluated to determine the trypsin 
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activity as a function of microgel concentration as well as determining an effective 
method of deactivating trypsin prior to exposure to cells. Microgel concentrations of 0, 
1.5, 3, and 6 mg/ml were incubated with 0.6 mg/ml trypsin at 37°C for 90 minutes. In the 
first experiment, DMEM with 2% fetal bovine serum was added to the degradation 
solution at 0, 80, or 160 μl amounts to quench the trypsin activity. As shown in Figure 
6.9, the samples receiving no DMEM had a strong linear correlation in absorbance 
increase over time; as previously reported, the greater the slope of this linear fit the 
higher the trypsin activity [34]. Slope and R
2
 values of the linear fit for each particle 
concentration are shown in Table 6.2, and it can be seen that trypsin activity is reduced in 
the presence of higher microgel concentrations. This confirms that trypsin activity is 
being consumed by the peptide crosslinks within the microgels, leading to the 
degradation of the microgels as desired. At all concentrations tested absorbance did not 
reach a plateau, meaning that trypsin was in excess relative to peptide crosslinks and 
could likely be used at a lower concentration to achieve degradation.  
Therefore, in a subsequent study microgel concentration was held constant at 2 
mg/ml and trypsin concentration was varied from 0.0375-0.6 mg/ml. As seen in Figure 
6.10A, the lowest two trypsin concentrations of trypsin solutions containing no microgels 
have final absorbance values below that of the control, PBS, indicating no appreciable 
trypsin activity. Therefore, we can expect to see little degradation at those concentrations. 
As expected, samples taken after 90 minutes of incubation with microgels quickly 
reached a plateau during the trypsin assay, shown in Figure 6.10B, confirming low 
activity. Trypsin concentrations of 0.3 and 0.6 mg/ml were sufficient to maintain enough 
trypsin activity to degrade peptide crosslinks in the microgels. Further narrowing the 
range of trypsin concentrations, the activity assay was used to determine that trypsin 
concentrations down to 0.2 mg/ml maintained sufficient activity during degradation with 
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microgels (data not shown). Figure 6.10C demonstrates that the trypsin activity was 
effectively quenched by incubation at 70°C for 5 minutes.  
Upon addition of DMEM containing serum, trypsin activity is entirely consumed 
by reaction with protein in the serum and the increase in absorbance due to reaction with 
BAEE is negligible. This is desirable for subsequent exposure to cells in later studies, as 
trypsin can have a negative impact on cell metabolism and behavior. However, the 
downside is that the microgel concentration is significantly diluted upon addition of the 
DMEM so initial degradation reactions must be highly concentrated.  
In the next study, trypsin was deactivated by heating for a short amount of time. 
According to the literature, a 5 minute incubation period in temperatures ranging from 
60-80°C should be sufficient to deactivate the trypsin [35]. Following the 90 minute 
degradation period in 0.6 mg/ml trypsin, samples at each microgel concentration were 
incubated at 60, 70, or 80°C for 5 minutes. The BAEE trypsin activity assay indicated 
that samples incubated at 60°C still contained some trypsin activity, as evidenced by the 
positive increase in absorbance over time shown in Figure 6.11A. However, the slope 
was much less than that of samples with active trypsin with values ranging from only 16-
26 a.u./min compared to 64-80 a.u./min.  
Samples incubated at 70°C and 80°C for 5 minutes had negligible trypsin activity, 
shown in Figure 6.11B. This method of deactivation could be advantageous to the 
addition of DMEM, as microgels remain concentrated and less material will be needed 
for subsequent studies. The effect of particles and inactivated trypsin on cell metabolism 
should be thoroughly investigated, though.  
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6.3.4 Cytotoxicity 
Cytotoxicity studies were performed with various microgel concentrations to find 
the maximum concentration that L929 murine fibroblast and RAW 264.7 murine 
macrophage  cells could withstand without disruption to metabolic activity. Microgels 
were incubated in 1.2 or 0.6 mg/ml trypsin solution for at least 4 hours to ensure 
degradation of the microgels; PBS buffer was used as a control. As trypsin can have 
negative effects on cell function [36], particularly antigen-presenting ability of 
macrophages [37], the trypsin was deactivated by the addtion of excess cell media prior 
to the addtion to cells. Cells were incubated with degraded microgel solutions for 8 hours 
to assess cytotoxic effect. Figures 6.12A and 6.12B show L929 and RAW 264.7 cell 
proliferation, respectively, relative to a cells incubated in normal media without 
microgels. Viability greater than 80% is considered acceptable in our evaulation. For all 
formulations and concentrations, cell proliferation is greater than 80% relative to the cells 
incubated in normal media. This was somewhat unexpected, as concentrations above 1.25 
mg/ml of nondegradable particles with a similar formulation induced some cytotoxicity 
in human carcinoma cells [9]4. This supports the hypothesis that the size of the 
nondegradable particles posed a physical impediment of cellular activity due to the 
density of the sedimenting particles covering the cell monolayer. It was concluded that 
these degradation conditions and the degraded microgels within these concentrations 
posed minimal cytotoxic threat to these two cell lines. 
6.3.5 Loading and Release 
Insulin, a small therapeutic protein ~5.8 kDa, was used in loading and release 
studies as an oral delivery method for insulin has been widely investigated for many 
                                                 
4 See also Section 5.3.6 
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years. Protein concentration was measured in the supeRNAtant following the 4 hour 
loading period with microgels, then again in the supeRNAtant following collapse of the 
microgels in 0.5 N HCl. Protein that was likely surface loaded was lost during the HCl 
wash. However, a significant amount of protein remained loaded following the HCl 
wash, disproving the possibility of diffusion from the microgels in low pH conditions. 
Loading efficiencies were calculated as follows, where co is the initial protein 
concentration, cf is the final protein concentration, masso is the initial mass of protein in 
solution, massf is the final mass of protein in solution, and massp is the mass of polymer 
in solution:  
𝐿𝑜𝑎𝑑𝑖𝑛𝑔 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 =  
𝑐𝑜−𝑐𝑓
𝑐𝑜
∗ 100    (6.6) 
 
𝑊𝑒𝑖𝑔ℎ𝑡 𝐿𝑜𝑎𝑑𝑖𝑛𝑔 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 =  
𝑚𝑎𝑠𝑠𝑜−𝑚𝑎𝑠𝑠𝑓
𝑚𝑎𝑠𝑠𝑜−𝑚𝑎𝑠𝑠𝑓+𝑚𝑎𝑠𝑠𝑝
∗ 100  (6.7) 
The overall loading efficiency of the insulin, shown in Figure 6.13A, was ~41% 
and the weight loading efficiency of insulin was 5.7%, shown in Figure 6.13B. Though 
the loading and weight efficiencies leave room for improvement, they were comparable 
to those reported for similar hydrogel systems with large proteins [9, 11].  
Release studies were carried out by incubating the microgels in SGF or SIF for 90 
minutes, and samples were taken at 5, 10, 15, 30, 60 and 90 minutes. Unfortunately, the 
ELISA was unable to detect any insulin in the samples (data not shown). Since the 
standards created from the insulin loading solution were detected by the ELISA, the lack 
of detection in the release samples is either due to degradation or insolubility in the 
release conditions.  
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6.4 CONCLUSIONS 
Synthesis of the linear polymer and crosslinked hydrogels was greatly affected by 
pH of the respective reaction solutions. The crosslinking reaction was most successful 
using linear polymer lyophilized at pH 8 in a two-part EDC-NHS linking reaction 
transitioned from pH 5 to pH 8. Incorporation of the peptide was consistently above 97% 
as determined by fluorescamine assay of the peptide remaining in solution, and 
incorporation was verified by IR spectra.  
Proteolytic degradation of the peptide crosslinks upon incubation with trypsin 
solutions, SIF, and rat intestinal fluid was demonstrated by reduced relative turbidity as a 
function of time and trypsin concentration. In contrast, relative turbidity of the microgel 
solutions remained constant upon incubation in PBS, SGF, and rat gastric fluid, verifying 
that the microgels were not susceptible to degradation by the gastric enzyme pepsin. The 
degradable microgels induced negligible cytotoxic effects, even at high concentration, in 
both the degraded and nondegraded states. These studies confirm the biodegradable 
behavior of the peptide crosslinked hydrogel is highly suitable for intestinal delivery 
applications.  
The P(MAA-co-NVP) polymer backbone demonstrated pH responsive behavior, 
swelling at neutral conditions and collapsing at low pH gastric conditions. However, 
complexation of the MAA groups at low pH was not complete, allowing some swelling at 
low pH conditions that could pose issues moving forward with oral delivery studies. 
Despite this potential drawback, the microgels were able to efficiently load the 
therapeutic protein insulin and retain the loaded protein in low pH conditions. Insulin 
release could not be determined due to instability in the release conditions. In conclusion, 
this work clearly demonstrates that the enzymatic response, relevant degradation 
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timescale, and high biocompatibility of this biodegradable microgel system endow it with 
significant potential as a vehicle for oral delivery of delicate therapeutics. 
  
 136 
6.5 TABLES 
Trial Polymer EDC NHS Peptide Result 
1 26 10 3.3 1 Failed 
2 53 10 3.3 1 Failed 
3 53 10 3.3 1 Solubility issues 
4 22 10 3.3 10 Hydro el 
5 10 10 3.3 10 Hydro el 
6 25 10 3.3 6.8 Hydro el 
7 22.5 10 3.3 6.8 Hydro el 
8 20 10 3.3 10 Hydro el 
9 17 10 3.3 10 Hydro el 
 Table 6.1: Crosslinking reaction formulations (by weight ratio) and outcomes. The best 
performing formulation (Trial 8) is highlighted in yellow.  
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Microgel Concentration 
(mg/ml) 
R
2
 Slope 
6 0.89 51.1 
3 0.99 64.4 
1.5 0.99 68.3 
0 0.99 80.7 
Table 6.2: Linear parameters of the activity assay of 0.6 mg/ml trypsin incubated with 
various concentrations of P(MAA-co-NVP) microgels containing 
degradable crosslinks for 90 minutes (37°C, pH 7.4, N=3). As indicated by 
the high linear correlation, the trypsin remains active at the end of the 
incubation period, and the activity is a function of microgel concentration 
incubated with the trypsin as indicated by the slope of the fitted line. 
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6.6 FIGURES 
 
 
Scheme 6.1: Peptide crosslinking reaction scheme. Carboxylic acid groups on the 
poly(methacrylic acid-co-N-vinylpyrrolidone) linear polymer are 
activated by EDC, then react with at least two of the five primary amine 
groups on the GRRRGK peptide to form a crosslinked hydrogel 
network.  
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Figure 6.1: Visual indication of hydrogel degradation in SIF (trypsin), SGF (pepsin), or 
PBS over a 4 hour incubation period. After synthesis and lyophilization, the 
hydrogel is fluffy, white, and chunky in appearance (Initial). At only 30 
minutes after addition of the various buffers, the hydrogel in SIF is no 
longer visible to the naked eye. Hydrogel incubated in SGF or PBS is still 
visible at the 4 hour time point.  
  
 
Initial 30 in 60 in  0 in 4 hrs 
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Figure 6.2: P(MAA-co-NVP) microgels with peptide crosslinks in the dry state, crushed 
and sieved to <30 μm. Particles were dusted onto a carbon-tape coated 
aluminum stub then coated with 10 nm Pt/Pd. A) scale bar = 10 μm; B) 
scale bar = 5 μm (HV=15.00 kV, WD=9.6 mm). 
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Figure 6.3: FT-IR spectra of uncrosslinked P(MAA-co-NVP) lyophilized at pH 4 or pH 
8 and peptide crosslinked P(MAA-co-NVP) at neutral pH; samples were 
pressed in a KBr disk.  
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Figure 6.4: FT-IR spectra of GRRRGK peptide, uncrosslinked P(MAA-co-NVP) 
lyophilized at pH 8, and peptide crosslinked P(MAA-co-NVP) at neutral 
pH; samples were pressed in a KBr disk. 
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Figure 6.5: FT-IR spectra of peptide crosslinked P(MAA-co-NVP) at neutral pH and 
peptide crosslinked P(MAA-co-NVP) degradation products following 
incubation with SGF, SIF, SIF without pancreatin, or a trypsin solution; 
samples were lyophilized and pressed in a KBr disk. 
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Figure 6.6: SEM micrographs of microgels after 90 minutes incubation in A) SGF 
(scale =10 μm); B) SIF (scale=10 μm); C) PBS (scale=10 μm); D) SGF 
(scale =5 μm); E) SIF (scale=5 μm); F) PBS (scale=5 μm); (EHT=5.00 kV, 
WD=15.6 mm). Following incubation, microgels were lyophilized and 
dusted onto a carbon-tape coated aluminum stub, then coated with 5 nm 
Pt/Pd. 
  
    C 
D E F 
 145 
 
Figure 6.7: Relative turbidity over time of 2 mg/ml solutions of P(MAA-co-NVP) 
microgels with degradable crosslinks incubated in trypsin solutions ranging  
from 0-0.6 mg/ml trypsin in PBS (37°C, pH 7.4, N=3).  
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Figure 6.8: Relative turbidity over time of 2 mg/ml solutions of P(MAA-co-NVP) 
microgels with degradable crosslinks incubated in PBS, 0.3 mg/ml trypsin in 
PBS, 0.6 mg/ml trypsin in PBS, rat gastric fluid
*
, or rat intestinal fluid 
(37°C, pH 7.4, N=3). *Gastric fluid error bars intentionally not shown to 
simplify the plot; error is ±0.24 on average in a consistent manner across the 
period of the study. 
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Figure 6.9: Activity assay of 0.6 mg/ml trypsin incubated with various concentrations of 
P(MAA-co-NVP) microgels containing degradable crosslinks for 90 
minutes, and then deactivated with 0, 80, or 160 μl DMEM (37°C, pH 7.4, 
N=3). Trypsin activity in the samples receiving no DMEM is evidenced by 
the strong linear correlation. Both volumes of DMEM were sufficient 
quench trypsin activity. 
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Figure 6.10: Activity assay of various trypsin concentrations incubated A) without 
microgels B) with 2 mg/ml P(MAA-co-NVP) microgels containing 
degradable crosslinks for 90 minutes, and C) deactivated at 70°C for 5 
minutes (degradation at 37°C, pH 7.4, N=3).  
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Figure 6.11: Activity assay of 0.6 mg/ml trypsin incubated with various concentrations of 
P(MAA-co-NVP) microgels containing degradable crosslinks for 90 
minutes, and then deactivated with 5 minutes incubation at A) 60°C and B) 
70°C or 80°C (degradation at 37°C, pH 7.4, N=3). Incubation at either 70°C 
or 80 °C was sufficient to deactivate trypsin. 
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Figure 6.12: Evaluation of degraded microgel exposure effect on cell metabolism using 
an MTS cell proliferation assay (Promega). Microgels were incubated in 
PBS or 1.2 mg/ml trypsin in PBS for 90 minutes at 37°C, then the enzyme 
activity was quenched by addition of media with serum. Murine fibroblast 
L929 and murine macrophage RAW 264.7 cells were incubated with 
degraded microgel solutions ranging from 0.43-2 mg/mL in culture media 
for 8 h. Following removal of the microgel solutions, the MTS assay was 
allowed to incubate for 90 min. Cell proliferation is relative to the positive 
control (culture media only, patterned bar) (N=3). 
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Figure 6.13: Loading efficiencies of degradable P(MAA-co-NVP) microgels with peptide 
crosslinker. Insulin (MW 5.8 kDa) was loaded into the microgels. Loading 
efficiency was based on amount of protein into microgels relative to initial 
amount in solution. Weight loading efficiency is weight of loaded protein 
relative to total weight of microgel and protein. Microgels were loaded over 
4 hours at 37°C (N=3). 
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Chapter 7: Biodegradable Microencapsulated Nanogels for Orally 
Delivered siRNA 
7.1 INTRODUCTION  
RNA interference, an endogenous mechanism for silencing specific genes [1], has 
exciting potential as a therapy for many diseases. In fact, there are approximately thirty 
recent or active clinical trials involving small interfering RNA (siRNA) therapy, but at 
least twenty of the studies utilize intravenous or injection-based methods of 
administration and none of the studies administer siRNA orally [2]. Oral delivery of 
siRNA would be particularly well-suited to treating diseases of the gastrointestinal (GI) 
tract, such as inflammatory bowel diseases, and intestinal absorption also offers a route to 
systemic delivery. However, there are many extracellular and intracellular barriers to oral 
siRNA delivery such as proteolytic degradation  [3], harsh pH environments  [4], and the 
necessity to achieve intracellular delivery and endosomal escape while maintaining the 
integrity of the siRNA  [5, 6], making successful oral delivery of siRNA a daunting task.  
The current strategies for oral delivery of siRNA to the intestine are relatively few 
in number, and they employ creative solutions that are only effective in a limited 
capacity. For example, Aouadi et al. [7] developed the first oral delivery system, in which 
a cationic core was loaded with layers of siRNA and additional polycationic polymer, and 
encapsulated in β1,3-ᴅ-glucan microshells. The system was very potent, reducing target 
protein expression by up to 80%, but lacked specificity in targeting and delivery.  
Amiji et al. [8, 9] developed a hybrid nanoparticle-in-microsphere oral delivery 
system to the intestinal mucosa in which FITC-gelatin nanoparticles were embedded in a 
poly(ε-caprolactone) matrix of less than 2-5 μm in diameter,. Though it performed well in 
vivo its ability to withstand low pH conditions and prevent premature release of siRNA is 
questionable.  
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Thioketal nanoparticles were designed by Wilson et al. [10] to be degraded by 
reactive oxygen species produced by phagocytes at the site of inflammation in the 
intestine, thereby delivering siRNA to knockdown a well-known inflammatory cytokine 
as a treatment for inflammation. The highly specific release mechanism of this system is 
quite appealing for treating inflammatory diseases of the gastrointestinal tract, but is not 
translatable to disease models in which inflammation is not present. Laroui et al. [11] 
published a report on branched polyethyleneimine complexed with siRNA, loaded into 
polylactides, and covered with polyvinyl alcohol in a multi-step synthesis process. The 
particles were then encapsulated in alginate or chitosan for oral administration to mice, 
where they were effective in reducing the target protein expression.  
These studies establish a solid foundation but leave significant room for 
improvement, particularly in terms of increasing delivery specificity, maintaining siRNA 
integrity, and increasing dosage efficacy. Consequently, there is great need to design an 
improved polymer carrier which can not only protect siRNA from harsh gastric 
conditions and target delivery to specific regions of diseased or healthy intestine, but can 
also facilitate cellular uptake and endosomal escape into the cytoplasm where RNAi 
occurs. One strategy to achieve this is by encapsulating polycationic nanogels within a 
biodegradable intestinal delivery vehicle. 
To achieve this goal, polycationic 2-(diethylamino)ethyl methacrylate-based 
nanogels were encapsulated within an enzymatically-degradable poly(methacrylic acid-
co-N-vinyl-2-pyrrolidone) hydrogel. Thus, the anionic hydrogel should protect the 
payload in gastric conditions but swell, degrade, and release the nanogels complexed with 
siRNA in intestinal conditions. Herein, the synthesis, biodegradation, siRNA loading, 
cellular uptake, cytotoxicity, and silencing efficiency of this novel microencapsulation 
system for oral siRNA delivery are described.  
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7.2 EXPERIMENTAL METHODS 
7.2.1 Chemicals 
Methacrylic acid (MAA), N-vinyl pyrrolidone (NVP), and Irgacure 184® (1-
hydroxy-cyclohexyl-phenylketone) were obtained from Sigma-Aldrich (St. Louis, MO). 
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) was obtained 
from Sigma Aldrich. N-hydroxysuccinimide (NHS) was obtained from Pierce 
Biotechnology, Inc. (Rockford, IL). The custom sequence oligopeptide GRRRGK was 
synthesized by CHI Scientific (Maynard, MA). All reagents were used as received. 
Purified pepsin from porcine gastric mucosa (≥2500 U/mg), pancreatin from porcine 
pancreas (4x USP specifications), Trypsin-EDTA solution (1X) and Nα-benzoyl-L-
arginine ethyl ester hydrochloride (BAEE) trypsin substrate were obtained from Sigma-
Aldrich. 4-Chloro-7-nitrobenzofurazan (NBD-Cl, 98%) was obtained from Acros 
Organics (Geel, Belgium). All other solvents and buffers were purchased from Fisher 
Scientific (Waltham, MA). Polycationic 2-(diethylamino)ethyl methacrylate-based 
nanogels (~100 nm diameter) were synthesized by Forbes et al. [12] and tagged with a 
fluorescent molecule, NBD-Cl, by Forbes et al. [13]. 
7.2.2 Synthesis and Purification 
7.2.2.1 Synthesis of Linear Polymer 
P(MAA-co-NVP) linear polymer was synthesized by photoinitiated, free-radical 
polymerization. MAA and NVP were added at a 1:1 molar ratio to a 1:1 (w/w) deionized 
water and ethanol solution to yield a 1:3 (w/w) total monomer to solvent ratio. 
Photoinitiator Irgacure 184
®
 was added at 1 wt% with respect to total monomer weight.  
The mixture was homogenized by sonication then the round bottom flask was 
sealed with a rubber septum. The solution was purged with nitrogen for 20 minutes, then 
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the reaction was initiated with a Dymax BlueWave® 200 UV point source (Dymax, 
Torrington, CT) at 100mW/cm
2
 intensity and allowed to polymerize for 30 minutes while 
stirring. 
Following polymerization, the linear polymer was purified from unreacted 
monomer by addition of 1 N hydrochloric acid (HCl) to precipitate polymer, 
centrifugation, and resuspension in deionized water. After 3 wash cycles, the polymer 
solution was frozen in liquid nitrogen (LN2) and lyophilized for at least 24 hours.  
7.2.2.2 Synthesis of Peptide Crosslinked Gels 
Linear P(MAA-co-NVP) was dissolved in a 1:1 (v/v) water:ethanol solution at a 
concentration of 50 mg/ml. EDC was dissolved in ethanol at a concentration of 50 mg/ml 
and NHS was dissolved in ethanol at a concentration of 16 mg/ml. The EDC and NHS 
solutions were added to the polymer solution at a ratio of 6:3:1 polymer:EDC:NHS by 
weight. The solution was mixed by vortex briefly, then allowed to react for ~3 min with 
shaking. Polycationic nanoparticles in a 10 mg/ml solution in ethanol were added at 10 
wt% relative to the P(MAA-co-NVP) and the solution was briefly mixed by vortex. The 
pH was raised to ~8 by the addition of 1 N sodium hydroxide (NaOH), and then a volume 
of 100 mg/ml peptide in ethanol solution was added to achieve a 2:1 weight ratio of 
polymer:peptide. The mixture was allowed to react overnight with shaking then purified 
by 3 wash cycles with water and centrifugation at 10,000 x g for 5 minutes. Following the 
washes, the polymer was frozen in LN2 and lyophilized for at least 24 hours. 
After lyophilization, the polymer was milled into a fine power by crushing with 
mortar and pestle. The powder was sifted to the size ranges of 30-75 μm and less than 30 
μm by ultraprecision ASTM sieves (Precision Eforming, Cortland, NY). 
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7.2.3 Cell Culture 
Human colon adenocarcinoma Caco-2, murine fibroblast L929, and murine 
macrophage RAW 264.7 cells obtained from American Type Culture Collection (ATCC, 
Rockwell, MD). All cell lines were cultured in Dulbecco’s modified Eagle medium 
(DMEM) (Mediatech, Herndon, VA) supplemented with 10% heat-inactivated 
HyClone™ Fetal Bovine Serum, USDA Tested (Fisher Scientific), 1% 200 mM L-
glutamine solution (Mediatech), 100 U/ml penicillin, and 100 μg/ml streptomycin 
(Mediatech). Cytotoxicity studies were performed using DMEM without phenol red 
supplemented with 2% heat-inactivated HyClone™ Fetal Bovine Serum, USDA Tested 
(Fisher Scientific), 1% non-essential amino acids (Mediatech), 100 U/ml penicillin, and 
100 μg/ml streptomycin (Mediatech) or OptiMEM® reduced serum media (no phenol 
red) (Life Technologies, Grand Island, NY). Transfection studies were completed in 
OptiMEM® reduced serum media (no phenol red). Cells were incubated at 37°C in a 5% 
CO2 environment. 
7.2.4 In vitro Cytotoxicity Study 
Cells were seeded at a density of 10,000 cells/well in a 96-well plate and allowed 
to incubate for 24 hours prior to the experiment. Microgels were degraded in 0.3-1.25 
mg/ml trypsin in phosphate buffered saline (PBS) at concentrations ranging from 1.3-6 
mg/ml. Degradation took place at 37°C with shaking for 90 minutes or 4 hours. Trypsin 
was deactivated by addition of 2X volume DMEM without phenol red containing 2% 
fetal bovine serum or by incubation at 70°C for 5 minutes. Cells were incubated with 
degraded microgels for 18 hours at 37°C and 5% CO2. The cytotoxic effect of the 
microgels was evaluated using a CellTiter 96® Aqueous One Solution Cell Proliferation 
MTS Assay or a CytoTox-ONE™ Homogeneous Membrane Integrity Assay (Promega, 
Madison, WI). In the case of the proliferation assay, MTS was added to the wells and 
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incubated for 90 minutes at the same conditions before absorbance measurements were 
made at 490 nm using a Bio-Tek Synergy™ HT multi-mode plate reader (Winooski, VT). 
In the case of the membrane integrity assay, 50 μl of the cell media from each well was 
combined with 50 μl of the assay solution in a black-walled 96-well plate, incubated at 
room temp for 10 minutes, then the fluorescence was measured at 530/560 
(sensitivity=60) using a Bio-Tek Synergy™ HT multi-mode plate reader (Winooski, VT). 
Cytotoxicity is reported as ‘relative cell proliferation’ using the MTS assay and ‘percent 
viability’ using the membrane integrity assay.   
7.2.5 siRNA Loading 
Microgels containing NBD-labeled nanogels were loaded by equilibrium 
partitioning post-synthesis with Silencer® Select Negative Control No. 1 (Life 
Technologies), AllStars Mm/Rn Cell Death Control siRNA, AllStars Hs Cell Death 
Control siRNA, Negative Control siRNA (Qiagen, Hilden, Germany), or fluorescently 
labeled DyLight 647-labeled siRNA (Sense: DY647-
UAAGGCUAUGAAGAGAUACUU (Thermo Scientific, Lafayette, CO). Microgels 
were incubated at a concentration of 12 mg/ml at 37°C for 1.5 hours in a 400 nM or 100 
nM siRNA solution in nuclease-free PBS at pH ~5.5. Nuclease free 10X PBS was 
prepared by dissolving sodium chloride, potassium chloride, monobasic potassium 
phosphate, and sodium phosphate dibasic heptahydrate in water, treating with 0.1% v/v 
diethylpyrocarbonate (DEPC) overnight, and then autoclaving to remove DEPC. The 
microgels were collected by centrifugation at 10,000 x g for 5 minutes. The loaded 
microgels were stored at -20°C until further studies. siRNA loading was evaluated by 
Quant-iT™ RiboGreen® RNA Assay Kit (Invitrogen). 
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7.2.6 Microgel Degradation and siRNA Stability 
7.2.6.1 Microgel Degradation 
Microgels were degraded at various trypsin concentrations ranging from 0.2-1.2 
mg/ml in 1X phosphate buffered saline solution (pH 7.4), simulated gastric fluid, 
simulated intestinal fluid, rat gastric fluid or rat intestinal fluid.  
Simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) were prepared 
according to USP 29 [14]. Briefly, SGF was prepared by dissolving 2 g of sodium 
chloride and 3.2 g of purified pepsin from porcine stomach mucosa was dissolved in 
~800 ml deionized water. 7 ml of HCl was added, followed by enough water to make up 
to 1 L and the pH adjusted to 1.2. SIF was prepared by dissolving 6.8 g monobasic 
potassium phosphate in 250 ml deionized water, then 77 ml of 0.2 N NaOH was added 
while stirring. 500 ml additional water was added then 10 g pancreatin was mixed into 
the solution. The pH was adjusted to 6.8 using 0.2 N NaOH or HCl then the solution was 
made up to 1 L with water.   
Gastrointestinal fluids were harvested from Sprague Dawley juvenile male rats 
(250-300 g) according to a protocol published by Yamagata et al. with some 
modifications [15]. Briefly, after sacrificing the rat the stomach was excised and ligated 
at both ends. A needle was inserted to inject 5 ml of pH 1.2 HCl-NaCl buffer (same as 
SGF minus pepsin) and the gastric contents were collected in a 50 ml centrifuge tube. 
Similarly, a ~20 cm section of the upper small intestine was cannulated and flushed twice 
with 10 ml cold PBS (1X, pH 7.4). The fluid was collected as intestinal fluid in a 50 ml 
centrifuge tube. Both the harvested fluids were centrifuged at 3,200 x g, 4°C, for 15 min 
to separate solids from the fluids. The supeRNAtants were retained as rat gastric fluid 
and rat intestinal fluid, respectively. Protein content of the fluids was measured using a 
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NanoDrop 1000 spectrophotometer (Thermo Scientific, Wilimington, DE). Fluids were 
stored at -20°C until use. 
 Degradation was evaluated by measuring relative turbidity of the samples over 
time, as reported by Klinger and Landfester [16]. Microgels were suspended in trypsin 
solutions of varying concentration, PBS, SGF, SIF, or rat gastrointestinal fluids at various 
concentrations. 100 μl of each solution was added to a 96-well plate in triplicate, and the 
absorbance was measured at 500 nm in 5 minute intervals over 90 minutes using a Bio-
Tek Synergy™ HT multi-mode plate reader (Winooski, VT). The temperature was 
controlled at 37°C and the plate underwent shaking for 3 seconds before each 
measurement. 
Activity of the trypsin following incubation with particles and deactivation 
methods including addition of serum-containing cell culture media and 5 minutes 
incubation at 70°C was evaluated using a trypsin activity assay adapted from the protocol 
by Yanes et al. [17]. Briefly, degradation supeRNAtant was combined with 1 mg/ml 
BAEE in PBS at a 1:9 sample:BAEE ratio by volume. Immediately after addition of the 
BAEE, absorbance at 253 nm was measured at the minimum interval (typically 40-50 
seconds) for 5 minutes using a Bio-Tek Synergy™ HT multi-mode plate reader 
(Winooski, VT). 
7.2.6.2 Evaluation of siRNA Stability by Polyacrylamide Gel electrophoresis 
For polyacrylamide gel electrophoresis, samples were degraded in trypsin 
concentrations from 0.3-1.2 mg/ml for 90 min then the trypsin was deactivated with 
DMEM or heat. Samples were also incubated in rat gastric fluid, rat intestinal fluid, PBS, 
or SGF to determine release and stability of siRNA. Competitive polyanion assays were 
completed using solutions of heparin sodium salt from porcine intestinal mucosa (Sigma-
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Aldrich) to competitively complex with the polycationic nanogels and promote siRNA 
dissociation from the nanogels. Ribonuclease A from bovine pancreas (RNAse A) 
(Sigma-Aldrich) was used as a positive degradation control; siRNA was incubated in a 
0.05 mg/ml RNAse A solution for 90 minutes at 37°C.  Samples were diluted 1:1 by 
volume with Novex® TBE-urea sample loading buffer (2X) (Life Technologies), 
denatured at 70°C for 3 min, and loaded into a Novex® TBE-urea denaturing 
polyacrylamide gel with 15% crosslinking (Life Technologies). The gel was run at 
constant 180V for 70 min in 1X Novex® TBE running buffer (Life Technologies).  
Following the run, the gel was stained with SYBR green II (Sigma-Aldrich) diluted 
1:10,000 by volume in 1X TBE running buffer for 30 minutes with shaking, the gel was 
rinsed with DI water for 5 minutes with shaking, and then the gel was imaged with a 
Typhoon 9500 fluorescent imager using the SYBR green II filter, 50 μm pixel size, 500 
pmt. (GE Life Sciences, Pittsburgh, PA). 
7.2.7 Confocal Microscopy 
Microgels were fluorescently labeled with TAMRA-cadaverine (Biotium) via 
EDC-NHS reaction. Briefly, 15 mg microgels were mixed with 1.25 mg of EDC and 1.25 
mg NHS in 0.1 M MES buffer at pH 4.7. After a ~3 minute incubation period at room 
temperature, 15 μl of 0.5 mg/ml TAMRA-cadaverine solution was added and allowed to 
react for 2 hours at room temperature. The polymer was washed 5X by centrifugation at 
10,000 x g for 5 minutes and resuspension in 1 ml DI water to remove unreacted 
fluorophore. The final wash was left overnight to allow the polymer to fully swell. The 
microgels were centrifuged again, the supeRNAtant removed, and the remaining polymer 
flash-frozen in LN2 followed by lyophilization. Fluorescent microgels were incubated in 
 165 
PBS or trypsin at a concentration of 2 mg/ml for 90 minutes. Slides were prepared by 
mounting 10 μl of particle solution on slides with ProLong® gold antifade reagent. 
For cell uptake studies, coverslips (18 mm round, no. 1.5 thickness) were acid-
washed overnight with 1 N HCl at 60°C, rinsed with ethanol/water mixtures with 
successively increasing volume ratios of ethanol, and then the coverslips were placed in a 
12-well plate. RAW 274.6 cells were seeded in the wells at a density of 115,000 
cells/well. Microgels containing NBD-labeled nanogels, with or without fluorescently 
labeled DY647 siRNA, were degraded at a concentration of 2.5 mg/ml in 0.6 mg/ml 
trypsin for 60 minutes then incubated at 70°C for 5 minutes to deactivate trypsin. 24 
hours after plating the cells, the media was aspirated and replaced with 0.4 ml OptiMEM 
and 0.1 ml of degraded microgel solution. Lipofectamine 2000 (Life Technologies) 
loaded with fluorescently labeled DY647 siRNA was used as a positive control for 
siRNA delivery. Cells were incubated with the particles or Lipofectamine 2000 for 18 
hours.  
After the incubation period, the media was aspirated and the cells were washed 
3X with cold Dulbecco's phosphate buffered saline (DPBS, Sigma-Aldrich), fixed with 
cold IC fixation buffer containing 4% paraformaldehyde (Life Technologies), and 
washed 3X wish cold Hyclone™ Hank’s balanced salt solution (HBSS, Fisher 
Scientific). In some cases, the cell membrane was stained with 1 μg/ml AlexaFluor® 594 
conjugated wheat germ agglutin (Life Technologies) for 10 minutes then washed 2X with 
cold HBSS and once with cold, sterile DI water. ProLong® gold antifade reagent with or 
without DAPI stain (Life Technologies) was used to mount the coverslips on acid-washed 
slides. Slides were stored at -4°C until imaging. 
Slides were imaged with Zeiss LSM 710 confocal microscope with 40x- and 63x-
oil objectives. Sequential scanning was used to eliminate emission bleed-though between 
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channels. The pinhole was set to 1 AU in the green channel. The gain and offset for each 
channel were set using single stain controls, and were kept constant for the full series of 
images to allow image comparisons. Images were collected in 8 bit format with an 
average=4 to reduce noise, and all images underwent identical postprocessing (γ = 0.7 for 
red, blue, and green channels, γ = 0.1.3 for bright-field). 
7.2.8 ImageStream Flow Cytometry 
Microgels containing NBD-labeled nanogels and were incubated in PBS (pH 7.4) 
or 0.6 mg/ml trypsin solution at 1.5 mg/ml for 60 min then the trypsin was deactivated by 
incubation at 70°C for 5 minutes. Analysis of nanogel distribution and microgel 
degradation was conducted using Amnis ImageStream (Seattle, WA) imaging flow 
cytometer. Nanogels were excited with a 488 laser and detected in channel 2 (505-560 
nm) and bright field images were collected in channel 4 (595-660 nm). At least 10,000 
events were collected for analysis. Out-of-focus particles and debris were excluded from 
the analysis by gating the Gradient RMS feature in IDEAS® software; typically, events 
with Gradient RMS value <50 were considered out of focus. Fluorescence intensity in the 
green channel was gated to intensity values > 3000.  
7.2.9 Cell Transfection 
RAW 264.7 cells were seeded at 10,000 cells/well in 96-well cell culture plates 
for transfection studies. The RAW 264.7 cells were allowed to incubate approximately 48 
hours and the Caco-2 cells approximately 24 hours, until they reached a confluence of 
about 50%. 
After the appropriate cell growth period, microgels were loaded with siRNA for 
transfection studies using the same conditions described in Section 7.2.4. Microgels were 
loaded with AllStars Mm/Rn Cell Death Control siRNA, AllStars Hs Cell Death Control 
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siRNA, or Negative Control siRNA at a loading concentration of 400 nM. Microgels 
were degraded at a concentration of 3.5 or 2 mg/ml in 0.3 mg/ml trypsin in PBS at 37°C 
for 90 minutes. Nanoparticles were complexed with siRNA (AllStars Mm/Rn Cell Death 
Control siRNA, AllStars Hs Cell Death Control siRNA, or Negative Control siRNA) in 
1X PBS pH 5.5 at 0.125 mg/mL nanoparticles and 400 nM siRNA for ~15 prior to 
addition to cells. siRNA (400 nM) was incubated with 2 μl Lipofectamine 2000 (positive 
control) in 78 μl OptiMEM for ~15 minutes prior to addition to cells.  
The microgels were added to cells at a final concentration of 0.7 and 0.4 mg/mL 
in OptiMEM, nanoparticles were added to cells at a final concentration of 0.025 mg/ml in 
OptiMEM, and the Lipofectamine 2000 loading solution was added to cells at a 1:5 
dilution in OptiMEM. Cells were incubated with particles for 48 hours, at which point the 
media was removed by aspiration and replaces with CellTiter 96® Aqueous One Solution 
Cell Proliferation MTS Assay (Promega). Cells were incubated with MTS solution for 90 
minutes, and the absorbance at 490 and 690 nm was measured with a Bio-Tek Synergy™ 
HT multi-mode plate reader (Winooski, VT). The viability results for the AllStars Death 
and the Negative Control siRNA were compared by Student's t test (two-tailed, unequal 
variance) to check for statistically significant silencing. The silencing efficiency was 
evaluated using the absorbance of cells with death siRNA and cells with negative control 
siRNA as shown in Eq. 7.1: 
 
𝑠𝑖𝑙𝑒𝑛𝑐𝑖𝑛𝑔 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 = 100 𝑥 (1 −
𝐴𝐷𝑒𝑎𝑡ℎ
𝐴𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒
)  7.1 
7.3 RESULTS AND DISCUSSION 
P(MAA-co-NVP) was synthesized and crosslinked with peptide as described in 
Section 6.3, the only difference being the addition of polycationic nanogels prior to the 
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addition of the peptide. The polycationic nanogels were added at 10 wt% with respect to 
polymer weight and appeared brown in color due to the conjugated fluorophore NBD-Cl. 
Prior to use in the microgels, NBD-Cl was reacted in excess to primary amines present in 
the nanogels to serve a dual purpose; first, to impart fluorescent detection of the nanogels, 
and second, to protect the primary amines from reacting during the EDC-NHS reaction 
with the peptide crosslink.  
Upon addition of the peptide, the mixture was immediately turbid and 
precipitation of brown, crosslinked hydrogel was evident. After the reaction was 
complete, the hydrogel was washed by repeated centrifugation and resuspension in DI 
water to remove impurities. The supeRNAtant was retained from each wash to determine 
the incorporation efficiency of the nanogels. Following the washes, the hydrogel was 
frozen in LN2 and lyophilized. The dry product appeared as fluffy brown chunks, and was 
easily crushed into a powder consisting of particles <30 μm in size. 
7.3.1 Incorporation of Polycationic Nanogels 
The fluorescence of the nanogels in the wash supeRNAtant was measured using a 
Bio-Tek Synergy™ HT multi-mode plate reader and compared to the fluorescence values 
of known concentrations of nanogels. It was determined that 30-40% of the nanogels 
were incorporated into the hydrogel, bringing the final weight ratio to 3-4% with respect 
to the polymer weight.  
Incorporation of the polycationic nanogels was visualized using confocal laser 
scanning microscopy. The hydrogel particles were labeled with a TAMRA fluorophore 
that was reactive to carboxylic acid functional groups on the P(MAA-co-NVP). After 
purification, the particles were lyophilized and a known weight was resuspended in PBS 
(pH 7.4). Slides were prepared by dropping the particle solution onto a slide and fixing 
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the coverslips with ProLong® gold antifade reagent. Imaging of the particles confirmed 
the presence of the nanogels (green) within the P(MAA-co-NVP) particles (red), as seen 
in Figure 7.1. The porous structure of the hydrogels was also discernible in the bright 
field image, in Figure 7.1D. A Z-stack image, Figure 7.2, was obtained to verify the 
distribution of nanogels throughout the particle. Though the nanogels were throughout 
the particle, they did tend to be present in clusters or pockets, which is consistent with the 
method of crosslinking.  
7.3.2 Degradation of Microgels with Nanogels 
Degradation studies with SIF, SGF, trypsin, and PBS were completed to verify 
that incorporation of the nanogels did not affect degradation kinetics. As previously 
observed in hydrogels without nanogels5, the turbidity of the particle solutions could be 
used as a measure of degradation over time. Figure 7.3 shows the decrease in turbidity 
over time of 1.5-6 mg/ml microgels in 0.6 or 1.2 mg/ml trypsin. All concentrations 
plateaued at the lowest turbidity value within 90 minutes, which was approximately the 
same as microgels containing no nanogels. Therefore, it does not seem as if the nanogels 
significantly affect the degradation kinetics. However, as the relative turbidity plateaued 
at values of 18% and higher, it is possible that the nanogels prevent complete degradation 
of the microgels. This may be attributed to the reaction of some of the amine groups 
present in the nanogels during the EDC-NHS crosslinking reaction, effectively 
incorporating the nanogels as nondegradable crosslinks within the gel. While this is an 
undesirable side reaction that reduces the number of nanogels able to be released from the 
microgels, it is thought to be limited by the protection of the amine groups via NBD-Cl 
and is not prevalent enough to affect the ability of the microgels to degrade.  
                                                 
5 See Section 6.3.3 
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It was further noted that the initial change in turbidity over the first 20 minutes of 
exposure to trypsin was linear, as shown in Figure 7.4A (1.2 mg/ml trypsin) and Figure 
7.4B (0.6 mg/ml trypsin). The corresponding microgel to trypsin ratio versus initial rate 
of turbidity decrease values were then plotted to determine the relationship. The fit was 
nearly linear, as shown in Figure 7.5 (R
2
=0.98), and may be used to approximate 
degradation time of a known microgel to trypsin weight ratio.    
Additionally, trypsin activity assays with BAEE were performed to ensure the 
quenching of trypsin activity prior to exposure to cells. Microgels were incubated with 
1.2 mg/ml or 0.6 mg/ml trypsin in pH 7.4 PBS for 90 minutes at 37°C, and then subjected 
to deactivation by incubation at 70°C for 5 minutes or addition of 2X volume DMEM 
containing serum. Figure 7.6A shows the complete deactivation of 1.2 mg/ml trypsin by 
both heat and DMEM compared unadulterated trypsin solutions, and Figure 7.6B shows 
the same for 0.6 mg/ml trypsin solutions. Therefore, it was concluded that either was a 
satisfactory method of deactivating trypsin at concentrations at and below 1.2 mg/ml. 
As further confirmation of nanogel incorporation as well as visualization of 
degradation on the micro-scale, microgels in various solutions were imaged with 
ImageStream flow cytometry. This equipment enabled the analysis of entire populations 
of microgels using parameters such as fluorescence intensity in a particular channel or 
particle size as detected by bright field imaging. It allowed real-time imaging and 
quantification of the change in particle size distribution during degradation.  
Representative images obtained via ImageStream analysis of microgels incubated 
for 90 minutes in 1.2 mg/ml trypsin, 0.6 mg/ml trypsin, or pH 7.4 PBS are shown in 
Figure 7.7A, 7.7B, and 7.7C, respectively. Analysis of the microgel populations 
confirmed that at least 70% of the events detected had fluorescent intensities above a 
minimum threshold. Further, the events were gated to remove out-of-focus particles and 
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debris from further analysis. The images revealed distinct differences in the size and 
morphology of the microgels following incubation in the trypsin or PBS solutions; 
microgels exposed to trypsin are smaller in size and less porous in appearance than 
microgels exposed to only PBS. Additionally, the fluorescence intensity is very strong 
and dense in the trypsin samples, whereas it is more diffuse throughout the PBS samples. 
This could be an indication of formation of strongly fluorescent and highly compact 
complexes between nanogels and degraded hydrogel due to electrostatic binding, rather 
than diffusion of nanogels from the degradation hydrogel as desired.  
The size distribution of the events was also plotted in histogram form to better 
quantify the change in size as a function of degradation. Figure 7.8 compares the 
histogram plots of microgels incubated in A) 1.2 mg/ml trypsin, B) 0.6 mg/ml trypsin, 
and c) PBS. It was observed that compared to the PBS control the size range of microgels 
was greatly reduced from a maximum of 2800 μm2 to 600 μm2 upon incubation in 
trypsin, as would be expected due to enzymatic degradation. Also convincing was the 
shift in median particle area from 163 μm2 in PBS to 39 μm2 in trypsin. 
Similar results were obtained using ImageStream to visualize large populations of 
microgels incubated in SGF, SIF, or 1.2 mg/ml trypsin solution. Samples were run after 
0, 15, 30, 60, and 120 minutes of incubation in each of the conditions. As before, events 
were gated by fluorescence intensity as well as gradient RMS, a metric used to gate for 
images in the focal plane. Figure 7.9 compares representative images of microgels in 
each of the solutions at time zero, and Figure 7.10 compares the histogram plots of the 
size distribution of events in each solution at time zero. The size distribution of microgels 
in SGF and SIF was much broader than that of microgels in trypsin, and again the 
fluorescence was more diffuse in particles incubated in SGF and SIF than in trypsin. The 
median microgel sizes were 54, 79, and 23 μm2 in SGF, SIF, and trypsin, respectively. 
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Unfortunately, since it was not logistically possible to run the samples at exactly at time 
zero, some degradation had already occurred in the trypsin samples at the nominal time 
zero. Consequently there was a slight misrepresentation of the particle size and 
fluorescent intensity in the trypsin samples at the nominal time zero. 
However, the size and fluorescence visualization of the microgels after 120 
minutes of incubation was very indicative of the degradation over a longer period of time. 
Figure 7.11 shows representative images of the microgels in each condition and Figure 
7.12 shows histogram plots of the corresponding microgel size distributions. It is 
apparent from the images that again the size, morphology, and fluorescence intensity of 
microgels exposed to SIF and trypsin had discernible differences from that of microgels 
incubated in SGF, a non-degrading buffer. The degraded particles were small in size and 
entirely fluorescent compared to their larger undegraded counterparts with diffuse 
clusters of fluorescence. The histogram plots confirm quantitatively that the size range 
decreased upon exposure to degrading buffers, and the median sizes were 65 μm2 in SGF 
to 25 and 26 μm2 in SIF and trypsin, respectively. Therefore, after 120 minutes of 
incubation in the buffers, the median size of the microgels in SGF did not decrease, as 
expected, while the median sizes of microgels exposed to SIF and trypsin did decrease 
due to degradation.  
Figure 7.13 shows the median microgel size (μm2) at each time point in each of 
the three buffers. It can be seen that median size of the particles incubated in SGF 
fluctuated over time, but did not follow a decreasing trend. The median size of particles 
incubated in SIF, on the other hand, gradually decreased over the 120 minute incubation 
period, as would be expected of microgels slowly degraded in the presence of a 
physiologically relevant concentration of trypsin. Microgels exposed to 1.2 mg/ml 
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trypsin, however, decreased in median size due to degradation by the time of the first 
measurement and did not degrade further over the 120 minute period.  
 7.3.3 Cytotoxicity of Degraded Microgels with Nanogels 
As the degradation behavior of the microgels containing nanogels was consistent 
with a relevant timescale in simulated intestinal conditions, the next step was to ensure 
the cytocompatibility of the degraded and undegraded microgels in trypsin solutions of 
varying concentration. These studies were critical, as both polycationic polymers such as 
the nanogels [18] and active trypsin [19, 20], can have a detrimental effect on cell health 
and metabolism. Caco-2 human adenocarcinoma cells, often used to model the intestinal 
epithelium, and RAW 264.7 murine macrophage, used to model target cells for nanogel 
uptake, were used in these studies. Two cytotoxicity assays were used; the MTS cell 
proliferation assay was indicative of any changes to cell metabolism upon exposure to 
microgels, and the LDH membrane integrity assay was indicative of the viability of cells 
after exposure.  
Microgels were incubated in 1.25 or 0.625 mg/ml trypsin solution for at least 4 
hours to ensure degradation of the microgels; PBS buffer was used as a control. Trypsin 
was deactivated by the addtion of excess cell media prior to the addtion to Caco-2 cells. 
Cells were incubated with degraded microgel solutions for 18 hours to assess cytotoxic 
effect. Figures 7.14A and 7.14B show Caco-2 cell proliferation and viability, 
respectively, as a function of microgel and trypsin concentration relative to cells 
incubated in normal media without microgels. The cell proliferation was affected by the 
degraded microgels in a concentration-dependent manner; the highest concentration of 2 
mg/ml induced an unaccetpable amount of change in cell metabolism as measured by the 
MTS assay.  However, all concentrations maintained very high cell viability after 18 
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hours of incubation. Thus, high concentrations of degraded microgels may affect the 
metabolism of Caco-2 cells, but the do not kill the cells.  
A comprehensive study evaluating effect of trypsin concentration, culture 
medium, and trypsin concentration during degradation was performed in the RAW 264.7 
cells. Microgels at a concentration of 2 mg/ml were degraded in 0.15, 0.2, 0.25, and 0.3 
mg/ml trypsin for 90 minutes at 37°C, and then the trypsin was deactivated by incubation 
at 70°C for 5 minutes. The microgels were then added to the cells at a final concentration 
of 1 mg/ml or 0.4 mg/ml in OptiMEM or 1 mg/ml in DMEM. Two different culture 
media were tested as the OptiMEM is a reduced-serum medium, and the presence of 
serum is thought to negatively impact cellular uptake and transfection by nanoparticles. 
Therefore, it was hypothesized that increased uptake of nanoparticles with inherently 
cytotoxic cationic functional groups may be more disruptive to the cell metabolism or 
cell membrane.  
Figure 7.15 shows the results of the MTS cell proliferation assay following 
incubation of the RAW 264.7 cells with the degraded microgels for 18 hours. Absorbance 
at 490 nm is relative to that of cells exposed only to culture medium for the 18 hour 
incubation period. In all three exposure conditions, undegraded microgels in PBS were 
slightly less disruptive to cell metabolism than degraded microgels, suggesting that 
degradation of the microgel matrix does cause increased cellular exposure to the 
potentially cytotoxic polycationic nanogels within.  
Figure 7.15A shows that the 1 mg/ml microgel concentration in OptiMEM did 
have an effect of cellular metabolism, as the relative absorbance was reduced below 50% 
at all trypsin concentrations. Also important to note is that cells exposed to the 
deactivated trypsin without microgels also experienced a reduction in relative 
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absorbance, indicating the negative effect of high trypsin concentrations on cell 
metabolism. 
Figure 7.15B indicates that the same microgel concentration in serum-containing 
DMEM resulted in less effect on cell metabolism due to the degraded microgels, as the 
relative absorbance of trypsin with and without microgels was approximately the same. 
This could be due to the serum content causing nonspecific protein binding to the 
nanogels, resulting in a reduction in both cytotoxicity and cellular uptake. It is important 
to note, though, that this concentration of microgels did result in a 30% reduction in 
absorbance relative to the control cells incubated in DMEM only. Therefore, this 
microgel concentration still significantly affects cell metabolism.  
Finally, Figure 7.15C shows the results of the MTS assay of RAW 264.7 cells 
incubated with 0.4 mg/ml degraded microgels in OptiMEM culture medium. As 
expected, the lower microgel concentration resulted in less disruption of cell metabolism 
relative to cells exposed only to OptiMEM, with a decrease in relative absorbance of only 
~25% across all trypsin concentrations. There was also little difference in relative 
absorbance between cells incubation deactivated trypsin alone or deactivated trypsin with 
degraded microgels.  
The results from the LDH assay, shown in Figure 7.16, mirror the results from the 
MTS assay, with the only notable exception being a much more pronounced effect of 1 
mg/ml degraded microgels in DMEM on membrane integrity, shown in Figure 7.16B. 
Interestingly, this negative effect was a function of microgel:trypsin ratio, with ratios 
likely resulting in less degradation being less detrimental to cell viability. In fact, 
undegraded microgels in PBS were significantly less toxic at 70% viability than 
microgels incubated in the lowest trypsin concentration, at 40% viability. This strongly 
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suggests that the degradation products or release of nanogels from degraded microgels 
has a detrimental effect on cell membrane viability at this concentration.  
At the reduced concentration of 0.4 mg/ml in OptiMEM shown in Figure 7.16C, 
however, cell viability is quite high at >80% for all conditions tested. In subsequent cell 
transfection studies, these conditions were used to induce minimal toxic effect as a result 
of microgels or degradation conditions.   
7.3.4 siRNA Loading 
Loading studies were conducted with the Silencer® Select Negative Control No. 
1 scrambled sequence siRNA at 1000 nM or 400 nM to evaluate the ability of the 
microgels to load siRNA. Microgels were incubated with the siRNA at a particle 
concentration of 12 mg/ml in pH 5.5 PBS for up to 4 hours at room temperature with 
agitation. The loading pH was selected as both the microgels and nanogels are partially 
charged at this condition, facilitating swelling of the hydrogel networks to allow 
increased diffusion of siRNA to complex with the positively charged nanogels. Following 
incubation, the microgel/siRNA solutions were centrifuged to separate loaded microgels 
from siRNA remaining in solution. Afterwards, the siRNA content in the supeRNAtant 
was measured with the Quant-iT™ RiboGreen® RNA Assay Kit. 
 Loading efficiencies were calculated as follows, where co is the initial molar 
siRNA concentration, cf is the final molar siRNA concentration, and cp is the mass 
concentration of polymer in solution:  
 
𝐿𝑜𝑎𝑑𝑖𝑛𝑔 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 =  
𝑐𝑜−𝑐𝑓
𝑐𝑜
∗ 100  (7.2) 
 
𝑊𝑒𝑖𝑔ℎ𝑡 𝐿𝑜𝑎𝑑𝑖𝑛𝑔 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 =  
𝑚𝑜𝑙𝑒𝑠𝑜−𝑚𝑜𝑙𝑒𝑠𝑓
𝑚𝑎𝑠𝑠𝑝
 (7.3) 
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Representative weight and loading efficiencies of the scrambled siRNA are shown 
in Figure 7.17. This scrambled siRNA sequence achieved weight efficiencies of 0.06 and 
0.02 nmol siRNA/mg polymer and loading efficiencies of 75% and 59% in 1000 nM and 
400 nM siRNA loading concentrations, respectively. The weight and loading efficiencies 
were highest in the loading solution with the greater siRNA concentration, as would be 
expected due to the greater concentration gradient acting as a diffusional driving force.  
In general for a variety of siRNAs tested, weight efficiencies ranged from 0.02-0.11 nmol 
siRNA/mg polymer, and loading efficiencies ranged from 59-90%. The variation in 
loading efficiency was attributed to batch-to-batch variability in the microgels as well as 
differences in siRNA sequences. Incubation time for loading did not greatly affect 
efficiencies, and consequently the loading period was reduced to 1.5 hours to limit 
degradation of siRNA by hydrolysis.  
The loading efficiencies were consistently lower than those achieved with 
nanogels alone [21], but this was to be expected due to the increased complexity of 
diffusion through the microgel matrix as well as the possibility of unfavorable 
electrostatic repulsion between the polyanionic P(MAA-co-NVP) and negatively charged 
siRNA. Overall, the results indicate that these concerns are not prohibitive to loading 
siRNA into the microgels as significant loading of the siRNA was achieved.  
7.3.5 Microgel Degradation and siRNA Stability 
As siRNA is quite susceptible to degradation by proteases [3], there was concern 
that the stability and integrity of the siRNA could be compromised during the trypsin-
induced degradation of the microgels. Therefore, the stability of the siRNA following 
incubation in various conditions was evaluated by polyacrylamide gel electrophoresis 
(PAGE), as has been reported previously in the literature [22]. PAGE separates molecules 
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by electrophoretic mobility, which is a function of the size, conformation and charge of 
the molecule. Thus, it is widely used to determine the stability of various biological 
molecules including proteins, RNA, and DNA.  
In the case of denaturing PAGE, as was utilized in the studies herein, the higher 
order structure of the siRNA was denatured by exposure to urea, limiting the dependence 
of electrophoretic mobility to size and charge alone. In this way, the degradation of 
siRNA in various conditions was examined. Microgels with nanogels loaded with siRNA, 
nanogels complexed with siRNA, and siRNA alone were incubated in 0.3 mg/ml trypsin 
in PBS, rat intestinal fluid, rat gastric fluid, PBS, or SGF for 90 minutes at 37°C followed 
by 5 minutes incubation at 70°C to deactivate trypsin. Microgels were incubated at a 
concentration of 5 mg/ml, nanogels at a concentration of 0.4 mg/ml, and siRNA at a 
concentration of 400 nM. Figure 7.18A shows the image of the gel; it was noted that the 
samples incubated with trypsin showed signs of significant siRNA degradation, 
evidenced by the smaller molecular weight bands in lanes 1, 6, and 11. However, it was 
positive that at least some of the siRNA remained stable in rat intestinal fluid and PBS 
(lanes 2, 7, 12 and 4, 9, 14, respectively), conditions where siRNA degradation is 
undesirable. As expected, rat gastric and SGF conditions resulted in noticeable siRNA 
degradation (lanes 3, 8, 13 and 5, 10, 15, respectively). Few concrete assertions can be 
made regarding siRNA release from the degraded microgels and nanogels other than the 
fact that it is taking place, as evidenced by the bands corresponding to the stable siRNA 
band in lane 14.  
The same siRNA-loaded samples incubated in the various conditions were then 
incubated in 0.5 mg/ml heparin in OptiMEM to better evaluate release of siRNA in the 
various conditions. Heparin was used as a competitive polyanion to induce dissociation 
of the siRNA from the polycationic nanogels, as other researchers have reported [23, 24]. 
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Figure 7.18B shows the image of the gel of the samples after incubation with heparin. 
Again, it was observed that free, undegraded siRNA was present in all samples with the 
exception of the samples incubated at high trypsin concentration. The presence of heparin 
did not seem to increase dissociation of the siRNA. Of course, it is impossible to say 
conclusively whether or not the free siRNA increased upon incubation with heparin 
without extracting and quantifying siRNA in the gel, but it was determined that the effort 
required to quantify the siRNA was not justified in this experiment. The presence of free, 
undegraded siRNA following incubation in physiologically relevant proteolytic 
conditions was confirmed, and this proof-of-concept was sufficient for these studies.  
Looking for closely at the effect of trypsin on siRNA stability, siRNA, siRNA 
complexed with nanogels, and microgels with nanogels loaded with siRNA were 
degraded in 0.6 mg/ml trypsin for 1 hour at 37°C, and then the trypsin was deactivated by 
incubation at 70°C for 5 minutes. One set was added to PBS an identical set was added to 
a 0.5 mg/ml heparin solution to promote dissociation of siRNA. As a control, siRNA was 
incubated in 0.05, 0.1, and 0.5 mg/ml Ribonuclease A to fully degrade the siRNA.  
Figure 7.19A shows the PAGE results. Intact siRNA bands were clearly shown in 
lanes 1 (without heparin) and 5 (with heparin), though some bands of degraded siRNA 
were also present. Faint bands of intact siRNA were present in the nanogel samples 
(lanes 2 and 6) as well as in one of the degraded microgel samples (lanes 4 and 8). Again, 
it seemed as if heparin had no effect on the amount of free siRNA. It was unexpected that 
only one of the microgel samples contained intact siRNA, it is possible that the sample in 
lanes 3 and 7 was contaminated with an RNase. The bands of siRNA fully degraded by 
RNase can be seen in lane 9; the higher concentrations of RNase degraded the siRNA to 
such an extent that it ran off the gel and was no longer detectable.  
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To verify that the degradation observed in all samples was not due to the 
incubation temperature or pH at which the siRNA was incubated, siRNA alone was 
incubated on ice, at room temperature followed by 90°C for 5 minutes, pH 5.5 PBS at 
37°C, pH 8.5 PBS at 37°C, with microgels at loading conditions, and in 1.2 or 0.6 mg/ml 
trypsin with and without particles at 37°C. As shown in Figure 7.19B, only the siRNA 
exposed to trypsin, with or without microgels, experienced degradation. This confirms 
that the high trypsin activity was the culprit behind the degraded siRNA and not 
hydrolysis at elevated temperature.   
While it was encouraging that some free, intact siRNA was released from 
microgels and nanogels, the amount of siRNA degraded by trypsin was disconcerting. 
Fortunately, the concentrations of trypsin used in these studies are much higher than 
physiologically relevant trypsin levels. As demonstrated in rat intestinal fluid, the ability 
of these microgel systems to deliver intact siRNA in physiological or in vivo conditions 
may be much greater than these studies project.     
7.3.6 Confocal Microscopy to Verify InteRNAlization 
Confocal laser scanning laser microscopy was used to verify cellular 
inteRNAlization of nanogels from degraded microgels. Microgels containing 
fluorescently tagged nanogels were incubated in 0.6 mg/ml trypsin for 90 minutes to 
degrade the microgel matrix and allow release of the nanogels. Following degradation, 
the samples were incubated at 70°C for 5 minutes to deactivate the trypsin and the 
degraded microgels were added to cells at a final concentration of 0.5 mg/ml in 
OptiMEM. The cells were incubated for 18 hours with the degraded particles then fixed, 
stained with fluorescently labeled wheat germ agglutinin, a cell membrane marker, then 
extensively washed and mounted onto slides with ProLong® gold antifade reagent 
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containing DAPI nuclear stain. Nanogels alone were used for comparison, as the cellular 
inteRNAlization of the nanogels has been previously documented [13]. All images were 
representative of the entire cell population; in each condition tested, the cells were at 
approximately 60% confluence and appeared to be in good health as determined by the 
bright field images. 
Figure 7.20 shows the fluorescent and bright field images of RAW 264.7 cells 
incubated with A) nanogels and B) degraded microgels containing nanogels. In both 
cases, comparison of the artificially-colored green in the third panel with the bright field 
images in the fifth panel as well as the fluorescent overlay in the fourth panel indicated 
the presence of nanogels in proximity to the nuclei of cells, suggesting inteRNAlization. 
Interesting to note is the high prevalence of micron-size particles with green fluorescence 
both near and around the cells in the degraded microgel samples; this lends credibility to 
the working theory that upon degradation the nanogels do not completely release from 
the microgel matrix. Rather, they may be electrostatically bound with degraded microgel 
products in a highly fluorescent complex that is microns in size.  
To verify inteRNAlization of nanogels, Z-stack images through the cells were 
taken. An orthogonal view of the Z-stacks, shown in Figure 7.21, confirmed the presence 
of the nanogels within the artificially-colored red cell membranes. Within the orthogonal 
view, the main panel displays the x-y plane, the bottom panel displays the x-z plane, and 
the right panel displays the z-y plane. In both the cells with nanogels, Figure 7.21A, and 
the cells with degraded microgels and nanogels, Figure 7.21B, the nanogels were 
localized within the cells membranes, which was likely indicative of endosomal 
compartmentalization. In the case of the degraded microgels with nanogels, at least some 
of the potentially electrostatically-bound nanogel complexes were still able to be 
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inteRNAlized by cells. Therefore, the complexation does not entirely prohibit 
inteRNAlization, but may affect efficacy and siRNA delivery.  
With the goal of getting a better idea of the electrostatic interactions between the 
microgels, nanogels, and siRNA, all three of which are charged species, microgels and 
nanogels loaded with DY 647-siRNA were also degraded and incubated with RAW 264.7 
cells in the same manner. Figure 7.22 shows images of cells incubated with A) degraded 
microgels containing nanogels and siRNA; B) nanogels complexed with siRNA; and C) 
TAMRA-labeled microgels with nanogels and siRNA. Again, in all three cases the 
fluorescence of the nanogels in relation to the bright field image suggests that cellular 
uptake of the nanogels may be occurring. Additionally, the fluorescence of the siRNA is 
in good spatial agreement with the nanogel fluorescence, indicating complexation 
between the two species. As before, the relatively large clusters of degraded microgel and 
nanogels are visible around the cells in the bright field images of A and C, and there is 
associated fluorescence of each of the charged molecules corresponds to these clusters. 
This strongly suggests complexation between microgels, nanogels, and siRNA, but it is 
impossible to conclude whether or not the complexes are still capable of transfection and 
gene silencing from microscopy images alone.  
7.3.7 Transfection of Murine Macrophage and Human Adenocarcinoma Cells 
Transfection conditions were determined by the best cytotoxicity, degradation, 
and siRNA stability results. RAW 264.7 murine macrophage and Caco-2 human 
adenocarcinoma cells were incubated with siRNA and degraded microgels (0.4 and 0.7 
mg/ml), undegraded microgels (0.7 mg/ml), nanogels (0.025 mg/ml), commercially 
available transfection agent Lipofectamine 2000, or naked siRNA. Both cell lines were 
treated identically, with the exception of mouse and human variant AllStars Death 
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siRNA. Silencing was measured by an MTS assay of cell proliferation relative to that of 
scrambled siRNA controls. Experiments were run in quadruplicate and were repeated 
across two sets of each cell line. 
As shown in Figure 7.23, similar gene silencing was obtained in both the A) 
RAW 264.7 and B) Caco-2 cell lines. At all concentrations and conditions tested, the 
microgels were unable to achieve greater than 20% silencing, and in some instances the 
variation between experiments was quite large. In fact, in the RAW cells the silencing by 
the degraded microgels with nanogels was significantly less than the silencing by 
nanogels with siRNA (T-test, p<0.05). Silencing efficiency was of a similar magnitude in 
the Caco-2 cells, but none of the samples performed significantly better than the others in 
this cell line.  
Though the nanogels were able to achieve a significant silencing efficiency in the 
RAW 264.7 cells, the percentage is still much less than what has been previously 
reported of these particles [13], so it is possible that the experimental conditions are not 
conducive to high transfection and silencing. It is much more likely, however, that the 
electrostatic interactions between P(MAA-co-NVP), the nanogels, and the siRNA are 
complicating transfection and silencing. Additionally, as the MTS assay is a measure of 
cell metabolism rather than cell death, it may not be the ideal assay to evaluate silencing 
efficiency. It was used in these studies to allow for direct comparison to the previous 
work by Forbes and Peppas [13]. 
However, a positive aspect of the transfection studies was that the viability of the 
cells exposed only to the various hydrogel particles (no siRNA) was consistently at or 
greater than 60%. Toxicity of transfection agents is a continual challenge in delivering 
siRNA, and fortunately neither the nanogels nor the degradable microgels containing 
nanogels induced very high levels of toxicity during transfection. Also encouraging was 
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the repeatability of these results in separate studies; though well-to-well variability was 
high for a few samples, the magnitude of average silencing efficiency and viability was 
consistent from study to study as well as across cell lines, making the results more 
credible.  
7.4 CONCLUSIONS 
Nanogels were encapsulated in enzymatically-degradable P(MAA-co-NVP) 
microgels via a facile crosslinking reaction. Nanogel incorporation and distribution was 
confirmed by fluorescent spectroscopy and confocal microscopy. Enzyme-specific 
degradation of the microgels was evaluated by decrease in relative turbidity over time as 
well as ImageStream flow cytometry; the degradation timescale was relevant to intestinal 
residence time and the degradation products induced minimal cytotoxic effects at low 
concentrations.  
siRNA was efficiently loaded into the microgel systems due to equilibrium 
partitioning and charge interactions. However, the siRNA did experience reduced 
stability following incubation in the microgel degradation conditions, particularly at high 
trypsin concentrations. Despite the attack by trypsin on the siRNA, a detectable amount 
was released from the microgel system and escaped degradation, especially in the 
physiologically relevant buffers, which is promising for future in vivo applications.  
Cellular uptake of nanogels released from degraded microgels was confirmed in 
RAW 264.7 cells by confocal microscopy. Both ImageStream analysis and confocal 
microscopy suggest that electrostatic complexation is occurring between the negatively 
charged degraded P(MAA-co-NVP) and positively charged nanogels, but some of the 
complexes, free nanogels, or both are inteRNAlized by the cells. However, the ability of 
the system to induce gene silencing is somewhat disappointing, perhaps due to loss of 
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siRNA stability upon incubation with trypsin or due to electrostatic interactions 
interfering with the delivery. Though the ability of the system to induce gene silencing is 
somewhat disappointing, the transfection efficiencies are consistent across both Raw 
264.7 and Caco-2 cell lines.  
Future work on this system should focus on tuning the charge densities of the 
nanogels and microgel encapsulation system to limit electrostatic binding. The 
performance of this system should also be evaluated in vivo or in conditions more closely 
resembling in vivo to verify the biodegradability and silencing efficiency; it is possible 
that a greater portion of the siRNA will remain stable at physiological trypsin 
concentrations, and competing charged molecules in the intestinal environment may 
decrease the electrostatic binding via competitive dissociation.    
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7.5 FIGURES 
 
Figure 7.1: Image of P(MAA-co-NVP) microgel crosslinked by degradable peptide and 
encapsulating polycationic nanogels taken by confocal laser scanning 
microscopy. A) Nanogels labeled with NBD-Cl (green); B) P(MAA-co-
NVP) microgel matrix labeled with TAMRA-cadaverine (red); C) green and 
red overlay showing nanogel distribution in microgel; D) bright field image 
of microgel. (Scale bar = 30 μm) 
  
  
C D 
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Figure 7.2: Orthogonal view of Z-stack image of P(MAA-co-NVP) microgel 
crosslinked by degradable peptide and encapsulating polycationic nanogels 
taken by confocal laser scanning microscopy. Nanogels labeled with NBD-
Cl (green) in P(MAA-co-NVP) microgel matrix labeled with TAMRA-
cadaverine (red). (Scale bar = 30 μm) 
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Figure 7.3: Relative turbidity over time of various concentrations of P(MAA-co-NVP) 
microgels with degradable crosslinks encapsulating nanogels during 
incubation in 0.6 and 1.2  mg/ml trypsin in PBS (37°C, pH 7.4, N=3).  
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Figure 7.4: Relative turbidity over the first 20 minutes of incubation of trypsin with 
various concentrations of P(MAA-co-NVP) microgels with degradable 
crosslinks encapsulating nanogels; A) 1.2 mg/ml trypsin; B) 0.6 mg/ml 
trypsin in PBS (37°C, pH 7.4, N=3). Initial decrease in relative turbidity was 
fitted with a linear fit (R
2
>0.98). 
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Figure 7.5: The microgel:trypsin weight ratio versus initial rate of turbidity decrease 
was correlated with a linear fit (R2=0.98). The relationship may be used to 
approximate degradation time of a known microgel:trypsin weight ratio. 
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Figure 7.6: BAEE activity assay of A) 1.2 mg/ml trypsin; B) 0.6 mg/ml trypsin 
incubated with various concentrations of P(MAA-co-NVP) microgels 
containing degradable crosslinks for 90 minutes, and then deactivated by 5 
minutes incubation at 70°C or addition of 2X volume of DMEM 
(degradation at 37°C, pH 7.4, N=3).  
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Figure 7.7: Representative images obtained via ImageStream analysis of microgels 
encapsulating fluorescent nanogels incubated for 90 minutes in A) 1.2 
mg/ml trypsin (scale bar = 7 μm), B) 0.6 mg/ml trypsin (scale bar = 7 μm), 
or C) pH 7.4 PBS (scale bar = 10 μm). Left: bright field, middle: green 
channel (nanogels), right: overlay. 
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Figure 7.8: Histogram plots of particle size (μm2) obtained by ImageStream analysis of 
microgels encapsulating fluorescent nanogels incubated for 90 minutes in A) 
1.2 mg/ml trypsin, B) 0.6 mg/ml trypsin, or C) pH 7.4 PBS. 
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Figure 7.9: Representative images obtained via ImageStream analysis of microgels 
encapsulating fluorescent nanogels incubated for ~0 minutes in A) SGF 
(scale bar = 7 μm), B) SIF (scale bar = 7 μm), or C) 0.6 mg/ml trypsin (scale 
bar = 7 μm). Left: bright field, middle: green channel (nanogels), right: 
overlay.  
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Figure 7.10: Histogram plots of particle size (μm2) obtained by ImageStream analysis of 
microgels encapsulating fluorescent nanogels incubated for ~0 minutes in 
A) SGF, B) SIF, or C) 0.6 mg/ml trypsin. 
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Figure 7.11: Representative images obtained via ImageStream analysis of microgels 
encapsulating fluorescent nanogels incubated for 120 minutes in A) SGF 
(scale bar = 7 μm), B) SIF (scale bar = 7 μm), or C) 0.6 mg/ml trypsin (scale 
bar = 7 μm). Left: bright field, middle: green channel (nanogels), right: 
overlay.  
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Figure 7.12: Histogram plots of particle size (μm2) obtained by ImageStream analysis of 
microgels encapsulating fluorescent nanogels incubated for 120 minutes in 
A) SGF, B) SIF, or C) 0.6 mg/ml trypsin. 
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Figure 7.13: Median particle size (μm2) values obtained by ImageStream analysis of 
microgels encapsulating fluorescent nanogels at various time points during 
the 120 minute degradation period. 
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Figure 7.14: Evaluation of degraded microgel and trypsin exposure effect on cell 
metabolism using a A) MTS cell proliferation assay (Promega) and B) LDH 
membrane integrity assay (Promega). Microgels were incubated in PBS or 
various trypsin concentrations for 4 hours at 37°C, then the trypsin was 
deactivated by 2X addition of DMEM. Human adenocarcinoma Caco-2 cells 
were incubated with degraded microgel solutions at various concentrations 
for 18 hours. Following microgel incubation, the MTS and LDH assays 
were used to evaluate cytotoxicity. (N=3).  
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Figure 7.15: Evaluation of degraded microgel and trypsin exposure effect on cell 
metabolism using a MTS cell proliferation assay (Promega). Microgels were 
incubated in PBS or various trypsin concentrations for 90 minutes at 37°C, 
then the trypsin was deactivated by incubation at 70°C for 5 minutes. 
Murine macrophage RAW 264.7 cells were incubated with degraded 
microgel solutions at A) 1 mg/ml in OptiMEM; B) 1 mg/ml in DMEM; or 
C) 0.4 mg/ml in OptiMEM for 18 hours. Following microgel incubation, the 
MTS assay was allowed to incubate for 90 min. Absorbance at 490 nm is 
relative to the positive control (culture media only, patterned bar) (N=3).  
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Figure 7.16: Evaluation of degraded microgel and trypsin exposure effect on cell 
metabolism using a LDH membrane integrity assay (Promega). Microgels 
were incubated in PBS or various trypsin concentrations for 90 minutes at 
37°C, then the trypsin was deactivated by incubation at 70°C for 5 minutes. 
Murine macrophage RAW 264.7 cells were incubated with degraded 
microgel solutions at A) 1 mg/ml in OptiMEM; B) 1 mg/ml in DMEM; or 
C) 0.4 mg/ml in OptiMEM for 18 hours. Following microgel incubation, the 
LDH assay was used to evaluate cell viability (N=3). 
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Figure 7.17: Representative siRNA loading efficiencies of degradable P(MAA-co-NVP) 
microgels with peptide crosslinker and encapsulated polycationic nanogels. 
Loading efficiency was based on amount of siRNA in microgels relative to 
initial amount in solution. Weight loading efficiency is moles of siRNA 
relative to the weight of microgels. Microgels were loaded over 4 hours at 
room temperature (N=3). 
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Figure 7.18: PAGE evaluation of siRNA degradation after siRNA-loaded microgels were 
incubated in 1) 0.3 mg/ml trypsin; 2) rat intestinal fluid; 3) rat gastric fluid; 
4) PBS; or 5) SGF; siRNA-complex nanogels incubated with 6) 0.3 mg/ml 
trypsin; 7) rat intestinal fluid; 8) rat gastric fluid; 9) PBS; or 10) SGF; or 
siRNA incubated with 11) 0.3 mg/ml trypsin; 12) rat intestinal fluid; 13) rat 
gastric fluid; 14) PBS; or 15) SGF. Solutions were run A) immediately after 
incubation in the buffers or B) after an additional 15 minute incubation with 
heparin solution.   
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Figure 7.19: A) PAGE evaluation of siRNA degradation after 1) siRNA-loaded 
microgels; 2) siRNA and nanogels; 3) microgels with nanogels and siRNA; 
and 4) microgels with nanogels and siRNA were incubated with 0.6 mg/ml 
trypsin for 90 minutes; after 5) siRNA-loaded microgels; 6) siRNA and 
nanogels; 7) microgels with nanogels and siRNA; and 8) microgels with 
nanogels and siRNA were incubated with 0.6 mg/ml trypsin for 90 minutes 
followed by 15 minutes incubation with heparin; and 9-10) incubation of 
siRNA with different concentrations RNase.  
 B) PAGE evaluation of siRNA degradation after 1) siRNA on ice; 2) siRNA 
at room temperature; 3) siRNA in pH 5.5 PBS; 4) siRNA in pH 8.5 PBS; 5) 
siRNAloaded with microgels; 6) siRNA in 1.2 mg/ml trypsin; 7) siRNA in 
0.6 mg/ml trypsin; 8) siRNA and microgels in 1.2 mg/ml trypsin; 9) siRNA 
and microgels in 0.6 mg/ml trypsin. 
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Figure 7.20: Confocal laser scanning microscopy fluorescent and bright field images of 
RAW 264.7 cells incubated with A) nanogels and B) degraded microgels 
containing nanogels (Scale bar = 20 μm).  
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Figure 7.21: Confocal laser scanning microscopy fluorescent Z-stack orthogonal images 
of RAW 264.7 cells incubated with A) nanogels and B) degraded microgels 
containing nanogels (Scale bar = 10 μm). 
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Figure 7.22: Confocal laser scanning microscopy fluorescent and bright field images of 
RAW 264.7 cells incubated with A) degraded microgels with fluorescently-
tagged nanogels and fluorescently-tagged siRNA; B) fluorescently-tagged 
nanogels with fluorescently tagged siRNA; and C) fluorescently-tagged 
degraded microgels containing fluorescently-tagged nanogels and 
fluorescently-tagged siRNA (Scale bar = 20 μm).  
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Figure 7.23: Gene knockdown by degraded and undegraded microgels containing 
nanogels, nanogels, commercially available Lipofectamine 2000, or naked 
siRNA. AllStars Death and Negative Control (Qiagen) were used, and MTS 
cell proliferation assay was used to quantify silencing efficiency (N=4, *p< 
0.05). 
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Chapter 8: Conclusions and Recommendations for Future Research 
8.1 CONCLUSIONS 
RNA interference mediated by siRNA holds great promise as a treatment for 
many diseases that are associated with aberrant gene expression. However, to date many 
of the siRNA-based therapies that have made it to the clinical trial stage are administered 
via injection, and the oral administration route has yet to be successfully utilized. This is 
attributed to the diverse and plentiful challenges facing oral delivery of siRNA: 
degradation by proteases, extreme pH conditions, short half-life in circulation, relatively 
large size and negative charge, and lysosomal degradation. Thus, a carrier that has the 
ability to load siRNA via electrostatic complexation, protect the delicate siRNA during 
transit through the gastrointestinal tract, deliver the siRNA to the small intestine, and 
facilitate cellular uptake and endosomal escape is needed to overcome these challenges. 
Polymers with pH responsive behavior are well-poised to meet these challenges. 
Polycationic nanogels have been developed in the Peppas lab and their ability to bind 
siRNA, cross the cell membrane, and induce gene silencing has been demonstrated [1-3]. 
On the other hand, anionic hydrogels have been widely used to deliver drugs and protein 
therapeutics to the small intestine. Thus, a combination of polymers with inverse pH 
responsive behavior may be able to meet the requirements as a carrier for orally delivered 
siRNA. 
The goal of this work was to develop, synthesize, and characterize an anionic 
hydrogel material capable of encapsulating and releasing polycationic nanogels to deliver 
siRNA. Two major approaches were explored, one with nondegradable crosslinkers and 
one with biodegradable, biomolecule-based crosslinkers. Both approaches utilized 
poly(methacrylic acid-co-N-vinylpyrrolidone), an anionic polymer that is protonated and 
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collapsed at low pH conditions, but ionized and swollen at high pH conditions, making it 
suitable for oral drug delivery applications.  
Formulations with two different nondegradable crosslinking agents, tetra(ethylene 
glycol) dimethacrylate (TEGDMA) and poly(ethylene glycol) dimethacrylate (n=400) 
(PEGDMA),  and varying cationic nanogel incorporation were synthesized by UV-
initiated bulk free radical polymerization. Nanogel incorporation within the microgels 
was confirmed by fluorescent microscopy. The pH responsive swelling behavior of the 
different formulations indicated that hydrogels with the shorter TEGDMA crosslinking 
agent experienced higher weight swelling ratios with increased nanogel content while the 
swelling of the PEGDMA gels were not dependent upon nanogel content. As the 
PEGDMA formulations exhibited consistent and favorable pH responsive swelling 
behavior independent of nanogel encapsulation, a protein and a small molecule model 
therapeutic were successfully loaded into the PEGDMA microgels with and without 
nanogels. The release efficiencies of both the model therapeutics were lower than 
expected, and nanogel content did not affect loading or release efficiency. The major 
issue with this system, however, was its inability to release the encapsulated nanogels. 
Without the release of the nanogels, siRNA has a low probability of cellular uptake and 
endosomal escape.  
This prompted a redesign of the anionic P(MAA-co-NVP) microgel system to 
incorporate a biodegradable crosslinker that is responsive to enzymes present in different 
regions of the intestine. Linear P(MAA-co-NVP) was first synthesized by UV-initiated 
solution polymerization, paying close attention to the charge state of the polymer after 
purification. The crosslinking reaction was most successful using linear polymer 
lyophilized at pH 8 in a two-part EDC-NHS linking reaction transitioned from pH 5 to 
pH 8. Incorporation of the peptide was consistently above 97% as determined by 
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fluorescamine assay of the peptide remaining in solution, and incorporation was verified 
by IR spectra. Nanogels were incorporated simply by addition to the solution just prior to 
the EDC-NHS crosslinking reaction, and the encapsulation of nanogels was confirmed by 
fluorescence spectroscopy and microscopy.  
Proteolytic degradation of the peptide-crosslinked microgels, both with and 
without nanogels, during incubation with trypsin solutions, simulated intestinal fluid 
(SIF), and rat intestinal fluid was demonstrated by reduced relative turbidity as a function 
of time and trypsin concentration. In contrast, relative turbidity of the microgel solutions 
remained constant upon incubation in phosphate buffered saline pH 7.4 (PBS), simulated 
gastric fluid (SGF), and rat gastric fluid, verifying that degradation was specific to the 
intestinal enzyme trypsin. The relative turbidity of nearly all trypsin and microgel 
concentrations tested reached a plateau within 90 minutes, indicating complete 
degradation. The microgels in SIF and rat intestinal fluid, on the other hand, required up 
to 4 hours to fully degrade, but this is still a relevant time scale for intestinal delivery. 
ImageStream flow cytometry was used to further analyze and quantify microgel 
degradation; over two hours in SIF, the median size of the microgels decreased by 68% 
whereas the median size of microgels in SGF actually increased by 20%.  
The degradable microgels induced a cytotoxic effect in a concentration-dependent 
manner in both the degraded and nondegraded states, but at low concentrations the 
changes in cell metabolism were tolerable. The cell viability after 8-18 hours of exposure 
to microgel concentrations less than 0.4 mg/ml was consistently greater than 90% as 
measured by an LDH membrane integrity assay. These trends were consistent for 
formulations with and without nanogels, though the toxicity of the cationic nanogels 
became apparent at a concentration of 1 mg/ml of microgels. These studies confirm that 
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the biodegradable behavior and biocompatibility of the peptide crosslinked hydrogel was 
highly suitable for intestinal delivery applications.  
The P(MAA-co-NVP) polymer backbone retained its pH responsive behavior 
after the crosslinking reaction. Despite potential concerns of incomplete complexation at 
low pH conditions, the microgels were able to load the therapeutic protein insulin with 
about 40% loading efficiency as well as retain the loaded protein in low pH conditions. 
Similarly, siRNA was loaded into the microgel systems containing polycationic 
nanogels by equilibrium partitioning and charge interactions with the nanogels with 60-
80% efficiency, depending on the type and concentration of siRNA. However, the siRNA 
experienced some degradation during incubation in simulated intestinal conditions, 
particularly at high trypsin concentrations, used to degrade the microgels. Despite the 
attack by trypsin on the siRNA, nondegraded siRNA was released from the microgel 
system, especially in the more physiologically relevant buffers, as detected by 
polyacrylamide gel electrophoresis.  
Cellular uptake of nanogels released from degraded microgels was confirmed in 
RAW 264.7 murine macrophage cells by confocal microscopy. Both ImageStream 
analysis and confocal microscopy suggest that electrostatic complexation is occurring 
between the negatively charged degraded P(MAA-co-NVP) and positively charged 
nanogels, but some of the complexes, free nanogels, or both are still inteRNAlized by the 
cells. Despite the inteRNAlization of nanogels, the ability of the delivery system to 
induce gene silencing in RAW 264.7 and Caco-2 human adenocarcinoma cells was 
somewhat disappointing, at less than 20% silencing efficiency and significantly less than 
the silencing efficiency attained by the nanogels alone in RAW 264.7 cells. This may be 
due to loss of siRNA stability upon incubation in intestinal conditions and/or electrostatic 
interactions interfering with release nanogels and siRNA. Though the ability of the 
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system to induce gene silencing was somewhat disappointing, the transfection 
efficiencies were consistent and repeatable across both RAW 264.7 and Caco-2 cell lines, 
making the results credible and reducing concerns about variability within the microgel 
composition.  
This work demonstrates that polycationic nanogels can be encapsulated in anionic 
P(MAA-co-NVP) microgels via two different synthesis methods, but a biodegradable 
crosslinker is necessary to release the nanogels from the matrix. The trypsin-degradable 
GRRRGK peptide was incorporated as a crosslinker via facile EDC-NHS reaction with 
P(MAA-co-NVP). The ability of this microgel encapsulation system to degrade in 
response to a specific enzyme on a relevant timescale, induce minimal cytotoxicity, load 
siRNA, deliver a detectable amount of viable siRNA, and release nanogels for cellular 
uptake endow it with significant potential as a vehicle for oral delivery of siRNA that 
should be further studied and improved.  
8.2 RECOMMENDATIONS FOR FUTURE RESEARCH 
Future work on this system could be directed toward tuning the charge densities 
of the nanogels and the microgel encapsulation system to limit electrostatic binding. This 
may be achieved by changing the molar ratio of MAA:NVP or the weight incorporation 
of nanogels in the microgels.  
Transfection with the improved systems may be executed to determine the effect 
of charge interactions on silencing efficiency. Transfection conditions such as trypsin 
concentration during degradation, microgel concentration, during transfection, 
transfection media, and transfection duration should also be further optimized to decrease 
electrostatic interactions, limit siRNA degradation, and increase silencing efficiency. 
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Different gene targets could be explored, as various siRNAs and cell models may 
react to the microgel systems differently. Some gene targets that are common in the 
literature and for which siRNAs are commercially available are GAPDH, a ubiquitous 
gene that maintains normal cell metabolism, and TNF-α [4-6], a cytokine overexpressed 
in inflammatory diseases.  
Further, the performance of this microgel system should be evaluated in vivo or at 
least in more physiologically accurate cell model conditions to verify the biodegradability 
and silencing efficiency; it is possible that a greater portion of the siRNA will remain 
stable at physiological trypsin concentrations, and competing charged molecules in the 
intestinal environment may decrease the electrostatic binding via competitive 
dissociation. It would be of interest to use the microgels to deliver anti-TNF-α siRNA 
orally to a dextran sodium sulfate-induced colitis mouse model [4, 5] or evaluate 
systemic knockdown of TNF-α via epithelial permeation in an in vitro or in vivo model 
[7, 8]. 
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Appendix A: Emulsion Polymerization of Poly(methacrylic acid-co-N-
vinyl-2-pyrrolidone) Particles 
A.1 INTRODUCTION 
Design parameters of an effective oral delivery vehicle for small interfering RNA 
(siRNA) include ability to transverse the digestive tract, cross the cell membrane, and 
escape into the cell cytosol, all while maintaining the bioactivity of the easily-degraded 
siRNA. Anionic hydrogels have been shown to have suitable properties for oral delivery 
of delicate proteins[1, 2], and may have utility in as part of a composite hydrogel system 
to deliver encapsulated siRNA to the site of cell uptake.  
Emulsion polymerizations consist of monomer droplets dispersed in a nonsolvent 
continuous phase and are stabilized by surfactants at concentrations above the critical 
micelle concentration. Upon addition of the initiator to the dispersant phase, free radicals 
diffuse into the surfactant micelles to initiate polymerization within the micelles [3]. 
Thus, emulsion polymerizations have the advantage of using micelle size to control the 
size of the resulting latex particles [4].  
A typical emulsion employs an aqueous dispersant phase with hydrophobic 
monomers. Hydrophilic monomers such as methacrylic acid (MAA) require an inverse 
emulsion, or water-in-oil (W/O) emulsion. The hydrophilic-lipophilic balance (HLB), or 
the ratio of hydrophilic to lipophilic groups present on a surfactant or in a surfactant 
system [5], is a critical aspect of a successful inverse emulsion [6]. Additionally, 
monomers with acid functional groups, such as methacrylic acid, introduce stability 
issues into the emulsion [7].  
The aim of this work was the development of a novel inverse emulsion 
photopolymerization to synthesize hydrophilic, pH-responsive anionic poly(methacrylic 
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acid-co-N-vinyl-2-pyrrolidone) hydrogel particles that may be used as part of a composite 
hydrogel system for the oral delivery of siRNA to the gastrointestinal tract.  
A.2 EXPERIMENTAL METHODS 
A.2.1 Chemicals 
Methacrylic acid (MAA and N-vinyl-2-pyrrolidone (NVP) were obtained from 
Sigma-Aldrich (St. Louis, MO). Poly(ethylene glycol) (400) dimethacrylate (PEGDMA) 
was purchased fro  Polysciences, Inc. (Warrin ton, PA).   ween™ 80 (poly[ethylene 
 lycol](80) sorbitan  onooleate) or  ween™ 20 (poly[ethylene  lycol](20) sorbitan 
 onooleate) and Span™ 80  (sorbitan  onooleate) were obtained fro  Si  a Aldrich.  
Mineral oil was obtained from Thermo-Fisher. Irgacure 184
®
 (1-hydroxy-cyclohexyl-
phenylketone) was purchased from Sigma-Aldrich. All reagents were used as received. 
A.2.2 Emulsion Polymerization  
Inverse emulsion compositions were based on emulsion recipes reported by 
Kriwet et al. [4] and consisted of 25% (w/w) hydrophilic phase, 5% (w/w) monomer, 2-5 
% (w/w) surfactant, and the remainder was mineral oil. MAA:NVP molar ratio was held 
constant at 1:1, and PEGDMA was added at 1 mol% with respect to total monomer 
content.  
First, the  ineral oil and surfactants  ween™ 80 (poly[ethylene  lycol](80) 
sorbitan onooleate) or  ween™ 20 (poly[ethylene  lycol](20) sorbitan onooleate) and 
Span™ 80  (sorbitan  onooleate) were co bined to for  the continuous phase.  he 
monomers and sodium hydroxide (1 N) were added to water to form the hydrophilic 
phase. The hydrophilic phase was then be added to the lipophilic phase while stirring, 
followed by the addition of 1 wt % Irgacure® 184 with respect to the total monomer 
content.  
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The phases were emulsified using a Misonix Ultrasonicator (Misonix, Inc., 
Newtown, CT) at 90 W for 10 seconds on/10 seconds off for a total of 20 minutes, 
transferred to a round bottom flask, then bubbled with nitrogen for 20 minutes to remove 
the free radical scavenger oxygen. Polymerization was initiated with a Dymax 
BlueWave® 200 UV point source (Dymax, Torrington, CT) for a period of time 
proportional to the volume of the emulsion (i.e., 3 hours for 100 ml reaction volume) with 
constant stirring. Following polymerization, the latex particles were extracted from the 
emulsion by precipitation with 2-propanol and further purified by washes with acetone, 
followed by dialysis against DI water in 12-14 kDa MWCO dialysis tubing (Spectrum 
Labs, Rancho Dominguez, CA) for 10 days. The polymer particles were then lyophilized 
and stored in a desiccator at room temperature. 
A.2.3 Emulsion Characterization 
Emulsion stability was evaluated by using a Bio- ek Syner y™ H   ulti-mode 
plate reader (Winooski, VT) to measure the UV/VIS absorbance spectra of the emulsions 
over time, as changes in turbidity indicate instability. Emulsions were screened in a high-
throughput manner in 96-well plates.  
SEM samples were prepared by drop-casting polymer solutions at concentrations 
of 1-2.5 mg/mL in water onto carbon-tape covered aluminum stubs. After drying, the 
samples were coated with 10-12 nm of Pt/Pd coating using a Cressington 208 Benchtop 
sputter coater (Watford, England). Scanning electron microscopy images were obtained 
using an FEI Quanta 650 FEG scanning electron microscope (Hillsboro, OR). SEM 
micrographs were used to evaluate the stability of the emulsion during polymerization as 
well as the size and morphology of the resulting particles.  
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Dynamic light scattering (DLS) measurements were made using a Malvern 
Zetasizer Nano ZS (Worcestershire, UK) to determine the size and zeta potential of the 
polymer particles as a function of pH. Particles were run at a concentration of 0.5 mg/mL 
in water.  
A.3 RESULTS AND DISCUSSION 
Surfactants, surfactant ratios, and the degree of neutralization (DN) of MAA were 
varied within the ranges shown in Table A.1 to evaluate the effect on emulsion stability. 
Emulsions were examined visually over time to detect any coalescence, flocculation, 
creaming, or Ostwald ripening that could be indicative of instability. Additionally, the 
absorbance spectra of the emulsions were measured over time to correlate turbidity to 
stability. Emulsions that changed in turbidity or showed any of the aforementioned 
characteristics of instability were deemed unstable.  
Figure A.1 shows representative images of emulsions at time=0 and time=60. The 
emulsion formulation on the left, E61, remained turbid over 60 minutes and showed no 
signs of separation, indicating good stability. Emulsions 62-65, however, either changed 
in turbidity, coalesced, or both, indicating instability. Figure A.2 shows that the 
absorbance measurements were in good agreement with the visual observations, with the 
absorbance values dropping in the unstable emulsions. 
The emulsion compositions were recorded on a teRNAry phase diagram to 
determine regions of stability. For Span 80:Tween 20 formulations with 2 wt% 
surfactant, 75:25-50:50 Span:Tween ratio, and 40-80% DN, no distinct region of stability 
was present, as seen in Figure A.3. At 3 wt% surfactant, 75:25-50:50 Span:Tween ratio, 
and 40-80% DN, a region of stability was observed at or near 50:50 Span:Tween ratio 
and did not depend on DN in this region, as shown in Figure A.5. Corresponding 
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absorbance spectra are shown in Figures A.4 and A.6, and it can be seen that there was a 
clear division in absorbance spectra between stable and unstable emulsions with 2 wt% 
surfactant, but the absorbance spectra were less conclusive in the 3 wt% surfactant 
emulsions.  
Overall, emulsions prepared with Span 80 and Tween 80 were more stable than 
emulsions prepared with Span 80 and Tween 20. For Span 80:Tween 80 formulations 
with 2 wt% surfactant, 75:25-50:50 Span:Tween ratio, and 40-80% DN, nearly all the 
emulsions were stable over 60 minutes, as seen in Figure A.7. The same was true for 
emulsions with 3 wt% surfactant, 75:25-50:50 Span:Tween ratio, and 40-80% DN, as 
shown in Figure A.9. Additionally, the corresponding absorbance spectra, shown in 
Figures A.8 and A.10, were in 100% agreement with visual observations of emulsion 
stability, demonstrated by the distinct differences in absorbance values.  
Based on these results, a surfactant amount of 2 wt% and Span 80:Tween 80 of 
75:25 was chosen as the best performing emulsion conditions. This ratio of surfactant has 
an HLB of approximately 6.9, which is just above the range of 3-6 recommended for 
inverse emulsions [8]. The degree of neutralization of MAA was next varied from 40-
80% and the resulting polymer was further characterized. At the end of the 
polymerization, some sediment was present in the emulsions with the two lowest DN, 
indicating instability of the product. This was verified by SEM, shown in Figure A.11. 
To verify the pH-responsive behavior of the polymer particles, DLS was used to 
measure the zeta potential and Z-average size of particles from the 2 wt% and Span 
80:Tween 80 of 75:25 emulsion with the highest DN, 80%. As shown in Figure A.12, 
there was an inverse relationship between zeta potential and Z-average size of the 
particles as the pH increased from 2 to 8. It should be noted that accurate size 
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measurements could not be obtained below pH 4, as the particles were protonated at low 
pH and prone to aggregation due to hydrogen bonding.  
A.4 CONCLUSIONS 
Best-performing co-surfactant systems and W/O emulsion compositions were 
determined to achieve a stable photoemulsion polymerization for synthesis of hydrophilic 
P(MAA-co-NVP) hydrogel particles. A high-throughput method was developed to screen 
emulsion stability over time of 96 formulations at once using absorbance measurements 
obtained from a plate reader; correlation to visual observations of stability was 100% for 
Span 80:Tween 80 formulations. Particles were able to be extracted from the emulsion 
and purified. The pH-response and zeta potential of the polymer indicated that it may be a 
suitable material to be used in a composite hydrogel system for oral delivery applications.  
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A.5 TABLES 
Parameter Range Tested 
Dual surfactant system Span 80, Tween 20 
Span 80, Tween 80 
Ratio of Tween:Span 0:100 - 50:50 
Surfactant amount 
(relative to entire weight of emulsion) 
2-5% 
Degree of Neutralization (DN) 
(Moles NaOH relative to moles of MAA) 
40-80% 
Table A1: Parameters varied to determine effect on emulsion stability.  
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A.5 FIGURES 
Figure A.1: Representative images of emulsions at time=0 and time=60 minutes. 
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Figure A.2: Absorbance spectra of emulsions at A) time=0 and B) time=60 minutes.  
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Figure A.3: TeRNAry phase plot of emulsions with 2 wt% Span 80/Tween 20 co-
surfactant system.   
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Figure A.4: Absorbance spectra of emulsions with 2 wt% Span 80/Tween 20 co-
surfactant system.  
 
  
 230 
 
Figure A.5: TeRNAry phase plot of emulsions with 3 wt% Span 80/Tween 20 co-
surfactant system.   
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Figure A.6: Absorbance spectra of emulsions with 3 wt% Span 80/Tween 20 co-
surfactant system.  
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Figure A.7: TeRNAry phase plot of emulsions with 2 wt% Span 80/Tween 80 co-
surfactant system.   
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Figure A.8: Absorbance spectra of emulsions with 2 wt% Span 80/Tween 80 co-
surfactant system.  
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Figure A.9: TeRNAry phase plot of emulsions with 3 wt% Span 80/Tween 80 co-
surfactant system.   
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Figure A.10: Absorbance spectra of emulsions with 2 wt% Span 80/Tween 80 co-
surfactant system.  
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Figure A.11: SEM micrographs of particles from A) an unstable emulsion with low DN 
and B) a stable emulsion with high DN. (Scale bar= 10 μ ).  
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Figure A.12: Z-average size and zeta potential measurements made using DLS of 
P(MAA-co-NVP) particles synthesized via a stable emulsion polymerization 
(0.5 mg/ml in water).   
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Appendix B: Abbreviations 
AGO-2  argonaute-2 
ARGET  activator regenerated by electron transfer 
ATRP   atom transfer radical polymerization 
AuCM   cysteamine-modified gold nanoparticles 
BAEE   Nα-benzoyl-L-arginine ethyl ester hydrochloride 
BSA   bovine serum albumin  
CD   celiac disease 
CdSe   cadmium selenide 
β-CD   β-cyclodextrin 
DEPC   diethylpyrocarbonate 
DLS   dynamic light scattering 
DMEM  Dulbecco’s modified Eagle medium 
DN   degree of neutralization 
EDC   1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride 
FRET   fluorescent resonance energy transfer 
FTIR   Fourier transform infrared spectroscopy 
GeRP   β-1,3-ᴅ-glucan-encapsulated siRNA particle 
GFD   gluten-free diet 
GI   gastrointestinal 
HA   hyaluronic acid 
HCl   hydrochloric acid 
HLA   human leukocyte antigen 
HLB   hydrophilic-lipophilic balance 
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IBD   inflammatory bowel disease 
IL-6   interleukin-6 
IPN   interpenetrating polymer network 
KGM   konjac glucomannan 
L-Arg   L –arginine 
LN2   liquid nitrogen 
LPS   lipopolysaccharide 
MAA   methacrylic acid 
MMC   migrating myoelectric complex 
mRNA   messenger RNA 
MTX   methotrexate 
MWCO  molecular weight cut-off 
NaOH   sodium hydroxide 
NBD-Cl  4-chloro-7-nitrobenzofurazan 
NHS   N-hydroxysuccinimide 
NiMOS  nanoparticle-in-microsphere 
NVP    N-vinyl-2-pyrrolidone 
P(MAA-co-NVP) poly(methacrylic acid-co-N-vinylpyrrolidone) 
PAAD   poly(acrylic acid) derivatives 
PAGE   polyacrylamide gel electrophoresis 
PASP   poly(aspartic acid) 
PBS   phosphate buffered saline 
PCL   poly(ε-caprolactone) 
PDEAEMA  poly[2-(diethylamino) ethyl methacrylate] 
PEG   poly(ethylene glycol) 
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PEGDMA   poly(ethylene glycol) dimethacrylate 
pEGFP  enhanced green fluorescent protein 
PEI   polyethyleneimine 
PGA   poly(glutamic acid) 
PLL   poly(L-lysine) 
PMAA   poly(methacrylic acid) 
QD   quantum dot 
RNA   ribonucleic acid 
RNAi   RNA interference 
RNAse A  ribonuclease A 
RT-PCR  reverse transcription- polymerase chain reaction 
SEM   scanning electron microscopy 
SGF   simulated gastric fluid 
SIF   simulated intestinal fluid 
siRNA   small interfering RNA 
TBAEMA  2-(tert-butylamino)ethyl methacrylate 
TBMA   tert-butyl methacrylate 
TEGDMA  tetra(ethylene glycol) dimethacrylate 
TGA   thermal gravimetric analysis  
TKN   thioketal nanoparticle 
TMC-Cys  trimethyl chitosan-cysteine conjugate 
TNF-α   tumor necrosis factor-α 
W/O   water-in-oil 
ZnS   zinc sulfide 
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Appendix C: Publications, Presentations and Coursework 
C.1 PUBLICATIONS 
1. Knipe, J.M. and Peppas, N.A. “Microencapsulated Nanogels for siRNA 
Delivery,” In Preparation.  
2. Knipe, J.M., Chen, F., and Peppas, N.A. “Enzymatically Degradable Hydrogels 
for Site-Specific Intestinal Delivery,” In Preparation.  
3. Knipe, J.M. and Peppas, N.A. “Multi-responsive Hydrogels for Drug Delivery 
and Tissue Engineering Applications,” Regenerative Biomaterials, Accepted. 
4. Knipe, J.M., Chen, F., and Peppas, N.A. "Multi-responsive polyanionic 
microgels with inverse pH-responsive behavior by encapsulation of polycationic 
nanogels,” JouRNAl of Applied Polymer Science, 131, 2014, 40098-40105.  
5. Knipe, J.M., Peters, J.T., and Peppas, N.A. “Theranostic agents for gene delivery 
and spatiotemporal imaging,” Nano Today, 8, 2013, 21-38. 
C.2 PRESENTATIONS 
1. Knipe, J.M., Chen, F., and Peppas, N.A. “Enzymatically Degradable Microgels 
for the Oral Delivery of siRNA,” Biomedical Engineering Society Annual 
Meeting, San Antonio, TX. October 24, 2014. (Accepted.) 
2. Knipe, J.M., Chen, F., Khot, S., and Peppas, N.A. “Microencapsulated Nanogel 
System for the Oral Delivery of siRNA,” American Association of 
Pharmaceutical Scientists Annual Meeting, San Antonio, TX. November 11, 
2013. (Poster.) 
3. Knipe, J.M., Chen, F., Khot, S., and Peppas, N.A. “Biodegradable 
microencapsulated nanogel system for the oral delivery of siRNA,” WE13 Annual 
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Conference of The Society of Women Engineers, Baltimore, MD. October 24, 
2013. (Oral presentation and poster.) 
4. Knipe, J.M. and Peppas, N.A. “Microencapsulated polymeric systems for the oral 
delivery of siRNA,” Biomaterials Day of the Society for Biomaterials, Austin, 
TX. May 31, 2013. 
5. Knipe, J.M. and Peppas, N.A. “Microencapsulated polymeric systems for the oral 
delivery of siRNA,” Graduate and Industry Networking Event, Austin, TX. 
February 27, 2013. 
6. Knipe, J.M., Pham, T.N, and Peppas, N.A. “Nanoscale Anionic Hydrogel 
Prepared by Emulsion Polymerization for Oral Delivery of siRNA,” AIChE 
Annual Meeting, Pittsburgh, PA. November 1, 2012. (Oral presentation.) 
7. Knipe, J.M. and Peppas, N.A. “Synthesis and Characterization of Composite 
Hydrogel Particles for Oral Delivery of siRNA,” Biomedical Engineering Society 
Annual Meeting, Atlanta, GA. October 25, 2012. (Oral presentation.) 
8. Knipe, J.M. and Peppas, N.A. “Synthesis and Characterization of Composite 
Hydrogel Particles for Oral Delivery of Small Interfering RNA,” Biomaterials 
Day of the Society for Biomaterials, Houston, TX. July 27, 2012. 
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C.3 COURSEWORK 
1. CHE 381N FLUID FLOW AND HEAT TRANSFER   
2. CHE 381P ADV ANALYSIS FOR CHEM ENGINEER  
3. CHE 387K ADVANCED THERMODYNAMICS 
4. CHE 392 POLYMER SCIENCE  
5. CH 392N PHYS CHEM OF MACROMOLEC SYSTEM 
6. CHE 384 ADV ENGINEERING BIOMATERIALS 
7. CHE 384 MASS TRANSFER IN POLYMERS 
8. LEB 380 14-INTELLECTUAL PROPERTY 
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